US20080050739A1 - Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats - Google Patents
Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats Download PDFInfo
- Publication number
- US20080050739A1 US20080050739A1 US11/763,426 US76342607A US2008050739A1 US 20080050739 A1 US20080050739 A1 US 20080050739A1 US 76342607 A US76342607 A US 76342607A US 2008050739 A1 US2008050739 A1 US 2008050739A1
- Authority
- US
- United States
- Prior art keywords
- fetal
- cells
- sample
- maternal
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001605 fetal effect Effects 0.000 title claims abstract description 238
- 230000005856 abnormality Effects 0.000 title claims abstract description 33
- 102000054765 polymorphisms of proteins Human genes 0.000 title claims abstract description 6
- 108091092878 Microsatellite Proteins 0.000 title description 54
- 238000003745 diagnosis Methods 0.000 title description 4
- 230000008774 maternal effect Effects 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 93
- 208000036878 aneuploidy Diseases 0.000 claims abstract description 33
- 231100001075 aneuploidy Toxicity 0.000 claims abstract description 28
- 238000012360 testing method Methods 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 298
- 239000000523 sample Substances 0.000 claims description 169
- 108700028369 Alleles Proteins 0.000 claims description 101
- 210000004369 blood Anatomy 0.000 claims description 47
- 239000008280 blood Substances 0.000 claims description 47
- 238000000926 separation method Methods 0.000 claims description 47
- 210000000349 chromosome Anatomy 0.000 claims description 46
- 238000004458 analytical method Methods 0.000 claims description 45
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 30
- 230000003321 amplification Effects 0.000 claims description 28
- 208000037280 Trisomy Diseases 0.000 claims description 27
- 238000013499 data model Methods 0.000 claims description 15
- 201000010374 Down Syndrome Diseases 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 9
- 238000007885 magnetic separation Methods 0.000 claims description 8
- 238000004590 computer program Methods 0.000 claims description 7
- 239000013068 control sample Substances 0.000 claims description 7
- 210000002593 Y chromosome Anatomy 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000011529 RT qPCR Methods 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 4
- 210000001766 X chromosome Anatomy 0.000 claims description 3
- 201000006360 Edwards syndrome Diseases 0.000 claims description 2
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 2
- 201000009928 Patau syndrome Diseases 0.000 claims description 2
- 206010044686 Trisomy 13 Diseases 0.000 claims description 2
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 claims description 2
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 206010053884 trisomy 18 Diseases 0.000 claims description 2
- 238000001001 laser micro-dissection Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 64
- 238000001514 detection method Methods 0.000 description 38
- 238000001818 capillary gel electrophoresis Methods 0.000 description 34
- 230000005291 magnetic effect Effects 0.000 description 33
- 230000008775 paternal effect Effects 0.000 description 33
- 210000003743 erythrocyte Anatomy 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 16
- 210000004940 nucleus Anatomy 0.000 description 15
- 108010054147 Hemoglobins Proteins 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 14
- 238000007857 nested PCR Methods 0.000 description 14
- 239000013074 reference sample Substances 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- 238000003491 array Methods 0.000 description 12
- 210000003754 fetus Anatomy 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010067770 Endopeptidase K Proteins 0.000 description 10
- 239000000090 biomarker Substances 0.000 description 10
- 239000012491 analyte Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 108091093088 Amplicon Proteins 0.000 description 8
- 206010044688 Trisomy 21 Diseases 0.000 description 8
- 210000004700 fetal blood Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 6
- 208000026487 Triploidy Diseases 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 5
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000002669 amniocentesis Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000012160 loading buffer Substances 0.000 description 5
- 239000006249 magnetic particle Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 4
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 4
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 4
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 208000003028 Stuttering Diseases 0.000 description 4
- 230000003322 aneuploid effect Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- -1 Fe3+ Chemical class 0.000 description 3
- 102100030826 Hemoglobin subunit epsilon Human genes 0.000 description 3
- 108091005879 Hemoglobin subunit epsilon Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020003217 Nuclear RNA Proteins 0.000 description 3
- 102000043141 Nuclear RNA Human genes 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 206010003883 azoospermia Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008175 fetal development Effects 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003924 normoblast Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 210000003765 sex chromosome Anatomy 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 230000036266 weeks of gestation Effects 0.000 description 3
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100030387 Hemoglobin subunit zeta Human genes 0.000 description 2
- 108091005905 Hemoglobin subunit zeta Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 208000035199 Tetraploidy Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002218 isotachophoresis Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 208000030454 monosomy Diseases 0.000 description 2
- 208000012978 nondisjunction Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 208000027223 tetraploidy syndrome Diseases 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000001325 yolk sac Anatomy 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000011374 Alagille syndrome Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000014392 Cat-eye syndrome Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 102100029058 Coagulation factor XIII B chain Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011385 Cri-du-chat syndrome Diseases 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010069382 Hereditary neuropathy with liability to pressure palsies Diseases 0.000 description 1
- 102100035009 Holocytochrome c-type synthase Human genes 0.000 description 1
- 101000918352 Homo sapiens Coagulation factor XIII A chain Proteins 0.000 description 1
- 101000918350 Homo sapiens Coagulation factor XIII B chain Proteins 0.000 description 1
- 101000946589 Homo sapiens Holocytochrome c-type synthase Proteins 0.000 description 1
- 101001129182 Homo sapiens Patatin-like phospholipase domain-containing protein 4 Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 208000001804 Monosomy 5p Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000036830 Normal foetus Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102100031252 Patatin-like phospholipase domain-containing protein 4 Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102220493065 Protein Flattop_D16S_mutation Human genes 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
- 102100022978 Sex-determining region Y protein Human genes 0.000 description 1
- 101710188553 Sex-determining region Y protein Proteins 0.000 description 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710139423 THO complex subunit 1 Proteins 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 201000001305 Williams-Beuren syndrome Diseases 0.000 description 1
- 208000001001 X-linked ichthyosis Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 108010053584 alpha-Globins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000002045 capillary electrochromatography Methods 0.000 description 1
- 238000000533 capillary isoelectric focusing Methods 0.000 description 1
- 238000005515 capillary zone electrophoresis Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000005347 demagnetization Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 101150116409 dys-1 gene Proteins 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 108010055798 epsilon-Globins Proteins 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108010038853 gamma-Globins Proteins 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 201000003702 glycerol kinase deficiency Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026203 inborn glycerol kinase deficiency Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000004244 micellar electrokinetic capillary chromatography Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000013206 minimal dilution Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012821 model calculation Methods 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 208000036897 pentasomy Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 208000026079 recessive X-linked ichthyosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000011908 tetrasomy Diseases 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
- 238000001039 wet etching Methods 0.000 description 1
- 108010062463 zeta-Globins Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Definitions
- Analysis of specific cells can give insight into a variety of diseases. These analyses can provide non-invasive tests for detection, diagnosis and prognosis of diseases, thereby eliminating the risk of invasive diagnosis. For instance, social developments have resulted in an increased number of prenatal tests. However, the available methods today, amniocentesis and chorionic villus sampling (CVS) are potentially harmful to the mother and to the fetus. The rate of miscarriage for pregnant women undergoing amniocentesis is increased by 0.5-1%, and that figure is slightly higher for CVS.
- non-invasive tests for detection, diagnosis and prognosis of diseases.
- maternal serum alpha-fetoprotein, and levels of unconjugated estriol and human chorionic gonadotropin are used to identify a proportion of fetuses with Down's syndrome, however, these tests are not one hundred percent accurate.
- ultrasonography is used to determine congenital defects involving neural tube defects and limb abnormalities, but is useful only after fifteen weeks' gestation.
- the methods of the present invention allow for the detection of fetal cells and fetal abnormalities when fetal cells are present in a mixed population of cells, even when maternal cells dominate the mixture.
- fetal cells are rare as compared to the presence of maternal cells in the blood. Therefore, any proposed analysis of fetal cells to diagnose fetal abnormalities requires enrichment of fetal cells. Enriching fetal cells from maternal peripheral blood is challenging, time intensive and any analysis derived therefrom is prone to error. The present invention addresses these challenges.
- the present invention relates to methods for determining the presence of fetal cells and fetal abnormalities when fetal cells are present in a mixed sample (e.g. maternal blood sample).
- determining the presence of fetal cells or of a fetal abnormality includes comparing the level of genomic DNA from a mixed sample to the level of genomic DNA in a control sample.
- the control or reference sample can be a mixed sample that has been sufficiently diluted to be free of fetal cells.
- the mixed sample can contain at least one fetal cell and one non-fetal cell. In other embodiments, the sample comprises up to 50% fetal cells.
- determining the presence of fetal cells and/or abnormalities involves quantifying one or more regions of genomic DNA regions from the mixed sample and determining from the quantification the presence of a fetal abnormality.
- regions are polymorphic e.g. short tandem repeat (STR) regions.
- fetal abnormalities that can be determined by quantifying regions on one or more chromosomes include trisomy 13, trisomy 18, trisomy 21 (Dow-Syndrome), Klinefelter Syndrome (XXY) and other irregular number of sex or autosomal chromosomes.
- abnormal fetal genotypes that can be determined by quantifying regions on one or more chromosomes include, but are not limited to, aneuploidy such as, monosomy of one or more chromosomes (X chromosome monosomy, also known as Turner's syndrome), trisomy of one or more chromosomes (such as 13, 18, 21, and X), tetrasomy and pentasomy of one or more chromosomes (which in humans is most commonly observed in the sex chromosomes, e.g.
- aneuploidy such as, monosomy of one or more chromosomes (X chromosome monosomy, also known as Turner's syndrome), trisomy of one or more chromosomes (such as 13, 18, 21, and X), tetrasomy and pentasomy of one or more chromosomes (which in humans is most commonly observed in the sex chromosomes, e.g.
- an abnormal fetal genotype is a segmental aneuploidy.
- segmental aneuploidy examples include, but are not Limited to, 1p36 duplication, dup(17)(p11.2p11.2) syndrome, Down syndrome, Pelizaeus-Merzbacher disease, dup(22)(q11.2q11.2) syndrome, and cat-eye syndrome.
- an abnormal fetal genotype is due to one or more deletions of sex or autosomal chromosomes, which may result in a condition such as Cri-du-chat syndrome, Wolf-Hirschorn, Williams-Beuren syndrome, Charcot-Marie-Tooth disease, Hereditary neuropathy with liability to pressure palsies, Smith-Magenis syndrome, Neurofibromatosis, Alagille syndrome, Velocardiofacial syndrome, DiGeorge syndrome, Steroid sulfatase deficiency, Kallmann syndrome, Microphthalmia with linear skin defects, Adrenal hypoplasia, Glycerol kinase deficiency, Pelizaeus-Merzbacher disease, Testis-determining factor on Y, Azospermia (factor a), Azospermia (factor b), Azospermia (factor c), or 1p36 deletion.
- a decrease in chromosomal number results in an XO syndrome.
- the methods herein can distinguish maternal trisomy from paternal trisomy, and total aneuploidy from segmental aneuploidy. Segmental aneuploidies can be caused by an intra-chromosomal event such as a deletion, duplication or translocation event. Additionally, the methods herein can be used to identify monoploidy, triploidy, tetraploidy, pentaploidy and other higher multiples of the normal haploid state. In some embodiments, the maternal or paternal origin of the fetal abnormality can be determined.
- the genomic DNA region(s) can be quantified by amplifying the regions using, for example, PCR, or preferably quantitative PCR. Alternatively, quantification of the regions can be achieved using capillary gel electrophoresis (CGE). In some embodiments, total genomic DNA is pre-amplified prior to the quantitative amplification step to increase the overall abundance of DNA. Such pre-amplification step can involve the use of multiple displacement amplification.
- the genomic DNA regions quantified can be in one chromosome or in 2 or more chromosomes.
- the polymorphic regions can be quantified on either or both sex chromosomes X and Y, and on autosomal chromosomes including chromosomes 13, 18 and 21.
- a mixed sample suspected of having fetal cells can be enriched for fetal cells.
- Fetal cell enrichment can be accomplished using any method known in the art including size-based separation, affinity (e.g. magnetic) separation, FACS, laser microdisection, and magnetic bead separation.
- a mixed sample containing as few as 10 fetal cells can be enriched.
- the fetal cells in the enriched sample constitute less than 50% of the total number of cells.
- the size-based separation method includes applying a mixed sample into a system that separates a first component of the mixed sample (e.g. fetal cells), which comprises cells that are larger than a critical size, in a first direction, and a second component of the mixed sample (e.g. enucleated maternal red blood cells), which comprises cells that are smaller than a critical size, towards a second exit port.
- a first component of the mixed sample e.g. fetal cells
- a second component of the mixed sample e.g. enucleated maternal red blood cells
- the separation system can be a device that includes one or more arrays of obstacles that form a network of gaps.
- enrichment that is achieved by size-based separation is followed by one or more additional enrichment procedures including magnetic separation, fluorescence activated cell sorting (FACS), laser microdisection, and magnetic bead separation.
- FACS fluorescence activated cell sorting
- a sample enriched by size-based separation is subjected to affinity/magnetic separation and is further enriched for rare cells using fluorescence activated cell sorting (FACS) or selective lysis of a subset of the cells (e.g. fetal cells).
- kits for detecting the fetal abnormalities wherein the kits include separation devices and the reagents needed to perform the genetic analysis.
- the kit may include arrays for size based enrichment, a device for magnetic enrichment and reagents for performing PCR.
- the methods can further comprise inputting the data from the quantification step into data model(s) for the association of DNA quantity with maternal and non-maternal alleles.
- the invention provides for a computer program product, which includes a computer executable logic recorded on a computer readable medium that can be used for diagnosing a fetal abnormality.
- the computer program is designed to receive data from one of more quantified DNA genomic regions from a mixed sample containing at least one fetal cell, determine the presence or absence of a fetal abnormality from the data, and generate an output that comprises the evaluation of the fetal abnormality. Methods for using the computer program product are also disclosed.
- FIG. 1 illustrates a flow chart of one embodiment of the present invention.
- FIGS. 2A-2D illustrate one embodiment of a size-based separation module.
- FIGS. 3A-3C illustrate one embodiment of an affinity separation module.
- FIG. 4 illustrates one embodiment of a magnetic separation module.
- FIG. 5 illustrates typical locus patterns arising from a normal (diploid) fetus and mother.
- FIG. 6 illustrates typical locus patterns arising from trisomic fetal cells.
- FIGS. 7A-7D illustrate various embodiments of a size-based separation module
- FIGS. 8A-8B illustrate cell smears of the product and waste fractions.
- FIGS. 9A-9F illustrate isolated fetal cells confirmed by the reliable presence of male Y chromosome.
- FIG. 10 illustrates trisomy 21 pathology in an isolated fetal nucleated red blood cell.
- FIG. 11 depicts a flow chart depicting the major steps involved in detecting paternal alleles in a fetal enriched sample using fluorescently labeled primers.
- FIG. 12 illustrates a table with STR loci that can be used for fetal detection.
- FIG. 13 illustrates a table with exemplary external primers for STR loci.
- FIG. 14 illustrates a table with exemplary internal primers for STR loci.
- FIG. 15 illustrates the resolution for the ABI 310 bioanalyzer.
- FIG. 16 illustrates the detection limit on fixed cord blood.
- FIG. 17 illustrates the detection of 10 fetal cells at 10% purity without nested PCR.
- FIG. 18 illustrates the generation of STR markers on fixed cells recovered from a slide.
- FIG. 19 illustrates detection of fetal alleles at less than 10% purity after nested PCR amplification of STRs.
- FIG. 20 illustrates the detection of single copies of a fetal cell genome by qPCR.
- FIG. 21 illustrates detection of single fetal cells in binned samples by SNP analysis.
- FIG. 22 illustrates a method of trisomy testing.
- the trisomy 21 screen is based on scoring of target cells obtained from maternal blood. Blood is processed using a cell separation module for hemoglobin enrichment (CSM-HE). Enriched cells are transferred to slides that are first stained and subsequently probed by FISH. Images are acquired, such as from bright field or fluorescent microscopy, and scored. The proportion of trisomic cells of certain classes serves as a classifier for risk of fetal trisomy 21.
- CSM-HE hemoglobin enrichment
- Fetal genome identification can performed using assays such as: (1) STR markers; (2) qPCR using primers and probes directed to loci, such as the multi-repeat DYZ locus on the Y-chromosome; (3) SNP detection; and (4) CGH (comparative genome hybridization) array detection.
- assays such as: (1) STR markers; (2) qPCR using primers and probes directed to loci, such as the multi-repeat DYZ locus on the Y-chromosome; (3) SNP detection; and (4) CGH (comparative genome hybridization) array detection.
- FIG. 23 illustrates assays that can produce information on the presence of aneuploidy and other genetic disorders in target cells
- Information on anueploidy and other genetic disorders in target cells may be acquired using technologies such as: (1) a CGH array established for chromosome counting, which can be used for aneuploidy determination and/or detection of intra-chromosomal deletions; (2) SNP/taqman assays, which can be used for detection of single nucleotide polymorphisms; and (3) ultra-deep sequencing, which can be used to produce partial or complete genome sequences for analysis.
- FIG. 24 illustrates methods of fetal diagnostic assays.
- Fetal cells are isolated by CSM-HE enrichment of target cells from blood.
- the designation of the fetal cells may be confirmed using techniques comprising FISH staining (using slides or membranes and optionally an automated detector), FACS, and/or binning.
- Binning may comprise distribution of enriched cells across wells in a plate (such as a 96 or 384 well plate), microencapsulation of cells in droplets that are separated in an emulsion, or by introduction of cells into microarrays of nanofluidic bins.
- Fetal cells are then identified using methods that may comprise the use of biomarkers (such as fetal (gamma) hemoglobin), allele-specific SNP panels that could detect fetal genome DNA, detection of differentially expressed maternal and fetal transcripts (such as Affymetrix chips), or primers and probes directed to fetal specific loci (such as the multi-repeat DYZ locus on the Y-chromosome).
- biomarkers such as fetal (gamma) hemoglobin
- allele-specific SNP panels that could detect fetal genome DNA, detection of differentially expressed maternal and fetal transcripts (such as Affymetrix chips), or primers and probes directed to fetal specific loci (such as the multi-repeat DYZ locus on the Y-chromosome).
- Binning sites that contain fetal cells are then be analyzed for aneuploidy and/or other genetic defects using a technique such as CGH array detection, ultra deep sequencing (such as Solexa, 454 or mass
- FIG. 25 illustrates methods of fetal diagnostic assays, further comprising the step of whole genome amplification prior to analysis of aneuploidy and/or other genetic defects.
- the present invention provides systems, apparatuses, and methods to detect the presence and condition (e.g. aneuploidy) of fetal cells in a mixed cell population, e.g. a sample wherein fetal cells consist of ⁇ 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or 0.5% of all cells in a mixed sample.
- a mixed cell population e.g. a sample wherein fetal cells consist of ⁇ 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or 0.5% of all cells in a mixed sample.
- FIG. 1 illustrates an overview of one embodiment of the present invention.
- a sample containing (or suspected of containing) 1 or more fetal cells is obtained.
- Samples can be obtained from an animal suspected of being pregnant, pregnant, or that has been pregnant to detect the presence of a fetus or fetal abnormality.
- Such animal can be a human or a domesticated animal such as a cow, chicken, pig, horse, rabbit, dog, cat, or goat.
- Samples derived from an animal or human can include, e.g., whole blood, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, lymph, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, secretions of the respiratory, intestinal or genitourinary tracts fluid.
- a blood sample can be optionally pre-treated or processed prior to enrichment.
- pre-treatment steps include the addition of a reagent such as a stabilizer, a preservative, a fixant, a lysing reagent, a diluent, an anti-apoptotic reagent, an anti-coagulation reagent, an anti-thrombotic reagent, magnetic property regulating reagent, a buffering reagent, an osmolality regulating reagent, a pH regulating reagent, and/or a cross-linking reagent.
- a reagent such as a stabilizer, a preservative, a fixant, a lysing reagent, a diluent, an anti-apoptotic reagent, an anti-coagulation reagent, an anti-thrombotic reagent, magnetic property regulating reagent, a buffering reagent, an osmolality regulating reagent, a pH regulating
- a preservative such an anti-coagulation agent and/or a stabilizer can be added to the sample prior to enrichment. This allows for extended time for analysis/detection.
- a sample such as a blood sample, can be enriched and/or analyzed under any of the methods and systems herein within 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hrs, 6 hrs, 3 hrs, 2 hrs, or 1 hr from the time the sample is obtained.
- a blood sample can be combined with an agent that selectively lysed one or more cells or components in a blood sample.
- fetal cells can be selectively lysed releasing their nuclei when a blood sample including fetal cells is combined with deionized water.
- Such selective lysis allows for the subsequent enrichment of fetal nuclei using, e.g., size or affinity based separation.
- platelets and/or enucleated red blood cells are selectively lysed to generate a sample enriched in nucleated cells, such as fetal nucleated red blood cells (fnRBC) and maternal nucleated blood cells (mnBC).
- fnRBC fetal nucleated red blood cells
- mnBC maternal nucleated blood cells
- the amount can vary depending upon animal size, its gestation period, and or the condition being screened. In some embodiments, up to 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mL of a sample is obtained. In some embodiments, 1-50, 2-40, 3-30, or 4-20 mL of sample is obtained. In some embodiments, more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mL of a sample is obtained.
- a blood sample can be obtained from a pregnant animal or human within 36, 24, 22, 20, 18, 16, 14, 12, 10, 8, 6 or 4 weeks of gestation.
- a reference sample is obtained.
- the reference sample consists of substantially all or all maternal cells.
- a reference sample is a maternal blood sample enriched for white blood cells (WBC's) such that it consists of substantially all or all maternal WBC's.
- WBC's white blood cells
- a reference sample is a diluted mixed sample wherein the dilution results in a sample free of fetal cells.
- a maternal blood sample of 10-50 ML can be diluted by at least 2, 5, 10, 20, 50, or 100 fold to reduce the likelihood that it will include fetal cells.
- step 102 when the sample to be tested or analyzed is a mixed sample (e.g. maternal blood sample), it is enriched for rare cells or rare DNA (e.g. fetal cells, fetal DNA or fetal nuclei) using one or more methods known in the art or disclosed herein. Such enrichment increases the ratio of fetal cells to non-fetal cells; the concentration of fetal DNA to non-fetal DNA; or the concentration of fetal cells in volume per total volume of the mixed sample.
- rare cells or rare DNA e.g. fetal cells, fetal DNA or fetal nuclei
- enrichment occurs by selective lysis as described above.
- enucleated cells may be selectively lysed prior to subsequent enrichment steps or fetal nucleated cells may be selectively lysed prior to separation of the fetal nuclei from other cells and components in the sample.
- size-based separation modules include filtration modules, sieves, matrixes, etc., including those disclosed in International Publication Nos, WO 2004/113877, WO 2004/0144651, and US Application Publication No. 2004/011956.
- a size-based separation module includes one or more arrays of obstacles that form a network of gaps.
- the obstacles are configured to direct particles (e.g. cells or nuclei) as they flow through the array/network of gaps into different directions or outlets based on the particle's hydrodynamic size.
- nucleated cells or cells having a hydrodynamic size larger than a critical size e.g., 8 microns
- a critical size e.g. 8 microns
- the enucleated cells or cells having a hydrodynamic size smaller than a critical size e.g., 8 microns
- a second outlet also located on the opposite side of the array of obstacles from the fluid flow inlet.
- An array can be configured to separate cells smaller than a critical size from those larger than the critical size by adjusting the size of the gaps, obstacles, and offset in the period between each successive row of obstacles.
- obstacles and/or gaps between obstacles can be up to 10, 20, 50, 70, 100, 120, 150, 170, or 200 microns in length or about 2, 4, 6, 8 or 10 microns in length.
- an array for size-based separation includes more than 100, 500, 1,000, 5,000, 10,000, 50,000 or 100,000 obstacles that are arranged into more than 10, 20, 50, 100, 200, 500, or 1000 rows.
- obstacles in a first row of obstacles are offset from a previous (upstream) row of obstacles by up to 50% of the period of the previous row of obstacles.
- obstacles in a first row of obstacles are offset from a previous row of obstacles by up to 45, 40, 35, 30, 25, 20, 15 or 10% the period of the previous row of obstacles.
- the distance between a first row of obstacles and a second row of obstacles can be up to 10, 20, 50, 70, 100, 120, 150, 170 or 200 microns.
- a particular offset can be continuous (repeating for multiple rows) or non-continuous.
- a separation module includes multiple discrete arrays of obstacles fluidly coupled such that they are in series with one another. Each array of obstacles has a continuous offset. But each subsequent (downstream) array of obstacles has an offset that is different from the previous (upstream) offset.
- each subsequent array of obstacles has a smaller offset that the previous array of obstacles.
- a plurality of arrays can be fluidly coupled in series or in parallel, (e.g., more than 2, 4, 6, 8, 10, 20, 30, 40, 50). Fluidly coupling separation modules (e.g., arrays) in parallel allows for high-throughput analysis of the sample, such that at least 1, 2, 5, 10, 20, 50, 100, 200, or 500 mL per hour flows through the enrichment modules or at least 1, 5, 10, or 50 million cells per hour are sorted or flow through the device.
- FIGS. 2A-2D illustrate one example of a size-based separation module.
- Obstacles (which may be of any shape) are coupled to a flat substrate to form an array of gaps.
- a transparent cover or lid may be used to cover the array.
- the obstacles form a two-dimensional array with each successive row shifted horizontally with respect to the previous row of obstacles, where the array of obstacles directs components having a hydrodynamic size smaller than a critical size in a first direction and components having a hydrodynamic size larger that a critical size in a second direction. See FIGS. 2B-2D .
- the flow of sample into the array of obstacles can be aligned at a small angle (flow angle) with respect to a line-of-sight of the array (lateral flow angle).
- the array is coupled to an infusion pump to perfuse the sample through the obstacles.
- the flow conditions of the size-based separation module described herein are such that cells are sorted by the array with minimal damage. This allows for downstream analysis of intact cells and intact nuclei to be more efficient and reliable.
- a size-based separation module comprises an array of obstacles configured to direct rare cells larger than a critical size to migrate along a line-of-sight within the array towards a first outlet or bypass channel leading to a first outlet, while directing cells and analytes smaller than a critical size through the array of obstacles in a different direction towards a second outlet.
- a variety of enrichment protocols may be utilized although gentle handling of the cells is preferred to reduce any mechanical damage to the cells or their DNA. This gentle handling also preserves the small number of fetal cells in the sample. Integrity of the nucleic acid being evaluated is an important feature in some embodiments to permit the distinction between the genomic material from the fetal cells and other cells in the sample.
- the enrichment and separation of the fetal cells using the arrays of obstacles produces gentle treatment which minimizes cellular damage and maximizes nucleic acid integrity permitting exceptional levels of separation and the ability to subsequently utilize various formats to very accurately analyze the genome of the cells which are present in the sample in extremely low numbers.
- enrichment of fetal cells occurs using one or more capture modules that selectively inhibit the mobility of one or more cells of interest.
- a capture module is fluidly coupled downstream to a size-based separation module.
- Capture modules can include a substrate having multiple obstacles that restrict the movement of cells or analytes greater than a critical size. Examples of capture modules that inhibit the migration of cells based on size are disclosed in U.S. Pat. Nos. 5,837,115 and 6,692,952.
- a capture module includes a two dimensional array of obstacles that selectively filters or captures cells or analytes having a hydrodynamic size greater than a particular gap size, e.g., critical sized.
- Arrays of obstacles adapted for separation by capture can include obstacles having one or more shapes and can be arranged in a uniform or non-uniform order.
- a two-dimensional array of obstacles is staggered such that each subsequent row of obstacles is offset from the previous row of obstacles to increase the number of interactions between the analytes being sorted (separated) and the obstacles.
- An affinity-based separation module capture analytes or cells of interest based on their affinity to a structure or particle as oppose to their size.
- An affinity-based separation module is an array of obstacles that are adapted for complete sample flow through, but for the fact that the obstacles are covered with binding moieties that selectively bind one or more analytes (e.g., cell population) of interest (e.g., red blood cells, fetal cells, or nucleated cells) or analytes not-of-interest (e.g., white blood cells).
- Binding moieties can include e.g., proteins (e.g., ligands/receptors), nucleic acids having complementary counterparts in retained analytes, antibodies, etc.
- an affinity-based separation module comprises a two-dimensional array of obstacles covered with one or more antibodies selected from the group consisting of: anti-CD71, anti-CD235a, anti-CD36, anti-carbohydrates, anti-selectin, anti-CD45, anti-GPA, and anti-antigen-i.
- FIG. 3A illustrates a path of a first analyte through an array of posts wherein an analyte that does not specifically bind to a post continues to migrate through the array, while an analyte that does bind a post is captured by the array.
- FIG. 3B is a picture of antibody coated posts.
- FIG. 3C illustrates one method of coupling of antibodies to a substrate (e.g., obstacles, side walls, etc.) as contemplated by the present invention. Examples of such affinity-based separation modules are described in International Publication No. WO 2004/029221 and U.S. application Ser. No. 10/529,453, both of which are incorporated by reference.
- a capture module utilizes a magnetic field to separate and/or enrich one or more analytes (cells) that has a magnetic property or magnetic potential.
- analytes cells
- red blood cells which are slightly diamagnetic (repelled by magnetic field) in physiological conditions can be made paramagnetic (attributed by magnetic field) by deoxygenation of the hemoglobin into methemoglobin.
- This magnetic property can be achieved through physical or chemical treatment of the red blood cells.
- a sample containing one or more red blood cells and one or more non-red blood cells can be enriched for the red blood cells by first inducing a magnetic property and then separating the above red blood cells from other analytes using a magnetic field (uniform or non-uniform).
- a maternal blood sample can flow first through a size-based separation module to remove enucleated cells and cellular components (e.g. analytes having a hydrodynamic size less than 6 ⁇ ms) based on size. Subsequently, the enriched nucleated cells (e.g., analytes having a hydrodynamic size greater than 6 ⁇ ms) white blood cells and nucleated red blood cells are treated with a reagent, such as CO 2 , N 2 or NaNO 2 , that changes the magnetic property of the red blood cells' hemoglobin.
- a reagent such as CO 2 , N 2 or NaNO 2
- the treated sample then flows through a magnetic field (e.g., a column coupled to an external magnet), such that the paramagnetic analytes (e.g., red blood cells) will be captured by the magnetic field while the white blood cells and any other non-red blood cells will flow through the device to result in a sample enriched in nucleated red blood cells (including fnRBC's).
- a magnetic field e.g., a column coupled to an external magnet
- Subsequent enrichment steps can be used to separate the rare cells (e.g. fnRBC's) from the non-rare maternal nucleated red blood cells (non-RBC's).
- a sample enriched by size-based separation followed by affinity/magnetic separation is further enriched for rare cells using fluorescence activated cell sorting (FACS) or selective lysis of a subset of the cells (e.g. fetal cells).
- FACS fluorescence activated cell sorting
- fetal cells are selectively bound to an anti-antigen i binding moiety (e.g. an antibody) to separate them from the mnRBC's.
- the antibody binds to a fetal cell ligand.
- the fetal cells are stimulated so as to induce expression of ligands which are targeted by an antibody.
- the fetal cells are lysed and the nuclei of the fetal cells are separated from other cellular components by binding them with an antibody.
- fetal cells are selectively bound to receptors which target fetal cell ligands.
- fetal cells are selectively bound to a lectin.
- fetal cells or fetal DNA is distinguished from non-fetal cells or non-fetal DNA by forcing the rare cells (fetal cells) to become apoptotic, thus condensing their nuclei and optionally ejecting their nuclei.
- Rare cells such as fetal cells can be forced into apoptosis using various means including subjecting the cells to hyperbaric pressure (e.g. 4% CO 2 ).
- the condensed nuclei can be detected and/or isolated for further analysis using any technique known in the art including DNA gel electrophoresis, in situ labeling of DNA nicks (terminal deoxynucleotidyl transferase (TdT))-mediated dUTP in situ nick labeling (also known as TUNEL) (Gavrieli, Y., et al., J.
- a magnetic particle e.g., a bead
- compound e.g., Fe 3+
- a bead coupled to an antibody that selectively binds to an analyte of interest can be decorated with an antibody elected from the group of anti CD71 or CD75.
- a magnetic compound, such as Fe 3+ can be couple to an antibody such as those described above.
- the magnetic particles or magnetic antibodies herein may be coupled to any one or more of the devices herein prior to contact with a sample or may be mixed with the sample prior to delivery of the sample to the device(s).
- Magnetic field used to separate analytes/cells in any of the embodiments herein can uniform or non-uniform as well as external or internal to the device(s) herein.
- An external magnetic field is one whose source is outside a device herein (e.g., container, channel, obstacles).
- An internal magnetic field is one whose source is within a device contemplated herein.
- An example of an internal magnetic field is one where magnetic particles may be attached to obstacles present in the device (or manipulated to create obstacles) to increase surface area for analytes to interact with to increase the likelihood of binding.
- Analytes captured by a magnetic field can be released by demagnetizing the magnetic regions retaining the magnetic particles. For selective release of analytes from regions, the demagnetization can be limited to selected obstacles or regions.
- the magnetic field can be designed to be electromagnetic, enabling turn-on and turn-off off the magnetic fields for each individual region or obstacle at will.
- FIG. 4 illustrates an embodiment of a device configured for capture and isolation of cells expressing the transferrin receptor from a complex mixture.
- Monoclonal antibodies to CD71 receptor are readily available off-the-shelf and can be covalently coupled to magnetic materials comprising any conventional ferroparticles, such as, but not limited to ferrous doped polystyrene and ferroparticles or ferro-colloids (e.g., from Miltenyi or Dynal).
- the anti CD71 bound to magnetic particles is flowed into the device.
- the antibody coated particles are drawn to the obstacles (e.g., posts), floor, and walls and are retained by the strength of the magnetic field interaction between the particles and the magnetic field.
- the particles between the obstacles and those loosely retained with the sphere of influence of the local magnetic fields away from the obstacles are removed by a rinse.
- One or more of the enrichment modules herein may be fluidly coupled in series or in parallel with one another.
- a first outlet from a separation module can be fluidly coupled to a capture module.
- the separation module and capture module are integrated such that a plurality of obstacles acts both to deflect certain analytes according to size and direct them in a path different than the direction of analyte(s) of interest, and also as a capture module to capture, retain, or bind certain analytes based on size, affinity, magnetism or other physical property.
- the enrichment steps performed have a specificity and/or sensitivity >50, 60, 70, 80, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 99.95%
- the retention rate of the enrichment module(s) herein is such that ⁇ 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.9% of the analytes or cells of interest (e.g., nucleated cells or nucleated red blood cells or nucleated from red blood cells) are retained.
- the enrichment modules are configured to remove ⁇ 50, 60, 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.9% of all unwanted analytes (e.g., red blood-platelet enriched cells) from a sample.
- unwanted analytes e.g., red blood-platelet enriched cells
- any or all of the enrichment steps can occur with minimal dilution of the sample.
- the analytes of interest are retained in an enriched solution that is less than 50, 40, 30, 20, 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, or 0.5 fold diluted from the original sample.
- any or all of the enrichment steps increase the concentration of the analyte of interest (fetal cell), for example, by transferring them from the fluid sample to an enriched fluid sample (sometimes in a new fluid medium, such as a buffer).
- the new concentration of the analyte of interest may be at least 2, 4, 6, 8, 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 2,000,000, 5,000,000, 10,000,000, 20,000,000, 50,000,000, 100,000,000, 200,000,000, 500,000,000, 1,000,000,000, 2,000,000,000, or 5,000,000,000 fold more concentrated than in the original samples.
- a 10 times concentration increase of a first cell type out of a blood sample means that the ratio of first cell type/all cells in a sample is 10 times greater after the sample was applied to the apparatus herein.
- Such concentration can take a fluid sample (e.g., a blood sample) of greater than 10, 15, 20, 50, or 100 mL total volume comprising rare components of interest, and it can concentrate such rare component of interest into a concentrated solution of less than 0.5, 1, 2, 3, 5, or 10 mL total volume.
- a fluid sample e.g., a blood sample
- concentration can take a fluid sample (e.g., a blood sample) of greater than 10, 15, 20, 50, or 100 mL total volume comprising rare components of interest, and it can concentrate such rare component of interest into a concentrated solution of less than 0.5, 1, 2, 3, 5, or 10 mL total volume.
- the final concentration of fetal cells in relation to non-fetal cells after enrichment can be about 1/10,000-1/10, or 1/1,000-1/100.
- the concentration of fetal cells to maternal cells may be up to 1/1,000-1/100, or 1/10 or as low as 1/100, 1/1,000 or 1/10,000.
- fetal cells are at a concentration of less than 1:2, 1:4, 1:10, 1:50, 1:100, 1:1000, 1:10,000, 1:100,000, 1,000,000, 1:10,000,000 or 1:100,000,000 of all cells in a mixed sample to be analyzed or at a concentration of less than 1 ⁇ 10 ⁇ 3 , 1 ⁇ 10 ⁇ 4 , 1 ⁇ 10, 1 ⁇ 10 ⁇ 6 , or 1 ⁇ 10 ⁇ 6 cells/ ⁇ L of the mixed sample.
- the number of fetal cells in a mixed sample (e.g. enriched sample) has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 100 total fetal cells.
- Enriched target cells may be “binned” prior to further analysis of the enriched cells ( FIGS. 24 and 25 ).
- Binning is any process which results in the reduction of complexity and/or total cell number of the enriched cell output.
- Binning may be performed by any method known in the art or described herein.
- One method of binning is by serial dilution. Such dilution may be carried out using any appropriate platform (e.g., PCR wells, microtiter plates) and appropriate buffers.
- Other methods include nanofluidic systems which can separate samples into droplets (e.g., BioTrove, Raindance, Fluidigm). Such nanofluidic systems may result in the presence of a single cell present in a nanodroplet.
- Binning may be preceded by positive selection for target cells including, hut not limited to, affinity binding (e.g. using anti-CD71 antibodies). Alternately, negative selection of non-target cells may precede binning.
- output from a size-based separation module may be passed through a magnetic hemoglobin enrichment module (MHEM) which selectively removes WBCs from the enriched sample by attracting magnetized hemoglobin-containing cells.
- MHEM magnetic hemoglobin enrichment module
- the possible cellular content of output from enriched maternal blood which has been passed through a size-based separation module may consist of: 1) approximately 20 fnRBC; 2) 1,500 nmRBC; 3) 4,000-40,000 WBC; 4) 15 ⁇ 10 6 RBC. If this sample is separated into 100 bins (PCR wells or other acceptable binning platform), each bin would be expected to contain: 1) 80 negative bins and 20 bins positive for one fnRBC; 2) 150 nmRBC; 3) 400-4,000 WBC; 4) 15 ⁇ 10 4 RBC.
- each bin would be expected to contain: 1) 9,980 negative bins and 20 bins positive for one fnRBC; 2) 8,500 negative bins and 1,500 bins positive for one mnC; 3) ⁇ 1-4 WBC; 4) 15 ⁇ 10 2 RBC.
- the number of bins may be increased or decreased depending on experimental design and/or the platform used for binning. Reduced complexity of the binned cell populations may facilitate further genetic and/or cellular analysis of the target cells by reducing the number of non-target cells in an individual bin.
- Analysis may be performed on individual bins to confirm the presence of target cells (e.g. fnRBC) in the individual bin.
- target cells e.g. fnRBC
- Such analysis may consist of any method known in the art including, but not limited to, FISH, PCR, STR detection, SNP analysis, biomarker detection, and sequence analysis ( FIGS. 24 and 25 ).
- fetal biomarkers may be used to detect and/or isolate fetal cells, after enrichment or after detection of fetal abnormality or lack thereof. For example, this may be performed by distinguishing between fetal and maternal nRBCs based on relative expression of a gene (e.g., DYS1, DYZ, CD-71, ⁇ - and ⁇ -globin) that is differentially expressed during fetal development.
- biomarker genes are differentially expressed in the first and/or second trimester.
- “Differentially expressed,” as applied to nucleotide sequences or polypeptide sequences in a cell or cell nuclei, refers to differences in over/under-expression of that sequence when compared to the level of expression of the same sequence in another sample, a control or a reference sample.
- expression differences can be temporal and/or cell-specific.
- differential expression of one or more biomarkers in the cell(s) of interest can be higher or lower relative to background cell populations. Detection of such difference in expression of the biomarker may indicate the presence of a rare cell (e.g., fnRBC) versus other cells in a mixed sample (e.g., background cell populations).
- a ratio of two or more such biomarkers that are differentially expressed can be measured and used to detect rare cells.
- fetal biomarkers comprise differentially expressed hemoglobins.
- Erythroblasts nRBCs
- nRBCs Erythroblasts
- trophoblast cells fetal erythroblasts are not prone to mosaic characteristics.
- Yolk sac erythroblasts synthesize ⁇ -, ⁇ -, ⁇ - and ⁇ -globins, these combine to form the embryonic hemoglobins.
- the primary site of erythropoiesis shifts from the yolk sac to the liver, the three embryonic hemoglobins are replaced by fetal hemoglobin (HbF) as the predominant oxygen transport system, and ⁇ - and ⁇ -globin production gives way to ⁇ -, ⁇ - and ⁇ -globin production within definitive erythrocytes (Peschle et al., 1985).
- HbF remains the principal hemoglobin until birth, when the second globin switch occurs and ⁇ -globin production accelerates.
- Hemoglobin (Hb) is a heterodimer composed of two identical ⁇ globin chains and two copies of a second globin. Due to differential gene expression during fetal development, the composition of the second chain changes from c globin during early embryonic development (1 to 4 weeks of gestation) to ⁇ globin during fetal development (6 to 8 weeks of gestation) to ⁇ globin in neonates and adults as illustrated in (Table 1). TABLE 1 Relative expression of ⁇ , ⁇ and ⁇ in maternal and fetal RBCs. ⁇ ⁇ B 1 st trimester Fetal ++ ++ ⁇ Maternal ⁇ +/ ⁇ ++ 2 nd trimester Fetal ⁇ ++ +/ ⁇ Maternal ⁇ +/ ⁇ ++
- fnRBCs In the late-first trimester, the earliest time that fetal cells may be sampled by CVS, fnRBCs contain, in addition to ⁇ globin, primarily ⁇ and ⁇ globin. In the early to mid second trimester, when amniocentesis is typically performed, fnRBCs contain primarily ⁇ globin with some adult is globin. Maternal cells contain almost exclusively ⁇ and ⁇ globin, with traces of ⁇ detectable in some samples. Therefore, by measuring the relative expression of the ⁇ , ⁇ and ⁇ genes in RBCs purified from maternal blood samples, the presence of fetal cells in the sample can be determined. Furthermore, positive controls can be utilized to assess failure of the FISH analysis itself.
- fetal cells are distinguished from maternal cells based on the differential expression of hemoglobins ⁇ , ⁇ or ⁇ .
- Expression levels or RNA levels can be determined in the cytoplasm or in the nucleus of cells.
- the methods herein involve determining levels of messenger RNA (in RNA), ribosomal RNA (rRNA), or nuclear RNA (nRNA).
- identification of fnRBCs can be achieved by measuring the levels of at least two hemoglobins in the cytoplasm or nucleus of a cell.
- identification and assay is from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 fetal nuclei.
- total nuclei arrayed on one or more slides can number from about 100, 200, 300, 400, 500, 700, 800, 5000, 10,000, 100,000, 1,000,000, 2,000,000 to about 3,000,000.
- a ratio for ⁇ / ⁇ or ⁇ / ⁇ is used to determine the presence of fetal cells, where a number less than one indicates that a fnRBC(s) is not present.
- the relative expression of ⁇ / ⁇ or ⁇ / ⁇ provides a fnRBC index (“FNI”), as measured by ⁇ or ⁇ relative to ⁇ .
- FNI fnRBC index
- a FNI for ⁇ / ⁇ greater than 5, 10, 15, 20, 25, 30, 35, 40, 45, 90, 180, 360, 720, 975, 1020, 1024, 1250 to about 1250 indicate that a fnRBC(s) is present.
- a FNI for ⁇ / ⁇ of less than about 1 indicates that a fnRBC(s) is not present.
- the above FNI is determined from a sample obtained during a first trimester, However, similar ratios can be used during second trimester and third trimester.
- the expression levels are determined by measuring nuclear RNA transcripts including, nascent or unprocessed transcripts. In another embodiment, expression levels are determined by measuring mRNA, including ribosomal RNA. There are many methods known in the art for imaging (e.g., measuring) nucleic acids or RNA including, but not limited to, using expression arrays from Affymetrix, Inc. or Illumina, Inc.
- RT-PCR primers can be designed by targeting the globin variable regions, selecting the amplicon size, and adjusting the primers annealing temperature to achieve equal PCR amplification efficiency.
- TaqMan probes can be designed for each of the amplicons with well-separated fluorescent dyes, Alexa Fluor®-355 for ⁇ , Alexa Fluor®-488 for A, and Alexa Fluor-555 for ⁇ .
- the specificity of these primers can be first verified using ⁇ , ⁇ , and ⁇ cDNA as templates.
- the primer sets that give the best specificity can be selected for further assay development.
- the primers can be selected from two exons spanning an intron sequence to amplify only the mRNA to eliminate the genomic DNA contamination.
- the primers selected can be tested first in a duplex format to verify their specificity, limit of detection, and amplification efficiency using target cDNA templates.
- the best combinations of primers can be further tested in a triplex format for its amplification efficiency, detection dynamic range, and limit of detection.
- RT-PCR RNA containing RNA sequences
- reagents such as One-step RT-PCR reagents, including Qiagen One-Step RT-PCR Kit and Applied Biosystems TaqMan One-Step RT-PCR Master Mix Reagents kit.
- Such reagents can be used to establish the expression ratio of ⁇ , ⁇ and ⁇ using purified RNA from enriched samples.
- Forward primers can be labeled for each of the targets, using Alexa fluor-355 for ⁇ , Alexa fluor-488 for ⁇ , and Alexa fluor-555 for ⁇ .
- Enriched cells can be deposited by cytospinning onto glass slides. Additionally, cytospinning the enriched cells can be performed after in situ RT-PCR.
- the reverse transcription time and PCR cycles can be optimized to maximize the amplicon signal:background ratio to have maximal separation of fetal over maternal signature.
- signal:background ratio is greater than 5, 10, 50 or 100 and the overall cell loss during the process is less than 50, 10 or 5%.
- the detection and analysis steps may involve quantifying genomic DNA regions from cells in a sample or enriched sample.
- the quantified genomic DNA regions are polymorphic sites such as short tandem repeats (STRs) or variable number of tandem repeats (VNTRs).
- step 103 polymorphic genomic DNA region(s) or whole genome(s) from the mixed sample and optionally reference sample are pre-amplified to increase the overall abundance of DNA used for quantification and analysis.
- Pre-amplification can be preformed using multiple displacement amplification (MDA) (Gonzalez et al. Envircon Microbiol; 7(7); 1024-S (2005)) or amplification with outer primers in a nested PCR approach. This permits detection and analysis of fetal DNA even if the total amount of fetal DNA in the mixed (e.g.
- MDA multiple displacement amplification
- enriched) sample is only up to 1 ⁇ g, 500 ng, 200 ng, 100 ng, 50 ng, 40 ng, 30 ng, 20 ng, 10 ng, 5 ng, 1 ng, 500 pg, 200 pg, 100 pg, 50 pg, 40 pg, 30 pg, 20 p, 10 pg, 5 pg, or 1 pg or between 1-5 ⁇ g, 5-10 ⁇ g, or 10-50 ⁇ g.
- Pre-amplification allows the products to be split into multiple reactions at the next step.
- polymorphic DNA region(s) such as short tandem repeats (STRs) or variable number of tandem repeats (VNTRs) are selected on suspected trisomic chromosome(s) (e.g., 13, 18, 21, X or Y) or chromosome(s) associated with a condition to be detected and optionally on control (non-trisomic) chromosomes.
- STRs short tandem repeats
- VNTRs variable number of tandem repeats
- STRs loci are selected for high heterozygosity (variety of alleles) so that the paternal allele of the fetal cells is more likely to be distinct in length from the maternal alleles. This results in an improved power to detect the presence of fetal cells in the mixed sample and potential fetal abnormalities in such cells.
- the polymorphic regions selected are STR loci, di-, tri-, tetra- or penta-nucleotide repeat loci can be used for detection and analysis of fetal cells.
- STR loci examples include: D21 S1414, D21 S1411, D21S1412, D21S11 MBP, D13S634, D13S631, D18S535, AmgXY, XHPRT, as well as those listed in FIG. 12 .
- the methods of the invention allow for the determination of maternal or paternal trisomy.
- the polymorphic loci selected are amplified. This can be used to detect non-maternal fetal alleles in the mixed sample and to determine the copy number of such alleles.
- primers are selected to be multiplexable (fairly uniform melting temperature, absence of cross-priming on the human genome, and absence of primer-primer interaction based on sequence analysis) with other primer pairs. Primers and loci are chosen so that the amplicon lengths from a given locus do not overlap with those from another locus.
- multiple dyes and multi-color fluorescence readout may be used to increase the multiplexing capacity, e.g. of a single CGE. This ensures that the loci are kept distinct in the readout (e.g. CGE readout).
- PCR primer pairs can be grouped and the same end-labeling is applied to the members of a group.
- PCR techniques that can be used to amplify the DNA regions herein include, but are not limited, to quantitative PCR, quantitative fluorescent PCR (QF-PCR), multiplex fluorescent PCR (MF-PCR), real time PCR (RT-PCR), single cell PCR, restriction fragment length polymorphism PCR(PCR-RELP), PCR-RFLP/RT-PCR-RFLP, hot start PCR, nested PCR, in situ polonony PCR, in situ rolling circle amplification (RCA), bridge PCR, picotiter PCR and emulsion PCR.
- QF-PCR quantitative fluorescent PCR
- MF-PCR multiplex fluorescent PCR
- RT-PCR real time PCR
- single cell PCR single cell PCR
- restriction fragment length polymorphism PCR(PCR-RELP) PCR-RFLP/RT-PCR-RFLP
- hot start PCR nested PCR
- in situ polonony PCR in situ rolling circle amplification (RCA)
- RCA in situ rolling circle amplification
- LCR ligase chain reaction
- transcription amplification self-sustained sequence replication
- selective amplification of target polynucleotide sequences consensus sequence primed polymerase chain reaction (CP-PCR), arbitrarily primed polymerase chain reaction (AP-PCR), degenerate oligonucleotide-primed PCR (DOP-PCR) and nucleic acid based sequence amplification (NABSA).
- CP-PCR consensus sequence primed polymerase chain reaction
- AP-PCR arbitrarily primed polymerase chain reaction
- DOP-PCR degenerate oligonucleotide-primed PCR
- NABSA nucleic acid based sequence amplification
- Other amplification methods that may be used to amplify specific polymorphic loci include those described in, U.S. Pat. Nos. 5,242,794, 5,494,810, 4,988,617 and 6,582,938.
- the amplified DNA polymorphic regions (e.g. STR loci) from both mixed and reference samples are characterized and quantified using any method known in the art.
- methods include, but are not limited to, gas chromatography, supercritical fluid chromatography, liquid chromatography, including partition chromatography, adsorption chromatography, ion exchange chromatography, size-exclusion chromatography, thin-layer chromatography, and affinity chromatography, electrophoresis, including capillary electrophoresis, capillary zone electrophoresis, capillary isoelectric focusing, capillary electrochromatography, micellar electrokinetic capillary chromatography, isotachophoresis, transient isotachophoresis and capillary gel electrophoresis, comparative genomic hybridization (CGH), microarrays, bead arrays, high-throughput genotyping technology, such as molecular inversion probe (MIP), and Genescan.
- CGH comparative genomic hybridization
- microarrays bea
- capillary gel electrophoresis is used to quantify STRs in both the mixed and reference samples. This can be used to detect non-maternal fetal alleles in the mixed sample and to determine the copy number of such alleles.
- the mixed sample and the reference sample can be analyzed in separate reactions, e.g. separate CGE lanes.
- the mixed and the reference sample can be run in the same reaction, e.g. same CGE lane, by using two different dye labels, e.g. differently labeled PCR primers.
- the alleles show up as peaks in the CGE.
- each trace typically will need to undergo a length transformation, such as a low-order (cubic or quartic) polynomial transformation, in order to map to the data from the trace corresponding to the previous amplification point.
- This mapping can be determined by adjusting the transformation parameters to achieve the best fit of the one data trace to the other, with both normalized to the same total sum of squares or summed peak heights.
- the maternal peaks at each locus provide an estimate of the secondary ‘stutter’ structure at each locus due to PCR errors.
- the locations of these small secondary peaks can be used to blank out length regions that are contaminated by this stutter when looking for and using the non-maternal allele peaks (as described herein for example).
- more sophisticated ‘decouvolution’ algorithms can be applied to remove the stutter Stoughton, et al., Electrophoresis; 18(1): 1-S (1997).
- the sample containing an unknown mixture of fetal and maternal cells is analyzed as in Step (b). This could be done in a separate CGE lane, or in the same CGE lane as the maternal sample by using two different dye labels on the PCR primers. Because each CGE trace has a slightly different relation between DNA fragment size (and sequence) and mobility, these data typically will need to undergo a length transformation, such as a low-order (cubic or quartic) polynomial transformation in order to map one trace onto the other to facilitate peak identification and model fitting. This mapping can be determined by adjusting the transformation parameters to achieve the best fit of the peak locations in one data trace to the other. This mapping will be well determined in the assumed situation where the maternal cells are more numerous than the fetal cells, because the maternal signature will dominate and will be shared in the two data sets.
- a length transformation such as a low-order (cubic or quartic) polynomial transformation
- FIG. 5 illustrates typical locus patterns arising from a normal (diploid) fetus and mother.
- the paternal allele is the same as the left hand maternal allele, and adds to its apparent height.
- the paternal allele has a length between the lengths of the maternal alleles.
- the maternal sample is homozygous leading to only one main peak, and the paternal allele is distinct from this allele.
- FIG. 6 illustrates locus patterns arising from trisomic fetal cells.
- the dashed trace represents mixed sample containing trisomic fetal cells, superposed on material sample trace (solid black).
- Trisomy causes excess amplitude in maternal alleles at loci contained within the aneuploid region (here assumed to contain Loci 1 and 2 but not Locus 3).
- the left hand maternal peak at Locus 1 contains contributions from the trisomy and from a paternal allele.
- step 107 data models are constructed. From the data obtained from the quantifying step different data models can be constructed depending upon different assumptions.
- a data model for the CGE patterns in FIGS. 5 and 6 can be as follows:
- data and data model is represented as discrete peak masses (or heights) and peak locations or as vectors of values representing the actual peak profiles.
- the ‘addition’ operation in Equations 1-3 denotes summation of peak height or mass at the discrete allele location.
- summation denotes summation of signals bin by bin over the CGE trace, and in this case it may be helpful to zero the data except in the immediate vicinity of actual peaks. Representation via peak characteristics is preferable when using the PCR linearization technique described above.
- the differences between the structure of the ⁇ -term that appears in the first and second equations above is determined.
- the first case there is an additional contribution to both maternal alleles along with the paternal allele
- the second case there is an additional contribution only to one of the maternal alleles along with the paternal allele.
- the essence of the presence/absence declaration for fetal cells lies in the evidence for ⁇ being greater than zero.
- step 108 the best overall fit of model to data is selected from among all the model sets.
- This modeling approach optimally uses information contained in the increase of chromosome copy number with aneuploidy and its association with the strength of non-maternal alleles.
- CGE signals representing m1 and m2 at each locus are obtained by profiling the maternal-only sample and mapping the peak locations to the corresponding ones of the mixed sample.
- the heights of m1 and m2 may be unequal, and this helps cortect for PCR amplification biases associated with particular alleles.
- the values of p, p1, p2, ⁇ , and ⁇ are determined from the mixed sample data by fitting Equations 1-3 to the data, optionally by using the least squares, or the maximum likelihood methods.
- Segmental aneuploidies also could be tested by hypothesizing that different contiguous subsets of loci are contained within the aneuploid region.
- ⁇ and ⁇ have to be determined and the parameters describing the paternal alleles have to be determined at each locus for each model variant.
- the paternal allele peak height and shape can be assumed to be an average of the known maternal ones at that locus, while the paternal allele location needs to be fit to the data.
- the possible locations for the paternal allele will be the location of m1, the location of m2, and ‘elsewhere in the locus window’ where this latter possibility involves a search over discrete shifts smaller than a typical peak half-width at half maximum.
- Prior probabilities on the choices of p, taken from population allele frequency data, can be used, if their product lengths can be predicted.
- suboptimal searches can be used for computational efficiency.
- one possible approach involves iterative methods, such as the following, which would be applied to each data model variant.
- step 109 the presence or absence of fetal DNA is determined using the models described above.
- the best overall fit for such models yields the values of ⁇ , ⁇ that can be called ⁇ max , ⁇ max .
- the ratio is a measure of the amount of evidence for fetal DNA.
- a threshold for declaring fetal DNA is the likelihood ratio of approximately 1000 or more.
- the likelihood calculation can be approximated by a Chi-squared calculation involving the sum of squared residuals between the data and the model, where each residual is normalized by the expected rms error.
- the test is declared to be non-informative. If it is decided that fetal DNA is present in the mixed sample, then the likelihoods of the data given the different data model types can be compared to declare trisomy or another condition.
- step 110 the likelihood ratios of trisomy models (Equations 1 and 3) to the normal model (Equation 2) are calculated and these ratios are compared to a predefined threshold.
- This threshold can be set so that in controlled tests all the trisomic cases are declared aneuploid, and so that it is expected that the vast majority (>99.9%) of all truly trisomic cases are declared aneuploid by the test.
- the likelihood ratio threshold is increased beyond what is necessary to declare all the known trisomic cases in the validation set by a factor of 1000/N, where N is the number of trisomy cases in the validation set.
- step 111 errors that may arise from the experimental procedure used to obtain the data can be taken into account in the model calculation(s).
- CGE data contain small additive errors associated with CGE readout and larger multiplicative errors associated with PCR amplification efficiencies being different from locus to locus and from allele to allele within a locus.
- the maternal-only data to define m1 and m2 peak characteristics at each locus, the effects of PCR amplification biases associated with different primers and different amplicons from the same primers have been mostly controlled. Nevertheless, small variations in the process from day to day and the statistics of small numbers of starting genome copies will cause some random errors to remain.
- the presence of fetal cells in a mixed sample and fetal abnormalities in said cells is determined without trying to integrate them in a data-model fitting procedure described above.
- steps 100 - 107 can be performed as described above.
- analysis using Equations 1 and 2 focuses on two indications.
- aneuploidy results in an excess of DNA for the trisomic chromosome, and this is indicated by the difference in mean strengths of the alleles on the trisomic chromosome compared to control chromosomes.
- a t-test can be applied to the two distributions of m1 and m2 peak heights.
- Equations 1 and 2 show that aneuploidy is associated with less inequality in the heights of m1 and m2 at a given locus, particularly for loci where the paternal allele is distinct from the maternal alleles, Loci are selected where a third (paternal) allele is visibly distinct from two maternal alleles, and the distribution of the inequalities (measured in %) between the m1 and m2 peaks are compared between suspected trisomy chromosomes and control chromosomes.
- peak heights first are normalized by the maternal-only sample. These two lines of evidence are combined to create an overall likelihood, such as by multiplying the probability values from the two lines of evidence.
- the presence/absence call is done in a simplified way by looking for loci where a third allele is clearly visible, and comparing the distribution of these peak heights between the maternal and mixed samples. Again, a t-test between these distributions gives the probability of fetal DNA being present.
- the methods herein only determine presence or absence of fetal DNA, and aneuploidy information is known from another sources (e.g. fluorescence in situ hybridization (FISH) assay).
- FISH fluorescence in situ hybridization
- FISH fluorescence in situ hybridization
- the process may be simplified by focusing on detecting the presence of non-maternal alleles without regard to associating them with increases in the maternal allele strengths at the same locus.
- a process similar to the one outlined above may be used but it is not as necessary to arrange the PCR product lengths so that the products from different loci have distinct length windows in the CGE readout.
- the alleles from the different loci can be allowed to fall essentially anywhere in the effective measurement length window of the CGE. It also is not necessary to ‘lineate’ the PCR result(s) via multiple CGE readouts at different stages in the PCR cycling as is suggested in step 107 .
- maternal-only and mixed samples are run and mapped to each other to align maternal allele peak locations, as described above.
- PCR is run to saturation, or nearly to saturation, to be sure to detect the low abundance fetal sequences.
- the evidence for fetal DNA then arises from extra peaks in the mixed-sample data with respect to the maternal-sample data.
- the chance of not seeing a distinct paternal allele (distinct from both maternal alleles) when fetal DNA is in fact present decreases approximately as (0.7 2 ) N , where N is the number of loci included.
- N is the number of loci included.
- the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case.
- the present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample. In some embodiments, one or more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 DNA polymorphism loci (particularly STRs) per target chromosome are analyzed to verify presence of fetal cells.
- any of the steps above can be performed by a computer program product that comprises a computer executable logic that is recorded on a computer readable medium.
- the computer program can execute some or all of the following functions: (i) controlling enrichment of fetal cells or DNA from mixed sample and reference sample, (ii) pre-amplifying DNA from both samples, (iii) amplifying specific polymorphic DNA regions from both samples, (iv) identifying and quantifying maternal alleles in the reference sample, (v) identifying maternal and non-maternal alleles in the mixed sample, (vi) fitting data on alleles detected from mixed and/or reference samples into data models, (vii) determining the presence or absence of fetal cells in the mixed sample, (viii) declaring nodal or abnormal phenotype for a fetus based on data models or declaring non-informative results, and (ix) declaring a specific fetal abnormality based on the above results.
- the computer executable logic can fit data on the quantity of DNA polymorphism(s) (e.g. STR's) into one or more data models.
- a data model provides a determination of a fetal abnormality from given data signals obtained by molecular analysis e.g. CGE.
- the computer executable logic provides for a determination of the presence or absence of a trisomy, and distinguish whether the trisomy is paternally derived or if it originates from a maternal non-disjunction event. For example, given the following data signals that can be obtained by molecular analysis (e.g. CGE)
- m1 which represents a signal obtained from one of the maternal alleles (m1) at a given locus
- p1 and p2 which are signals obtained from the paternal alleles at one given locus when a paternally derived trisomy occurs
- the computer executable logic can work in any computer that may be any of a variety of types of general-purpose computers such as a personal computer, network server, workstation, or other computer platform now or later developed.
- a computer program product is described comprising a computer usable medium having the computer executable logic (computer software program, including program code) stored therein.
- the computer executable logic can be executed by a processor, causing the processor to perform functions described herein.
- some functions are implemented primarily in hardware using, for example, a hardware state machine. Implementation of the hardware state machine so as to perform the functions described herein will be apparent to those skilled in the relevant arts.
- the program can provide a method of evaluating the presence or absence of trisomy in a mixed cell sample by accessing data that reflects the level of polymorphism(s) at two alleles at two or more given loci in a mixed sample (maternal and fetal cells) and in a sample enriched in fetal cells, relating the levels of polymorphism(s) to the number of maternal and fetal cells ( ⁇ and ⁇ in equations 1-3), and determining the presence or absence of trisomy in the samples.
- the computer executing the computer logic of the invention may also include a digital input device such as a scanner.
- the digital input device can provide information on the polymorphism levels/quantity.
- a scanner of this invention can provide an image of the DNA polymorphism (particularly STRs) according to method herein.
- a scanner can provide an image by detecting fluorescent, radioactive, or other emission; by detecting transmitted, reflected, or scattered radiation, by detecting electromagnetic properties or other characteristics; or by other techniques.
- the data detected is typically stored in a memory device in the form of a data file.
- a scanner may identify one or more labeled targets.
- a first DNA polymorphism may be labeled with a first dye that fluoresces at a particular characteristic frequency, or narrow band of frequencies, in response to an excitation source of a particular frequency.
- a second DNA polymorphism may be labeled with a second dye that fluoresces at a different characteristic frequency.
- the excitation sources for the second dye may, but need not, have a different excitation frequency than the source that excites the first dye, e.g., the excitation sources could be the same, or different, lasers.
- kits containing the devices and reagents for performing the enrichment and genetic analysis may include the materials for any individual step disclosed, any combination of devices and reagents or the devices and reagents for performing all of the steps.
- a kit may include the arrays for size-based enrichment, the device for magnetic separation of the cells and reagents for performing PCR or CGE.
- the reagents for performing multiple displacement amplification may be included. This is an exemplary kit and the kits can be constructed using any combination of disclosed materials and devices.
- the use of the size-based enrichment provides gentle handling that is particularly advantageous for permitting subsequent genetic analysis.
- FIGS. 7A-7D illustrates a schematic of the device used to separate nucleated cells from fetal cord blood.
- the arrays and channels were fabricated in silicon using standard photolithography and deep silicon reactive etching techniques. The etch depth is 140 ⁇ m. Through holes for fluid access are made using KOH wet etching. The silicon substrate was sealed on the etched face to form enclosed fluidic channels using a blood compatible pressure sensitive adhesive (9795, 3M, St Paul, Minn.).
- the device was mechanically mated to a plastic manifold with external fluidic reservoirs to deliver blood and buffer to the device and extract the generated fractions.
- An external pressure source was used to apply a pressure of 2.0 PSI to the buffer and blood reservoirs to modulate fluidic delivery and extraction from the packaged device.
- Nucleated cells from the blood were separated from enucleated cells (red blood cells and platelets), and plasma delivered into a buffer stream of calcium and magnesium-free Dulbecco's Phosphate Buffered Saline (14190-144, Invitrogen, Carlsbad, Calif.) containing 1% Bovine Serum Albumin (BSA) (A8412-100 ML, Sigma-Aldrich, St Louis, Mo.) and 2 mM EDTA (15575-020, Invitrogen, Carlsbad, Calif.).
- BSA Bovine Serum Albumin
- FIG. 8A-8B Cell smears of the product and waste fractions ( FIG. 8A-8B ) were prepared and stained with modified Wright-Giemsa (WG16, Sigma Aldrich, St. Louis, Mo.).
- Example 1 The device and process described in detail in Example 1 were used in combination with immunomagnetic affinity enrichment techniques to demonstrate the feasibility of isolating fetal cells from maternal blood.
- Nucleated cells from the blood were separated from enucleated cells (red blood cells and platelets), and plasma delivered into a buffer stream of calcium and magnesium-free Dulbecco's Phosphate Buffered Saline (14190-144, Invitrogen, Carlsbad, Calif.) containing 1% Bovine Serum Albumin (BSA) (A8412-100 mL, Sigma-Aldrich, St Louis, Mo.).
- BSA Bovine Serum Albumin
- the nucleated cell fraction was labeled with anti-CD71 microbeads (130-046-201, Miltenyi Biotech Inc., Auburn, Calif.) and enriched using the MiniMACSTM MS column (130-042-201, Miltenyi Biotech Inc., Auburn, Calif.) according to the manufacturer's specifications. Finally, the CD71-positive fraction was spotted onto glass slides.
- Measurement techniques Spotted slides were stained using fluorescence in situ hybridization (FISH) techniques according to the manufacturer's specifications using Vysis probes (Abbott Laboratories, Downer's Grove, Ill.). Samples were stained from the presence of X and Y chromosomes. In one case, a sample prepared from a known Trisomy 21 pregnancy was also stained for chromosome 21.
- FISH fluorescence in situ hybridization
- enriched fnRBC are binned by dividing the sample into 100 PCR wells. Prior to binning, enriched samples may be screened by FISH to determine the presence of any fnRBC containing an aneuploidy of interest. Because of the low number of fnRBC in maternal blood, only a portion of the wells will contain a single fnRBC (the other wells are expected to be negative for fnRBC).
- the cells are fixed in 2% Paraformaldehyde and stored at 4° C. Cells in each bin are pelleted and resuspended in 5 ⁇ l PBS plus 1 ⁇ l 20 mg/ml Proteinase K (Sigma #P-2308). Cells are lysed by incubation at 65° C. for 60 minutes followed by inactivation of the Proteinase K by incubation for 15 minutes at 95° C.
- primer sets (DYZ forward primer TCGAGTGCAATTCCATTCCG; DYZ reverse primer ATGGAATGGCATCAAACGGAA; and DYZ Taqman Probe 6FAM-TGGCTGTCCATTCCA-MGBNFQ), TaqMan Universal PCR master mix, No AmpErase and water are added.
- the samples are run and analysis is performed on an ABI 7300: 2 minutes at 50° C., 10 minutes 95° C. followed by 40 cycles of 95° C. (15 seconds) and 60° C. (1 minute).
- further analysis of bins containing fnRBC is performed. Positive bins may be pooled prior to further analysis.
- FIG. 20 shows the results expected from such an experiment.
- the data in FIG. 20 was collected by the following protocol. Nucleated red blood cells were enriched from cord cell blood of a male fetus by sucrose gradient two Heme Extractions (HE). The cells were fixed in 2% paraformaldehyde and stored at 4° C. Approximately 10 ⁇ 1000 cells were pelleted and resuspended each in 5 ⁇ l PBS plus 1 ⁇ l 20 mg/ml Proteinase K (Sigma #P-2308). Cells were lysed by incubation at 65° C. for 60 minutes followed by a inactivation of the Proteinase K by 15 minute at 95° C.
- HE Heme Extractions
- Maternal blood is processed through a size-based separation module, with or without subsequent MHEM enhancement of fnRBCs.
- the enhanced sample is then subjected to FISH analysis using probes specific to the aneuploidy of interest (e.g., triploidy 13, triploidy 18, and XYY).
- Individual positive cells are isolated by “plucking” individual positive cells from the enhanced sample using standard micromanipulation techniques.
- STR marker sets are amplified and analyzed to confirm that the FISH-positive aneuploid cell(s) are of fetal origin. For this analysis, comparison to the maternal genotype is typical.
- Table 2 An example of a potential resulting data set is shown in Table 2.
- Non-maternal alleles may be proven to be paternal alleles by paternal genotyping or genotyping of known fetal tissue samples. As can be seen, the presence of paternal alleles in the resulting cells, demonstrates that the cell is of fetal origin (cells # 1, 2, 9, and 10). Positive cells may be pooled for further analysis to diagnose aneuploidy of the fetus, or may be further analyzed individually.
- Maternal blood is processed through a size-based separation module, with or without subsequent MHEM enhancement of fnRBCs.
- the enhanced sample is then subjected to FISH analysis using probes specific to the aneuploidy of interest (e.g., triploidy 13, triploidy 18, and XYY).
- Probes specific to the aneuploidy of interest e.g., triploidy 13, triploidy 18, and XYY.
- Samples testing positive with FISH analysis are then binned into 96 microtiter wells, each well containing 15 ⁇ l of the enhanced sample. Of the 96 wells, 5-10 are expected to contain a single fnRBC and each well should contain approximately 1000 nucleated maternal cells (both WBC and mnRBC).
- Cells are pelleted and resuspended in 5 ⁇ l PBS plus 1 ⁇ l 20 mg/ml Proteinase K (Sigma #P-2308). Cells are lysed by incubation at 65° C. for 60 minutes followed by a inactivation of the Proteinase K by 15 minute at 95° C.
- the maternal genotype (BB) and fetal genotype (AB) for a particular set of SNPs is known.
- the genotypes A and B encompass all three SNPs and differ from each other at all three SNPs.
- the following sequence from chromosome 7 contains these three SNPs (rs7795605, rs7795611 and rs7795233 indicated in brackets, respectively) (ATGCAGCAAGGCACAGACTAA[G/A]CAAGGAGA[G/C]GCAAAATTTTC[A/G]TAGGGGAGAGAAATGGGTCATT).
- genomic DNA from binned enriched cells is amplified using primers specific to the outer portion of the fetal-specific allele A and which flank the interior SNP (forward primer ATGCAGCAAGGCACAGACTACG; reverse primer AGAGGCGACAGAAATGGGTCATT).
- amplification using real time SYBR Green PCR is performed with primers specific to the inner portion of allele A and which encompass the interior SNP (forward primer CAAGGCACAGACTAAGCAAGGAGAG; reverse primer GGCAAAATTTTCATAGGGGAGAGAAATGGGTCATT).
- FIG. 11 illustrates a diagram of the planned protocol for clinical practice where a reference sample (maternal blood) and a fetal enriched sample will be processed in parallel. Twelve polymorphic STRs are chosen (See FIG. 12 ) and associated nested PCR primers were designed ( FIG. 13-14 ).
- Cell Lysis Cells are lysed in a proteinase K solution by heating samples for 60 minutes at 65° C., followed by a heating step of 15 minutes at 95° C.
- a polymerase mix that includes 12 specialized STR primer pairs is added to the crude lysate.
- a master PCR mix is generated according to the number of samples as per the recipe below. For the reference sample 44 ⁇ L of the master mix are added directly to the cell lysate. For the sample recovered from the slide the volume of the reaction is adjusted as necessary. (e.g. 32 ⁇ L crude lysate in a 100 ⁇ L total reaction volume). A no template or negative control is generated to test for contamination.
- Nested PCR After PCR, optionally, diluted products are added to a second nested primer PCR reaction. Two ul aliquot of each 12-plex PCR reaction is diluted 40 fold (to 80 ul total) with nuclease free water from the PCR kit. The diluted fetal enriched 12-plex reaction could be used as template for a master mix for 8 nested PCR reactions with HAM labeled primers. A second master mix can be generated using the dilution from the maternal reference for 8 nested PCR reactions with VIC labeled primers. The following primer pairs are suggested. A no template or negative control is generated to test for contamination.
- Nested STR primer facts Reaction Fragment size rxn# temp STR primers ranges 1 68 CSF1P0 THO1 295-327, 171-215 2 68 TPOX CYARO4 220-256, 172-205 3 68 F13A 179-235 4 68 FIBRA 158-286 5 63 VWA D21S11 122-182 202-265 6 63 CD4 86-141 7 63 D14S1434 70-102 8 63 D22S1045 76-109
- Step Temp (C.) Time (mins) 1.0 95 0.5 2.0 94 0.5 3.0 X 1.5 4.0 72 1.5 5.0 cycle to step 2, 44 times 6.0 72 10
- the amplification with the nested PCR primers is run with an annealing temperature of 63° C. or 68° C. depending on the primer pair being amplified as indicated in FIG. 13 and FIG. 14 .
- PCR products are detected on an Agilent Bioanalyzer.
- the maternal reference VIC labeled PCR reaction products is diluted 10 fold in nano-pure water (17.8 uOhms).
- Another 10 fold dilution of the fetal enriched FAM-PCR products is generated.
- the ABI loading buffer is prepared by adding 0.5 ⁇ L LIZ 500 size standard to 12 ⁇ L Hi Di Formamide (scale as appropriate to the number of samples, include enough buffer for the negative control to test for contamination).
- 1 ⁇ L diluted PCR product is added to 12 ul loading buffer.
- the sample is heated to 95° C. for 2 minutes and then placed on ice.
- the samples are loaded onto the ABI 310 as per the manufacturer's instructions.
- STR primer facts table For analysis the ABI fragments output are examined for the expected peak sizes as per the nested STR primer facts table ( FIG. 13 and FIG. 14 ). For each STR locus is determined whether there are 1 or 2 alleles (homozygous or heterozygous) for the fetal enriched (PAM labeled sample) or the maternal reference (VIC labeled sample). Alleles generated from the fetal enriched (FAM labeled sample) that are not present in the maternal reference (VIC labeled sample) are unique to the fetus and verify the presence of fetal cells in the sample. If the number of fetal cells is particularly low ( ⁇ 5 cells), not all loci or alleles will always amplify. Allele drop out can generate a false negative.
- a false positive is most likely generated from contamination and has not been observed in tests to date. If the purity of fetal cells is particularly low ( ⁇ 10% in tests executed on the bioanalyzer) signal intensity of paternal alleles can be very weak. This can also generate a false negative result.
- the amplicons will have different fluorescent labels incorporated into them marking them as the maternal reference or the fetal enriched samples. The labels allow the samples to be loaded simultaneously into an ABI 310 capillary and differentiated. Paternal alleles are identified as those unique to the fetal enriched sample in comparison to the maternal reference. The efficiency of the overall process is determined after sufficient samples have been analyzed on the ABI 310 to establish the input cell purity and minimum number of fetal cells necessary to achieve 99% detection at 0.1% false positive rate.
- the protocol detection limit was determined using fixed cells from cord blood.
- Cord blood from clinical sample SVH0003C was subjected to erythrocyte lysis and the remaining leukocytes were fixed in a solution of PBS and 2% para-formaldehyde.
- Cell numbers were estimated from hemocytometer counts and dilutions made into a Tris protienase K (PK) solution.
- PK Tris protienase K
- a PCR cocktail including primers for STR loci TPOX and CSF1P0 was added directly to the crude lysate and amplified as described in Example 6. The products were analyzed on an Agilent bioanalyzer.
- FIGS. 15A-15B shows representative results. TPOX and CSF1P0 amplification products are underline in boxes. Detection for the PCR protocol from fixed cord blood can occur with less than 10 cells as shown by the result in FIG. 16 .
- FIG. 17 shows representative results. The mother and fetus are identical at the D21S11 locus but the child has a unique (paternal) allele at the VWA locus. FIG. 17 shows that detection of the paternal VWA allele is lost when the fetal purity drops below 10%.
- FIG. 18 shows representative results. VWA and LIPOL amplicons are underlined by boxes in the figure. These results show that STRs markers can be generated from fixed cells recovered from a slide.
- Mutliplex PCR reactions from samples with 10 fetal cells in a background of maternal cells generating at 10%, 5% and 2% fetal cells purity concentration were performed as described in Example 6.
- a dilution of the three multiplex PCR reactions was used as template in nested PCR reactions for STRs TPOX/CYAR04, VWA/D21S11, and D14S1434 as described in Example 6.
- FIG. 19 shows representative results.
- the underlined loci are known to have unique fetal alleles which are designated by arrows when visible in the gel. The three loci were visible when fetal cells constituted 10% of the sample.
- D14S1434 loci was visible when fetal cells constituted 5% and 2% of the sample.
- FIG. 15A shows that the Bioanalyzer can resolve a 16 base pair difference between the 99 base pair D14S1434 maternal allele and the 83 base pair paternal allele in a mixed fetal sample at 5% purity (also shown in FIG. 11 , lane 6).
- FIG. 15B shows that the output of fragments calibration standards. The output of an ABI310 fragment calibration standard is shown in blue or FAM label. Fragments of 232, 234, 236 and 238 are easily resolved from one another. For a resolution comparison note that the orange, VIC labeled, 246 size standard peak is 8 bases away from the FAM labeled 238 peak, half the distance as the maternal and paternal alleles in the Bioanalyzer trace.
- Genomic DNA from enriched fetal cells and a maternal control sample will be genotyped for specific STR loci in order to assess the presence of chromosomal abnormalities, such as trisomy. Due to the small number of fetal cells typically isolated from maternal blood it is advantageous to perform a pre-amplification step prior to analysis, using a protocol such as improved primer extension pre-amplification (IPEP) PCR.
- IPEP primer extension pre-amplification
- Cell lysis is carried out in 10 ul High Fidelity buffer (50 mM Tris-HCL, 22 mM (NH.sub.4).sub.2 SO.sub.4 2.5 mM MgCl.sub.2, pH 8.9) which also contained 4 mg/ml proteinase K and 0.5 vol % Tween 20 (Merck) for 12 hours at 48° C. The enzyme is then inactivated for 15 minutes at 94° C. Lysis is performed in parallel batches in 5 ul, 200 mM KOH, 50 mM dithiothreitol for 10 minutes at 65.degree. The batches are then neutralized with 5 ul 900 mM Tris HCl pH 8.3, 300 mM KCl.
- High Fidelity buffer 50 mM Tris-HCL, 22 mM (NH.sub.4).sub.2 SO.sub.4 2.5 mM MgCl.sub.2, pH 8.9
- the enzyme is then inactivated for 15 minutes at 94° C. Ly
- Preamplication is then carried out for each sample using completely randomized 15-mer primers (16 uM) and dNTP (100 uM) with 5 units of a mixture of Taq polymerase (Boehringer Mannheim) and Pwo polymerase (Boehringer Mannheim) in a ratio of 10:1 under standard PCR buffer conditions (50 mM Tris-HCL, 22 mM (NH 4 ) 2 SO 4 , 2.5 mM Mg 2 , pH 8.9, also containing 5% by vol. of DMSO) in a total volume of 60 ul with the following 50 thermal cycles: Step Temperature Time (1) 92° C. 1 Min 30 Sec; (2) 92° C. 40 Min (3) 37° C. 2 Min; (4) ramp: 0.1° C./sec to 55° C. (5) 55° C. 4 Min (6) 68° C. 30 Sec (7) go to step 2, 49 times (8) 8° C. 15 Min.
- Dye labeled primers will then be selected from Table 3 based on STR loci on a chromosomes of interest, such as 13, 18, 21 or X.
- the primers are designed so that one primer of each pair contains a fluorescent dye, such as ROX, HEX, JOE, NED, PAM, TAMARA or LIZ.
- the primers are placed into multiplex mixes based on expected product size, fluorescent tag compatibility and melting temperature. This allows multiple STR loci to be assayed at once and yet still conserves the amount of initial starting material required. All primers are initially diluted to a working dilution of 10 pM. The primers are then combined in a cocktail that has a final volume of 40 ul. Final primer concentration is determined by reaction optimization.
- Additional PCR grade water is added if the primer mix is below 40 ul.
- a reaction mix containing 6 ul of Sigma PCR grade water, 1.25 ul of Perkin Elmer Goldamp PCR buffer, 0.5 ul of dNTPs, 5 ul of the primer cocktail, 0.12 ul of Perkin Elmer Taq Gold Polymerase and 1.25 ul of Mg (25 mM) is mixed for each sample.
- a 1 ul sample containing preamplified DNA from enriched fetal cells or maternal control genomic DNA is added.
- the reaction mix is amplified in a DNA thermocyler, (PTC-200; MJ Research) using an amplification cycle optimized for the melting temperature of the primers and the amount of sample DNA.
- the amplification product will then analyzed using an automated DNA sequencer system, such as the ABI 310, 377, 3100, 3130, 3700 or 3730, or the Li-Cor 4000, 4100, 4200 or 4300.
- an automated DNA sequencer system such as the ABI 310, 377, 3100, 3130, 3700 or 3730, or the Li-Cor 4000, 4100, 4200 or 4300.
- 6 ul of products will be removed and combined with 1.6 ul of loading buffer mix.
- the master loading buffer mix contains 90 ul deionized formamide combined with 25 ul Perkin Elmer loading dye and 10 ul of a size standard, such as the ROX 350 size standard.
- a size standard such as the ROX 350 size standard.
- Various other standards can be used interchangeably depending on the sizes of the labeled PCR products.
- the loading buffer and sample are then heat denatured at 95° C. for 3 minutes followed by flash cooling on ice. 2 ul of the product/buffer mix is then
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 60/804,815, filed Jun. 14, 2006, which application is incorporated herein by reference.
- Analysis of specific cells can give insight into a variety of diseases. These analyses can provide non-invasive tests for detection, diagnosis and prognosis of diseases, thereby eliminating the risk of invasive diagnosis. For instance, social developments have resulted in an increased number of prenatal tests. However, the available methods today, amniocentesis and chorionic villus sampling (CVS) are potentially harmful to the mother and to the fetus. The rate of miscarriage for pregnant women undergoing amniocentesis is increased by 0.5-1%, and that figure is slightly higher for CVS. Because of the inherent risks posed by amniocentesis and CVS, these procedures are offered primarily to older women, i.e., those over 35 years of age, who have a statistically greater probability of bearing children with congenital defects. As a result, a pregnant woman at the age of 35 has to balance an average risk of 0.5-1% to induce an abortion by amniocentesis against an age related probability for
trisomy 21 of less than 0.3%. - To eliminate the risks associated with invasive prenatal screening procedures, non-invasive tests for detection, diagnosis and prognosis of diseases, have been utilized. For example, maternal serum alpha-fetoprotein, and levels of unconjugated estriol and human chorionic gonadotropin are used to identify a proportion of fetuses with Down's syndrome, however, these tests are not one hundred percent accurate. Similarly, ultrasonography is used to determine congenital defects involving neural tube defects and limb abnormalities, but is useful only after fifteen weeks' gestation.
- The methods of the present invention allow for the detection of fetal cells and fetal abnormalities when fetal cells are present in a mixed population of cells, even when maternal cells dominate the mixture.
- The presence of fetal cells in maternal circulation offers the opportunity to develop a prenatal diagnostic that obviates the risk associated with today's invasive diagnostics procedures. However, fetal cells are rare as compared to the presence of maternal cells in the blood. Therefore, any proposed analysis of fetal cells to diagnose fetal abnormalities requires enrichment of fetal cells. Enriching fetal cells from maternal peripheral blood is challenging, time intensive and any analysis derived therefrom is prone to error. The present invention addresses these challenges.
- The present invention relates to methods for determining the presence of fetal cells and fetal abnormalities when fetal cells are present in a mixed sample (e.g. maternal blood sample). In some embodiments, determining the presence of fetal cells or of a fetal abnormality includes comparing the level of genomic DNA from a mixed sample to the level of genomic DNA in a control sample. The control or reference sample can be a mixed sample that has been sufficiently diluted to be free of fetal cells. The mixed sample can contain at least one fetal cell and one non-fetal cell. In other embodiments, the sample comprises up to 50% fetal cells.
- In some embodiments, determining the presence of fetal cells and/or abnormalities involves quantifying one or more regions of genomic DNA regions from the mixed sample and determining from the quantification the presence of a fetal abnormality. Preferably, such regions are polymorphic e.g. short tandem repeat (STR) regions.
- Examples of fetal abnormalities that can be determined by quantifying regions on one or more chromosomes include
trisomy 13,trisomy 18, trisomy 21 (Dow-Syndrome), Klinefelter Syndrome (XXY) and other irregular number of sex or autosomal chromosomes. Other examples of abnormal fetal genotypes that can be determined by quantifying regions on one or more chromosomes include, but are not limited to, aneuploidy such as, monosomy of one or more chromosomes (X chromosome monosomy, also known as Turner's syndrome), trisomy of one or more chromosomes (such as 13, 18, 21, and X), tetrasomy and pentasomy of one or more chromosomes (which in humans is most commonly observed in the sex chromosomes, e.g. XXXX, XXYY, XXXY, XYYY, XXXXX, XXXXY, XXXYY, XYYYY and XXYYY), triploidy (tee of every chromosome, e.g. 69 chromosomes in humans), tetraploidy (four of every chromosome, e.g. 92 chromosomes in humans) and multiploidy. In some embodiments, an abnormal fetal genotype is a segmental aneuploidy. Examples of segmental aneuploidy include, but are not Limited to, 1p36 duplication, dup(17)(p11.2p11.2) syndrome, Down syndrome, Pelizaeus-Merzbacher disease, dup(22)(q11.2q11.2) syndrome, and cat-eye syndrome. In some cases, an abnormal fetal genotype is due to one or more deletions of sex or autosomal chromosomes, which may result in a condition such as Cri-du-chat syndrome, Wolf-Hirschorn, Williams-Beuren syndrome, Charcot-Marie-Tooth disease, Hereditary neuropathy with liability to pressure palsies, Smith-Magenis syndrome, Neurofibromatosis, Alagille syndrome, Velocardiofacial syndrome, DiGeorge syndrome, Steroid sulfatase deficiency, Kallmann syndrome, Microphthalmia with linear skin defects, Adrenal hypoplasia, Glycerol kinase deficiency, Pelizaeus-Merzbacher disease, Testis-determining factor on Y, Azospermia (factor a), Azospermia (factor b), Azospermia (factor c), or 1p36 deletion. In some embodiments, a decrease in chromosomal number results in an XO syndrome. - Furthermore, the methods herein can distinguish maternal trisomy from paternal trisomy, and total aneuploidy from segmental aneuploidy. Segmental aneuploidies can be caused by an intra-chromosomal event such as a deletion, duplication or translocation event. Additionally, the methods herein can be used to identify monoploidy, triploidy, tetraploidy, pentaploidy and other higher multiples of the normal haploid state. In some embodiments, the maternal or paternal origin of the fetal abnormality can be determined.
- The genomic DNA region(s) can be quantified by amplifying the regions using, for example, PCR, or preferably quantitative PCR. Alternatively, quantification of the regions can be achieved using capillary gel electrophoresis (CGE). In some embodiments, total genomic DNA is pre-amplified prior to the quantitative amplification step to increase the overall abundance of DNA. Such pre-amplification step can involve the use of multiple displacement amplification.
- In some embodiments the genomic DNA regions quantified can be in one chromosome or in 2 or more chromosomes. The polymorphic regions can be quantified on either or both sex chromosomes X and Y, and on autosomal
chromosomes including chromosomes - Prior to analysis a mixed sample suspected of having fetal cells (e.g. a maternal blood sample) can be enriched for fetal cells. Fetal cell enrichment can be accomplished using any method known in the art including size-based separation, affinity (e.g. magnetic) separation, FACS, laser microdisection, and magnetic bead separation. A mixed sample containing as few as 10 fetal cells can be enriched. In some embodiments, the fetal cells in the enriched sample constitute less than 50% of the total number of cells.
- In some embodiments, the size-based separation method includes applying a mixed sample into a system that separates a first component of the mixed sample (e.g. fetal cells), which comprises cells that are larger than a critical size, in a first direction, and a second component of the mixed sample (e.g. enucleated maternal red blood cells), which comprises cells that are smaller than a critical size, towards a second exit port. The separation system can be a device that includes one or more arrays of obstacles that form a network of gaps.
- In some embodiments, enrichment that is achieved by size-based separation is followed by one or more additional enrichment procedures including magnetic separation, fluorescence activated cell sorting (FACS), laser microdisection, and magnetic bead separation. In some embodiments, a sample enriched by size-based separation is subjected to affinity/magnetic separation and is further enriched for rare cells using fluorescence activated cell sorting (FACS) or selective lysis of a subset of the cells (e.g. fetal cells).
- In some embodiments there are provided kits for detecting the fetal abnormalities wherein the kits include separation devices and the reagents needed to perform the genetic analysis. For example, the kit may include arrays for size based enrichment, a device for magnetic enrichment and reagents for performing PCR.
- The methods can further comprise inputting the data from the quantification step into data model(s) for the association of DNA quantity with maternal and non-maternal alleles. The invention provides for a computer program product, which includes a computer executable logic recorded on a computer readable medium that can be used for diagnosing a fetal abnormality. The computer program is designed to receive data from one of more quantified DNA genomic regions from a mixed sample containing at least one fetal cell, determine the presence or absence of a fetal abnormality from the data, and generate an output that comprises the evaluation of the fetal abnormality. Methods for using the computer program product are also disclosed.
- The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
-
FIG. 1 illustrates a flow chart of one embodiment of the present invention. -
FIGS. 2A-2D illustrate one embodiment of a size-based separation module. -
FIGS. 3A-3C illustrate one embodiment of an affinity separation module. -
FIG. 4 illustrates one embodiment of a magnetic separation module. -
FIG. 5 illustrates typical locus patterns arising from a normal (diploid) fetus and mother. -
FIG. 6 illustrates typical locus patterns arising from trisomic fetal cells. -
FIGS. 7A-7D illustrate various embodiments of a size-based separation module, -
FIGS. 8A-8B illustrate cell smears of the product and waste fractions. -
FIGS. 9A-9F illustrate isolated fetal cells confirmed by the reliable presence of male Y chromosome. -
FIG. 10 illustratestrisomy 21 pathology in an isolated fetal nucleated red blood cell. -
FIG. 11 depicts a flow chart depicting the major steps involved in detecting paternal alleles in a fetal enriched sample using fluorescently labeled primers. -
FIG. 12 illustrates a table with STR loci that can be used for fetal detection. -
FIG. 13 illustrates a table with exemplary external primers for STR loci. -
FIG. 14 illustrates a table with exemplary internal primers for STR loci. -
FIG. 15 illustrates the resolution for the ABI 310 bioanalyzer. -
FIG. 16 illustrates the detection limit on fixed cord blood. -
FIG. 17 illustrates the detection of 10 fetal cells at 10% purity without nested PCR. -
FIG. 18 illustrates the generation of STR markers on fixed cells recovered from a slide. -
FIG. 19 illustrates detection of fetal alleles at less than 10% purity after nested PCR amplification of STRs. -
FIG. 20 illustrates the detection of single copies of a fetal cell genome by qPCR. -
FIG. 21 illustrates detection of single fetal cells in binned samples by SNP analysis. -
FIG. 22 illustrates a method of trisomy testing. Thetrisomy 21 screen is based on scoring of target cells obtained from maternal blood. Blood is processed using a cell separation module for hemoglobin enrichment (CSM-HE). Enriched cells are transferred to slides that are first stained and subsequently probed by FISH. Images are acquired, such as from bright field or fluorescent microscopy, and scored. The proportion of trisomic cells of certain classes serves as a classifier for risk offetal trisomy 21. Fetal genome identification can performed using assays such as: (1) STR markers; (2) qPCR using primers and probes directed to loci, such as the multi-repeat DYZ locus on the Y-chromosome; (3) SNP detection; and (4) CGH (comparative genome hybridization) array detection. -
FIG. 23 illustrates assays that can produce information on the presence of aneuploidy and other genetic disorders in target cells, Information on anueploidy and other genetic disorders in target cells may be acquired using technologies such as: (1) a CGH array established for chromosome counting, which can be used for aneuploidy determination and/or detection of intra-chromosomal deletions; (2) SNP/taqman assays, which can be used for detection of single nucleotide polymorphisms; and (3) ultra-deep sequencing, which can be used to produce partial or complete genome sequences for analysis. -
FIG. 24 illustrates methods of fetal diagnostic assays. Fetal cells are isolated by CSM-HE enrichment of target cells from blood. The designation of the fetal cells may be confirmed using techniques comprising FISH staining (using slides or membranes and optionally an automated detector), FACS, and/or binning. Binning may comprise distribution of enriched cells across wells in a plate (such as a 96 or 384 well plate), microencapsulation of cells in droplets that are separated in an emulsion, or by introduction of cells into microarrays of nanofluidic bins. Fetal cells are then identified using methods that may comprise the use of biomarkers (such as fetal (gamma) hemoglobin), allele-specific SNP panels that could detect fetal genome DNA, detection of differentially expressed maternal and fetal transcripts (such as Affymetrix chips), or primers and probes directed to fetal specific loci (such as the multi-repeat DYZ locus on the Y-chromosome). Binning sites that contain fetal cells are then be analyzed for aneuploidy and/or other genetic defects using a technique such as CGH array detection, ultra deep sequencing (such as Solexa, 454 or mass spectrometry), STR analysis, or SNP detection. -
FIG. 25 illustrates methods of fetal diagnostic assays, further comprising the step of whole genome amplification prior to analysis of aneuploidy and/or other genetic defects. - All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
- The present invention provides systems, apparatuses, and methods to detect the presence and condition (e.g. aneuploidy) of fetal cells in a mixed cell population, e.g. a sample wherein fetal cells consist of <50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or 0.5% of all cells in a mixed sample.
-
FIG. 1 illustrates an overview of one embodiment of the present invention. - In
step 100, a sample containing (or suspected of containing) 1 or more fetal cells is obtained. Samples can be obtained from an animal suspected of being pregnant, pregnant, or that has been pregnant to detect the presence of a fetus or fetal abnormality. Such animal can be a human or a domesticated animal such as a cow, chicken, pig, horse, rabbit, dog, cat, or goat. Samples derived from an animal or human can include, e.g., whole blood, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, lymph, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, secretions of the respiratory, intestinal or genitourinary tracts fluid. - To obtain a blood sample, any technique known in the art may be used, e.g. a syringe or other vacuum suction device. A blood sample can be optionally pre-treated or processed prior to enrichment. Examples of pre-treatment steps include the addition of a reagent such as a stabilizer, a preservative, a fixant, a lysing reagent, a diluent, an anti-apoptotic reagent, an anti-coagulation reagent, an anti-thrombotic reagent, magnetic property regulating reagent, a buffering reagent, an osmolality regulating reagent, a pH regulating reagent, and/or a cross-linking reagent.
- When a blood sample is obtained, a preservative such an anti-coagulation agent and/or a stabilizer can be added to the sample prior to enrichment. This allows for extended time for analysis/detection. Thus, a sample, such as a blood sample, can be enriched and/or analyzed under any of the methods and systems herein within 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hrs, 6 hrs, 3 hrs, 2 hrs, or 1 hr from the time the sample is obtained.
- In some embodiments, a blood sample can be combined with an agent that selectively lysed one or more cells or components in a blood sample. For example, fetal cells can be selectively lysed releasing their nuclei when a blood sample including fetal cells is combined with deionized water. Such selective lysis allows for the subsequent enrichment of fetal nuclei using, e.g., size or affinity based separation. In another example, platelets and/or enucleated red blood cells are selectively lysed to generate a sample enriched in nucleated cells, such as fetal nucleated red blood cells (fnRBC) and maternal nucleated blood cells (mnBC). The fnRBC's can subsequently be separated from the in BC's using, e.g., affinity to antigen-i or magnetism differences in fetal and adult hemoglobin.
- When obtaining a sample from an animal (e.g., blood sample), the amount can vary depending upon animal size, its gestation period, and or the condition being screened. In some embodiments, up to 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 mL of a sample is obtained. In some embodiments, 1-50, 2-40, 3-30, or 4-20 mL of sample is obtained. In some embodiments, more than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mL of a sample is obtained.
- To detect fetal abnormality, a blood sample can be obtained from a pregnant animal or human within 36, 24, 22, 20, 18, 16, 14, 12, 10, 8, 6 or 4 weeks of gestation.
- In
step 101, a reference sample is obtained. The reference sample consists of substantially all or all maternal cells. In some embodiments, a reference sample is a maternal blood sample enriched for white blood cells (WBC's) such that it consists of substantially all or all maternal WBC's. In some embodiments, a reference sample is a diluted mixed sample wherein the dilution results in a sample free of fetal cells. For example, a maternal blood sample of 10-50 ML can be diluted by at least 2, 5, 10, 20, 50, or 100 fold to reduce the likelihood that it will include fetal cells. - In
step 102, when the sample to be tested or analyzed is a mixed sample (e.g. maternal blood sample), it is enriched for rare cells or rare DNA (e.g. fetal cells, fetal DNA or fetal nuclei) using one or more methods known in the art or disclosed herein. Such enrichment increases the ratio of fetal cells to non-fetal cells; the concentration of fetal DNA to non-fetal DNA; or the concentration of fetal cells in volume per total volume of the mixed sample. - In some embodiments, enrichment occurs by selective lysis as described above. For example, enucleated cells may be selectively lysed prior to subsequent enrichment steps or fetal nucleated cells may be selectively lysed prior to separation of the fetal nuclei from other cells and components in the sample.
- In some embodiments, enrichment of fetal cells or fetal nuclei occurs using one or more size-based separation modules. Size-based separation modules include filtration modules, sieves, matrixes, etc., including those disclosed in International Publication Nos, WO 2004/113877, WO 2004/0144651, and US Application Publication No. 2004/011956.
- In some embodiments, a size-based separation module includes one or more arrays of obstacles that form a network of gaps. The obstacles are configured to direct particles (e.g. cells or nuclei) as they flow through the array/network of gaps into different directions or outlets based on the particle's hydrodynamic size. For example, as a blood sample flows through an array of obstacles, nucleated cells or cells having a hydrodynamic size larger than a critical size, e.g., 8 microns, are directed to a first outlet located on the opposite side of the array of obstacles from the fluid flow inlet, while the enucleated cells or cells having a hydrodynamic size smaller than a critical size, e.g., 8 microns, are directed to a second outlet also located on the opposite side of the array of obstacles from the fluid flow inlet.
- An array can be configured to separate cells smaller than a critical size from those larger than the critical size by adjusting the size of the gaps, obstacles, and offset in the period between each successive row of obstacles. For example, in some embodiments, obstacles and/or gaps between obstacles can be up to 10, 20, 50, 70, 100, 120, 150, 170, or 200 microns in length or about 2, 4, 6, 8 or 10 microns in length. In some embodiments, an array for size-based separation includes more than 100, 500, 1,000, 5,000, 10,000, 50,000 or 100,000 obstacles that are arranged into more than 10, 20, 50, 100, 200, 500, or 1000 rows. Preferably, obstacles in a first row of obstacles are offset from a previous (upstream) row of obstacles by up to 50% of the period of the previous row of obstacles. In some embodiments, obstacles in a first row of obstacles are offset from a previous row of obstacles by up to 45, 40, 35, 30, 25, 20, 15 or 10% the period of the previous row of obstacles. Furthermore, the distance between a first row of obstacles and a second row of obstacles can be up to 10, 20, 50, 70, 100, 120, 150, 170 or 200 microns. A particular offset can be continuous (repeating for multiple rows) or non-continuous. In some embodiments, a separation module includes multiple discrete arrays of obstacles fluidly coupled such that they are in series with one another. Each array of obstacles has a continuous offset. But each subsequent (downstream) array of obstacles has an offset that is different from the previous (upstream) offset. Preferably, each subsequent array of obstacles has a smaller offset that the previous array of obstacles. This allows for a refinement in the separation process as cells migrate through the array of obstacles. Thus, a plurality of arrays can be fluidly coupled in series or in parallel, (e.g., more than 2, 4, 6, 8, 10, 20, 30, 40, 50). Fluidly coupling separation modules (e.g., arrays) in parallel allows for high-throughput analysis of the sample, such that at least 1, 2, 5, 10, 20, 50, 100, 200, or 500 mL per hour flows through the enrichment modules or at least 1, 5, 10, or 50 million cells per hour are sorted or flow through the device.
-
FIGS. 2A-2D illustrate one example of a size-based separation module. Obstacles (which may be of any shape) are coupled to a flat substrate to form an array of gaps. A transparent cover or lid may be used to cover the array. The obstacles form a two-dimensional array with each successive row shifted horizontally with respect to the previous row of obstacles, where the array of obstacles directs components having a hydrodynamic size smaller than a critical size in a first direction and components having a hydrodynamic size larger that a critical size in a second direction. SeeFIGS. 2B-2D . The flow of sample into the array of obstacles can be aligned at a small angle (flow angle) with respect to a line-of-sight of the array (lateral flow angle). Optionally, the array is coupled to an infusion pump to perfuse the sample through the obstacles. The flow conditions of the size-based separation module described herein are such that cells are sorted by the array with minimal damage. This allows for downstream analysis of intact cells and intact nuclei to be more efficient and reliable. - In one embodiment, a size-based separation module comprises an array of obstacles configured to direct rare cells larger than a critical size to migrate along a line-of-sight within the array towards a first outlet or bypass channel leading to a first outlet, while directing cells and analytes smaller than a critical size through the array of obstacles in a different direction towards a second outlet.
- A variety of enrichment protocols may be utilized although gentle handling of the cells is preferred to reduce any mechanical damage to the cells or their DNA. This gentle handling also preserves the small number of fetal cells in the sample. Integrity of the nucleic acid being evaluated is an important feature in some embodiments to permit the distinction between the genomic material from the fetal cells and other cells in the sample. In particular, the enrichment and separation of the fetal cells using the arrays of obstacles produces gentle treatment which minimizes cellular damage and maximizes nucleic acid integrity permitting exceptional levels of separation and the ability to subsequently utilize various formats to very accurately analyze the genome of the cells which are present in the sample in extremely low numbers.
- In some embodiments, enrichment of fetal cells occurs using one or more capture modules that selectively inhibit the mobility of one or more cells of interest. Preferably a capture module is fluidly coupled downstream to a size-based separation module. Capture modules can include a substrate having multiple obstacles that restrict the movement of cells or analytes greater than a critical size. Examples of capture modules that inhibit the migration of cells based on size are disclosed in U.S. Pat. Nos. 5,837,115 and 6,692,952.
- In some embodiments, a capture module includes a two dimensional array of obstacles that selectively filters or captures cells or analytes having a hydrodynamic size greater than a particular gap size, e.g., critical sized. Arrays of obstacles adapted for separation by capture can include obstacles having one or more shapes and can be arranged in a uniform or non-uniform order. In some embodiments, a two-dimensional array of obstacles is staggered such that each subsequent row of obstacles is offset from the previous row of obstacles to increase the number of interactions between the analytes being sorted (separated) and the obstacles.
- Another example of a capture module is an affinity-based separation module. An affinity-based separation module capture analytes or cells of interest based on their affinity to a structure or particle as oppose to their size. One example of an affinity-based separation module is an array of obstacles that are adapted for complete sample flow through, but for the fact that the obstacles are covered with binding moieties that selectively bind one or more analytes (e.g., cell population) of interest (e.g., red blood cells, fetal cells, or nucleated cells) or analytes not-of-interest (e.g., white blood cells). Binding moieties can include e.g., proteins (e.g., ligands/receptors), nucleic acids having complementary counterparts in retained analytes, antibodies, etc. In some embodiments, an affinity-based separation module comprises a two-dimensional array of obstacles covered with one or more antibodies selected from the group consisting of: anti-CD71, anti-CD235a, anti-CD36, anti-carbohydrates, anti-selectin, anti-CD45, anti-GPA, and anti-antigen-i.
-
FIG. 3A illustrates a path of a first analyte through an array of posts wherein an analyte that does not specifically bind to a post continues to migrate through the array, while an analyte that does bind a post is captured by the array.FIG. 3B is a picture of antibody coated posts.FIG. 3C illustrates one method of coupling of antibodies to a substrate (e.g., obstacles, side walls, etc.) as contemplated by the present invention. Examples of such affinity-based separation modules are described in International Publication No. WO 2004/029221 and U.S. application Ser. No. 10/529,453, both of which are incorporated by reference. - In some embodiments, a capture module utilizes a magnetic field to separate and/or enrich one or more analytes (cells) that has a magnetic property or magnetic potential. For example, red blood cells which are slightly diamagnetic (repelled by magnetic field) in physiological conditions can be made paramagnetic (attributed by magnetic field) by deoxygenation of the hemoglobin into methemoglobin. This magnetic property can be achieved through physical or chemical treatment of the red blood cells. Thus, a sample containing one or more red blood cells and one or more non-red blood cells can be enriched for the red blood cells by first inducing a magnetic property and then separating the above red blood cells from other analytes using a magnetic field (uniform or non-uniform). For example, a maternal blood sample can flow first through a size-based separation module to remove enucleated cells and cellular components (e.g. analytes having a hydrodynamic size less than 6 μms) based on size. Subsequently, the enriched nucleated cells (e.g., analytes having a hydrodynamic size greater than 6 μms) white blood cells and nucleated red blood cells are treated with a reagent, such as CO2, N2 or NaNO2, that changes the magnetic property of the red blood cells' hemoglobin. The treated sample then flows through a magnetic field (e.g., a column coupled to an external magnet), such that the paramagnetic analytes (e.g., red blood cells) will be captured by the magnetic field while the white blood cells and any other non-red blood cells will flow through the device to result in a sample enriched in nucleated red blood cells (including fnRBC's). Additional examples of magnetic separation modules are described in U.S. application Ser. No. 11/323,971, filed Dec. 29, 2005 entitled “Devices and Methods for Magnetic Enrichment of Cells and Other Particles” and U.S. application Ser. No. 11/227,904, filed Sep. 15, 2005, entitled “Devices and Methods for Enrichment and Alteration of Cells and Other Particles”.
- Subsequent enrichment steps can be used to separate the rare cells (e.g. fnRBC's) from the non-rare maternal nucleated red blood cells (non-RBC's). In some embodiments, a sample enriched by size-based separation followed by affinity/magnetic separation is further enriched for rare cells using fluorescence activated cell sorting (FACS) or selective lysis of a subset of the cells (e.g. fetal cells). In some embodiments, fetal cells are selectively bound to an anti-antigen i binding moiety (e.g. an antibody) to separate them from the mnRBC's. In some embodiments, the antibody binds to a fetal cell ligand. In some related embodiments the fetal cells are stimulated so as to induce expression of ligands which are targeted by an antibody. In some embodiments the fetal cells are lysed and the nuclei of the fetal cells are separated from other cellular components by binding them with an antibody. In some embodiments, fetal cells are selectively bound to receptors which target fetal cell ligands. In some embodiments, fetal cells are selectively bound to a lectin. In some embodiments, fetal cells or fetal DNA is distinguished from non-fetal cells or non-fetal DNA by forcing the rare cells (fetal cells) to become apoptotic, thus condensing their nuclei and optionally ejecting their nuclei. Rare cells such as fetal cells can be forced into apoptosis using various means including subjecting the cells to hyperbaric pressure (e.g. 4% CO2). The condensed nuclei can be detected and/or isolated for further analysis using any technique known in the art including DNA gel electrophoresis, in situ labeling of DNA nicks (terminal deoxynucleotidyl transferase (TdT))-mediated dUTP in situ nick labeling (also known as TUNEL) (Gavrieli, Y., et al., J. Cell Biol 119:493-501 (1992)) and ligation of DNA strand breaks having one or two-
base 3′ overhangs (Taq polymerase-based in situ ligation). (Dideniko V., et al. J. Cell Biol. 135:1369-76 (1996)). - In some embodiments, when the analyte desired to be separated (e.g., red blood cells or white blood cells) is not ferromagnetic or does not have a magnetic property, a magnetic particle (e.g., a bead) or compound (e.g., Fe3+) can be coupled to the analyte to give it a magnetic property. In some embodiments, a bead coupled to an antibody that selectively binds to an analyte of interest can be decorated with an antibody elected from the group of anti CD71 or CD75. In some embodiments a magnetic compound, such as Fe3+, can be couple to an antibody such as those described above. The magnetic particles or magnetic antibodies herein may be coupled to any one or more of the devices herein prior to contact with a sample or may be mixed with the sample prior to delivery of the sample to the device(s).
- Magnetic field used to separate analytes/cells in any of the embodiments herein can uniform or non-uniform as well as external or internal to the device(s) herein. An external magnetic field is one whose source is outside a device herein (e.g., container, channel, obstacles). An internal magnetic field is one whose source is within a device contemplated herein. An example of an internal magnetic field is one where magnetic particles may be attached to obstacles present in the device (or manipulated to create obstacles) to increase surface area for analytes to interact with to increase the likelihood of binding. Analytes captured by a magnetic field can be released by demagnetizing the magnetic regions retaining the magnetic particles. For selective release of analytes from regions, the demagnetization can be limited to selected obstacles or regions. For example, the magnetic field can be designed to be electromagnetic, enabling turn-on and turn-off off the magnetic fields for each individual region or obstacle at will.
-
FIG. 4 illustrates an embodiment of a device configured for capture and isolation of cells expressing the transferrin receptor from a complex mixture. Monoclonal antibodies to CD71 receptor are readily available off-the-shelf and can be covalently coupled to magnetic materials comprising any conventional ferroparticles, such as, but not limited to ferrous doped polystyrene and ferroparticles or ferro-colloids (e.g., from Miltenyi or Dynal). The anti CD71 bound to magnetic particles is flowed into the device. The antibody coated particles are drawn to the obstacles (e.g., posts), floor, and walls and are retained by the strength of the magnetic field interaction between the particles and the magnetic field. The particles between the obstacles and those loosely retained with the sphere of influence of the local magnetic fields away from the obstacles are removed by a rinse. - One or more of the enrichment modules herein (e.g., size-based separation module(s) and capture module(s)) may be fluidly coupled in series or in parallel with one another. For example a first outlet from a separation module can be fluidly coupled to a capture module. In some embodiments, the separation module and capture module are integrated such that a plurality of obstacles acts both to deflect certain analytes according to size and direct them in a path different than the direction of analyte(s) of interest, and also as a capture module to capture, retain, or bind certain analytes based on size, affinity, magnetism or other physical property.
- In any of the embodiments herein, the enrichment steps performed have a specificity and/or sensitivity >50, 60, 70, 80, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 99.95% The retention rate of the enrichment module(s) herein is such that ≧50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.9% of the analytes or cells of interest (e.g., nucleated cells or nucleated red blood cells or nucleated from red blood cells) are retained. Simultaneously, the enrichment modules are configured to remove ≧−50, 60, 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.9% of all unwanted analytes (e.g., red blood-platelet enriched cells) from a sample.
- Any or all of the enrichment steps can occur with minimal dilution of the sample. For example, in some embodiments the analytes of interest are retained in an enriched solution that is less than 50, 40, 30, 20, 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.5, 4.0, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, or 0.5 fold diluted from the original sample. In some embodiments, any or all of the enrichment steps increase the concentration of the analyte of interest (fetal cell), for example, by transferring them from the fluid sample to an enriched fluid sample (sometimes in a new fluid medium, such as a buffer). The new concentration of the analyte of interest may be at least 2, 4, 6, 8, 10, 20, 50, 100, 200, 500, 1,000, 2,000, 5,000, 10,000, 20,000, 50,000, 100,000, 200,000, 500,000, 1,000,000, 2,000,000, 5,000,000, 10,000,000, 20,000,000, 50,000,000, 100,000,000, 200,000,000, 500,000,000, 1,000,000,000, 2,000,000,000, or 5,000,000,000 fold more concentrated than in the original samples. For example, a 10 times concentration increase of a first cell type out of a blood sample means that the ratio of first cell type/all cells in a sample is 10 times greater after the sample was applied to the apparatus herein. Such concentration can take a fluid sample (e.g., a blood sample) of greater than 10, 15, 20, 50, or 100 mL total volume comprising rare components of interest, and it can concentrate such rare component of interest into a concentrated solution of less than 0.5, 1, 2, 3, 5, or 10 mL total volume.
- The final concentration of fetal cells in relation to non-fetal cells after enrichment can be about 1/10,000-1/10, or 1/1,000-1/100. In some embodiments, the concentration of fetal cells to maternal cells may be up to 1/1,000-1/100, or 1/10 or as low as 1/100, 1/1,000 or 1/10,000.
- Thus, detection and analysis of the fetal cells can occur even if the non-fetal (e.g. maternal) cells are >50%, 60%, 70%, 80%, 90%, 95%, or 99% of all cells in a sample. In some embodiments, fetal cells are at a concentration of less than 1:2, 1:4, 1:10, 1:50, 1:100, 1:1000, 1:10,000, 1:100,000, 1,000,000, 1:10,000,000 or 1:100,000,000 of all cells in a mixed sample to be analyzed or at a concentration of less than 1×10−3, 1×10−4, 1×10, 1×10−−6, or 1×10−6 cells/μL of the mixed sample. Over all, the number of fetal cells in a mixed sample, (e.g. enriched sample) has up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 100 total fetal cells.
- Enriched target cells (e.g., fnRBC) may be “binned” prior to further analysis of the enriched cells (
FIGS. 24 and 25 ). Binning is any process which results in the reduction of complexity and/or total cell number of the enriched cell output. Binning may be performed by any method known in the art or described herein. One method of binning is by serial dilution. Such dilution may be carried out using any appropriate platform (e.g., PCR wells, microtiter plates) and appropriate buffers. Other methods include nanofluidic systems which can separate samples into droplets (e.g., BioTrove, Raindance, Fluidigm). Such nanofluidic systems may result in the presence of a single cell present in a nanodroplet. - Binning may be preceded by positive selection for target cells including, hut not limited to, affinity binding (e.g. using anti-CD71 antibodies). Alternately, negative selection of non-target cells may precede binning. For example, output from a size-based separation module may be passed through a magnetic hemoglobin enrichment module (MHEM) which selectively removes WBCs from the enriched sample by attracting magnetized hemoglobin-containing cells.
- For example, the possible cellular content of output from enriched maternal blood which has been passed through a size-based separation module (with or without further enrichment by passing the enriched sample through a MHEM) may consist of: 1) approximately 20 fnRBC; 2) 1,500 nmRBC; 3) 4,000-40,000 WBC; 4) 15×106 RBC. If this sample is separated into 100 bins (PCR wells or other acceptable binning platform), each bin would be expected to contain: 1) 80 negative bins and 20 bins positive for one fnRBC; 2) 150 nmRBC; 3) 400-4,000 WBC; 4) 15×104 RBC. If separated into 10,000 bins, each bin would be expected to contain: 1) 9,980 negative bins and 20 bins positive for one fnRBC; 2) 8,500 negative bins and 1,500 bins positive for one mnC; 3) <1-4 WBC; 4) 15×102 RBC. One of skill in the art will recognize that the number of bins may be increased or decreased depending on experimental design and/or the platform used for binning. Reduced complexity of the binned cell populations may facilitate further genetic and/or cellular analysis of the target cells by reducing the number of non-target cells in an individual bin.
- Analysis may be performed on individual bins to confirm the presence of target cells (e.g. fnRBC) in the individual bin. Such analysis may consist of any method known in the art including, but not limited to, FISH, PCR, STR detection, SNP analysis, biomarker detection, and sequence analysis (
FIGS. 24 and 25 ). - Fetal Biomarkers
- In some embodiments fetal biomarkers may be used to detect and/or isolate fetal cells, after enrichment or after detection of fetal abnormality or lack thereof. For example, this may be performed by distinguishing between fetal and maternal nRBCs based on relative expression of a gene (e.g., DYS1, DYZ, CD-71, ε- and ζ-globin) that is differentially expressed during fetal development. In preferred embodiments, biomarker genes are differentially expressed in the first and/or second trimester. “Differentially expressed,” as applied to nucleotide sequences or polypeptide sequences in a cell or cell nuclei, refers to differences in over/under-expression of that sequence when compared to the level of expression of the same sequence in another sample, a control or a reference sample. In some embodiments, expression differences can be temporal and/or cell-specific. For example, for cell-specific expression of biomarkers, differential expression of one or more biomarkers in the cell(s) of interest can be higher or lower relative to background cell populations. Detection of such difference in expression of the biomarker may indicate the presence of a rare cell (e.g., fnRBC) versus other cells in a mixed sample (e.g., background cell populations). In other embodiments, a ratio of two or more such biomarkers that are differentially expressed can be measured and used to detect rare cells.
- In one embodiment, fetal biomarkers comprise differentially expressed hemoglobins. Erythroblasts (nRBCs) are very abundant in the early fetal circulation, virtually absent in normal adult blood and by having a short finite lifespan, there is no risk of obtaining fnRBC which may persist from a previous pregnancy. Furthermore, unlike trophoblast cells, fetal erythroblasts are not prone to mosaic characteristics.
- Yolk sac erythroblasts synthesize ε-, ζ-, γ- and α-globins, these combine to form the embryonic hemoglobins. Between six and eight weeks, the primary site of erythropoiesis shifts from the yolk sac to the liver, the three embryonic hemoglobins are replaced by fetal hemoglobin (HbF) as the predominant oxygen transport system, and ε- and ζ-globin production gives way to γ-, α- and β-globin production within definitive erythrocytes (Peschle et al., 1985). HbF remains the principal hemoglobin until birth, when the second globin switch occurs and β-globin production accelerates.
- Hemoglobin (Hb) is a heterodimer composed of two identical α globin chains and two copies of a second globin. Due to differential gene expression during fetal development, the composition of the second chain changes from c globin during early embryonic development (1 to 4 weeks of gestation) to γ globin during fetal development (6 to 8 weeks of gestation) to β globin in neonates and adults as illustrated in (Table 1).
TABLE 1 Relative expression of ε, γ and β in maternal and fetal RBCs. ε γ B 1st trimester Fetal ++ ++ − Maternal − +/− ++ 2nd trimester Fetal − ++ +/− Maternal − +/− ++ - In the late-first trimester, the earliest time that fetal cells may be sampled by CVS, fnRBCs contain, in addition to α globin, primarily ε and γ globin. In the early to mid second trimester, when amniocentesis is typically performed, fnRBCs contain primarily γ globin with some adult is globin. Maternal cells contain almost exclusively α and β globin, with traces of γ detectable in some samples. Therefore, by measuring the relative expression of the ε, γ and β genes in RBCs purified from maternal blood samples, the presence of fetal cells in the sample can be determined. Furthermore, positive controls can be utilized to assess failure of the FISH analysis itself.
- In various embodiments, fetal cells are distinguished from maternal cells based on the differential expression of hemoglobins β, γ or ε. Expression levels or RNA levels can be determined in the cytoplasm or in the nucleus of cells. Thus in some embodiments, the methods herein involve determining levels of messenger RNA (in RNA), ribosomal RNA (rRNA), or nuclear RNA (nRNA).
- In some embodiments, identification of fnRBCs can be achieved by measuring the levels of at least two hemoglobins in the cytoplasm or nucleus of a cell. In various embodiments, identification and assay is from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 fetal nuclei. Furthermore, total nuclei arrayed on one or more slides can number from about 100, 200, 300, 400, 500, 700, 800, 5000, 10,000, 100,000, 1,000,000, 2,000,000 to about 3,000,000. In some embodiments, a ratio for γ/β or ε/β is used to determine the presence of fetal cells, where a number less than one indicates that a fnRBC(s) is not present. In some embodiments, the relative expression of γ/β or ε/β provides a fnRBC index (“FNI”), as measured by γ or ε relative to β. In some embodiments, a FNI for γ/β greater than 5, 10, 15, 20, 25, 30, 35, 40, 45, 90, 180, 360, 720, 975, 1020, 1024, 1250 to about 1250, indicate that a fnRBC(s) is present. In yet other embodiments, a FNI for γ/β of less than about 1 indicates that a fnRBC(s) is not present. Preferably, the above FNI is determined from a sample obtained during a first trimester, However, similar ratios can be used during second trimester and third trimester.
- In some embodiments, the expression levels are determined by measuring nuclear RNA transcripts including, nascent or unprocessed transcripts. In another embodiment, expression levels are determined by measuring mRNA, including ribosomal RNA. There are many methods known in the art for imaging (e.g., measuring) nucleic acids or RNA including, but not limited to, using expression arrays from Affymetrix, Inc. or Illumina, Inc.
- RT-PCR primers can be designed by targeting the globin variable regions, selecting the amplicon size, and adjusting the primers annealing temperature to achieve equal PCR amplification efficiency. Thus TaqMan probes can be designed for each of the amplicons with well-separated fluorescent dyes, Alexa Fluor®-355 for ε, Alexa Fluor®-488 for A, and Alexa Fluor-555 for β. The specificity of these primers can be first verified using ε, γ, and β cDNA as templates. The primer sets that give the best specificity can be selected for further assay development. As an alternative, the primers can be selected from two exons spanning an intron sequence to amplify only the mRNA to eliminate the genomic DNA contamination.
- The primers selected can be tested first in a duplex format to verify their specificity, limit of detection, and amplification efficiency using target cDNA templates. The best combinations of primers can be further tested in a triplex format for its amplification efficiency, detection dynamic range, and limit of detection.
- Various commercially available reagents are available for RT-PCR, such as One-step RT-PCR reagents, including Qiagen One-Step RT-PCR Kit and Applied Biosystems TaqMan One-Step RT-PCR Master Mix Reagents kit. Such reagents can be used to establish the expression ratio of ε, γ and β using purified RNA from enriched samples. Forward primers can be labeled for each of the targets, using Alexa fluor-355 for ε, Alexa fluor-488 for γ, and Alexa fluor-555 for β. Enriched cells can be deposited by cytospinning onto glass slides. Additionally, cytospinning the enriched cells can be performed after in situ RT-PCR. Thereafter, the presence of the fluorescent-labeled amplicons can be visualized by fluorescence microscopy. The reverse transcription time and PCR cycles can be optimized to maximize the amplicon signal:background ratio to have maximal separation of fetal over maternal signature. Preferably, signal:background ratio is greater than 5, 10, 50 or 100 and the overall cell loss during the process is less than 50, 10 or 5%.
- Fetal Cell Analysis
- The detection and analysis steps may involve quantifying genomic DNA regions from cells in a sample or enriched sample. In some embodiments, the quantified genomic DNA regions are polymorphic sites such as short tandem repeats (STRs) or variable number of tandem repeats (VNTRs).
- In
step 103, polymorphic genomic DNA region(s) or whole genome(s) from the mixed sample and optionally reference sample are pre-amplified to increase the overall abundance of DNA used for quantification and analysis. Pre-amplification can be preformed using multiple displacement amplification (MDA) (Gonzalez et al. Envircon Microbiol; 7(7); 1024-S (2005)) or amplification with outer primers in a nested PCR approach. This permits detection and analysis of fetal DNA even if the total amount of fetal DNA in the mixed (e.g. enriched) sample is only up to 1 μg, 500 ng, 200 ng, 100 ng, 50 ng, 40 ng, 30 ng, 20 ng, 10 ng, 5 ng, 1 ng, 500 pg, 200 pg, 100 pg, 50 pg, 40 pg, 30 pg, 20 p, 10 pg, 5 pg, or 1 pg or between 1-5 μg, 5-10 μg, or 10-50 μg. Pre-amplification allows the products to be split into multiple reactions at the next step. - In
step 104, polymorphic DNA region(s) such as short tandem repeats (STRs) or variable number of tandem repeats (VNTRs) are selected on suspected trisomic chromosome(s) (e.g., 13, 18, 21, X or Y) or chromosome(s) associated with a condition to be detected and optionally on control (non-trisomic) chromosomes. In some embodiments, 1 or more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 DNA polymorphic loci are selected per target chromosome. Multiple polymorphic regions can be analyzed independently or at the same time in the same reaction. The polymorphic DNA regions, e.g. STRs loci, are selected for high heterozygosity (variety of alleles) so that the paternal allele of the fetal cells is more likely to be distinct in length from the maternal alleles. This results in an improved power to detect the presence of fetal cells in the mixed sample and potential fetal abnormalities in such cells. When the polymorphic regions selected are STR loci, di-, tri-, tetra- or penta-nucleotide repeat loci can be used for detection and analysis of fetal cells. Examples of STR loci that may be selected include: D21 S1414, D21 S1411, D21S1412, D21S11 MBP, D13S634, D13S631, D18S535, AmgXY, XHPRT, as well as those listed inFIG. 12 . In some embodiment, the methods of the invention allow for the determination of maternal or paternal trisomy. - In
step 105, the polymorphic loci selected are amplified. This can be used to detect non-maternal fetal alleles in the mixed sample and to determine the copy number of such alleles. When amplifying more than one polymorphic loci or DNA regions, primers are selected to be multiplexable (fairly uniform melting temperature, absence of cross-priming on the human genome, and absence of primer-primer interaction based on sequence analysis) with other primer pairs. Primers and loci are chosen so that the amplicon lengths from a given locus do not overlap with those from another locus. - In some embodiments, multiple dyes and multi-color fluorescence readout may be used to increase the multiplexing capacity, e.g. of a single CGE. This ensures that the loci are kept distinct in the readout (e.g. CGE readout). In such a case, PCR primer pairs can be grouped and the same end-labeling is applied to the members of a group.
- Examples of primers known in the art that correspond to specific STR loci that can be used in the present invention are described in
FIG. 13 andFIG. 14 . - Examples of PCR techniques that can be used to amplify the DNA regions herein include, but are not limited, to quantitative PCR, quantitative fluorescent PCR (QF-PCR), multiplex fluorescent PCR (MF-PCR), real time PCR (RT-PCR), single cell PCR, restriction fragment length polymorphism PCR(PCR-RELP), PCR-RFLP/RT-PCR-RFLP, hot start PCR, nested PCR, in situ polonony PCR, in situ rolling circle amplification (RCA), bridge PCR, picotiter PCR and emulsion PCR. Other suitable amplification methods include the ligase chain reaction (LCR), transcription amplification, self-sustained sequence replication, selective amplification of target polynucleotide sequences, consensus sequence primed polymerase chain reaction (CP-PCR), arbitrarily primed polymerase chain reaction (AP-PCR), degenerate oligonucleotide-primed PCR (DOP-PCR) and nucleic acid based sequence amplification (NABSA). Other amplification methods that may be used to amplify specific polymorphic loci include those described in, U.S. Pat. Nos. 5,242,794, 5,494,810, 4,988,617 and 6,582,938.
- In
step 106, the amplified DNA polymorphic regions (e.g. STR loci) from both mixed and reference samples are characterized and quantified using any method known in the art. Examples of such methods include, but are not limited to, gas chromatography, supercritical fluid chromatography, liquid chromatography, including partition chromatography, adsorption chromatography, ion exchange chromatography, size-exclusion chromatography, thin-layer chromatography, and affinity chromatography, electrophoresis, including capillary electrophoresis, capillary zone electrophoresis, capillary isoelectric focusing, capillary electrochromatography, micellar electrokinetic capillary chromatography, isotachophoresis, transient isotachophoresis and capillary gel electrophoresis, comparative genomic hybridization (CGH), microarrays, bead arrays, high-throughput genotyping technology, such as molecular inversion probe (MIP), and Genescan. - In one embodiment, capillary gel electrophoresis (CGE) is used to quantify STRs in both the mixed and reference samples. This can be used to detect non-maternal fetal alleles in the mixed sample and to determine the copy number of such alleles. The mixed sample and the reference sample can be analyzed in separate reactions, e.g. separate CGE lanes. Alternatively, the mixed and the reference sample can be run in the same reaction, e.g. same CGE lane, by using two different dye labels, e.g. differently labeled PCR primers. When a reference sample is run through the PCR/CGE process, the alleles show up as peaks in the CGE. It is desirable, but not essential, to associate these peaks with known alleles in the population at each locus. When performing PCR/CGE it may be very useful to reduce the non-linearities in the response of PCR to input DNA copies (i.e. to effect more quantitative PCR) so that the data can be more easily related to models of aneuploidy. This ‘linearization’ can be accomplished by the following procedure:
- (a) The PCR reaction is initiated.
- (b) The PCR reaction is interrupted after N cycles (N=5 to 10) and ˜one third of the reaction products are removed and run on CGE. PCR cycling is re-initiated. Repeat until 40 PCR cycles or saturation is achieved.
- (c) CGE peak masses are determined and normalized to correct for the depletion of the reaction products at each iteration of (b).
- (d) A saturation (splining) curve is fit to the normalized data for each allele peak, and quantitative starting concentrations are inferred as in customary qPCR.
- The above procedure tends to accomplish quantitative PCR while enabling a high degree of multiplexing. Because each CGE run has a slightly different relation between DNA fragment size (and sequence) and mobility, each trace typically will need to undergo a length transformation, such as a low-order (cubic or quartic) polynomial transformation, in order to map to the data from the trace corresponding to the previous amplification point. This mapping can be determined by adjusting the transformation parameters to achieve the best fit of the one data trace to the other, with both normalized to the same total sum of squares or summed peak heights.
- The maternal peaks at each locus provide an estimate of the secondary ‘stutter’ structure at each locus due to PCR errors. The locations of these small secondary peaks can be used to blank out length regions that are contaminated by this stutter when looking for and using the non-maternal allele peaks (as described herein for example). Alternatively, more sophisticated ‘decouvolution’ algorithms can be applied to remove the stutter Stoughton, et al., Electrophoresis; 18(1): 1-S (1997).
- The sample containing an unknown mixture of fetal and maternal cells is analyzed as in Step (b). This could be done in a separate CGE lane, or in the same CGE lane as the maternal sample by using two different dye labels on the PCR primers. Because each CGE trace has a slightly different relation between DNA fragment size (and sequence) and mobility, these data typically will need to undergo a length transformation, such as a low-order (cubic or quartic) polynomial transformation in order to map one trace onto the other to facilitate peak identification and model fitting. This mapping can be determined by adjusting the transformation parameters to achieve the best fit of the peak locations in one data trace to the other. This mapping will be well determined in the assumed situation where the maternal cells are more numerous than the fetal cells, because the maternal signature will dominate and will be shared in the two data sets.
-
FIG. 5 illustrates typical locus patterns arising from a normal (diploid) fetus and mother. AtLocus 1, the paternal allele is the same as the left hand maternal allele, and adds to its apparent height. AtLocus 2, the paternal allele has a length between the lengths of the maternal alleles. In addition, there is a secondary ‘stutter’ peak on the shoulder of the right hand maternal peak. InLocus 3, the maternal sample is homozygous leading to only one main peak, and the paternal allele is distinct from this allele. -
FIG. 6 illustrates locus patterns arising from trisomic fetal cells. The dashed trace represents mixed sample containing trisomic fetal cells, superposed on material sample trace (solid black). Trisomy causes excess amplitude in maternal alleles at loci contained within the aneuploid region (here assumed to containLoci Locus 1 contains contributions from the trisomy and from a paternal allele. - In
step 107, data models are constructed. From the data obtained from the quantifying step different data models can be constructed depending upon different assumptions. - For example, a data model for the CGE patterns in
FIGS. 5 and 6 can be as follows: - Let m1 denote the CGE signal obtained from one of the maternal alleles at a given locus and m2 the signal obtained from the other maternal allele, which might be the same allele, Let p denote the CGE signal obtained from the paternal allele at a given locus. Let p1 and p2 denote the CGE signals obtained from the paternal alleles at a given locus when a paternally derived trisomy occurs. Let α and β denote the relative number of maternal and fetal cells, respectively. Then in the case of a chromosome with maternal non-dysjunction trisomy, the data will have the form
x=α(m1+m2)+β(m1+m2+p), (1) - A normal (diploid) chromosome will give
x=α(m1+m2)+β([m1 or m2]+p), (2) - and a paternally derived trisomy will give
x=α(m1+m2)+β([m1 or m2+p1]+p2). (3) - In some embodiments, data and data model is represented as discrete peak masses (or heights) and peak locations or as vectors of values representing the actual peak profiles. In the case of representation by peak characteristics, the ‘addition’ operation in Equations 1-3 denotes summation of peak height or mass at the discrete allele location. In the case where the fall peak profiles are represented, summation denotes summation of signals bin by bin over the CGE trace, and in this case it may be helpful to zero the data except in the immediate vicinity of actual peaks. Representation via peak characteristics is preferable when using the PCR linearization technique described above.
- To determine aneuploidy, the differences between the structure of the β-term that appears in the first and second equations above is determined. In the first case, there is an additional contribution to both maternal alleles along with the paternal allele, and in the second case there is an additional contribution only to one of the maternal alleles along with the paternal allele. The essence of the presence/absence declaration for fetal cells lies in the evidence for β being greater than zero.
- In
step 108, the best overall fit of model to data is selected from among all the model sets. This modeling approach optimally uses information contained in the increase of chromosome copy number with aneuploidy and its association with the strength of non-maternal alleles. - In some embodiments, CGE signals representing m1 and m2 at each locus are obtained by profiling the maternal-only sample and mapping the peak locations to the corresponding ones of the mixed sample. The heights of m1 and m2 may be unequal, and this helps cortect for PCR amplification biases associated with particular alleles, The values of p, p1, p2, α, and β are determined from the mixed sample data by fitting Equations 1-3 to the data, optionally by using the least squares, or the maximum likelihood methods.
- The three models need to be fit to each chromosome with suspected trisomy,
e.g. chromosomes Equations - Segmental aneuploidies also could be tested by hypothesizing that different contiguous subsets of loci are contained within the aneuploid region. With each model variant, α and β have to be determined and the parameters describing the paternal alleles have to be determined at each locus for each model variant. The paternal allele peak height and shape can be assumed to be an average of the known maternal ones at that locus, while the paternal allele location needs to be fit to the data. The possible locations for the paternal allele will be the location of m1, the location of m2, and ‘elsewhere in the locus window’ where this latter possibility involves a search over discrete shifts smaller than a typical peak half-width at half maximum. Prior probabilities on the choices of p, taken from population allele frequency data, can be used, if their product lengths can be predicted.
- In some cases, because of the number of parameters being fit, suboptimal searches can be used for computational efficiency. For example, one possible approach involves iterative methods, such as the following, which would be applied to each data model variant.
- (i) Set β to 0 and solve for α.
- (ii) Set β to a value where β/α is the smallest fetal/maternal cell ratio for which fetal cells are likely to be detectable.
- (iii) Solve for paternal allele location(s) at each locus, one locus at a time that minimize data-model residuals.
- (iv) Fix the paternal allele parameters and adjust β to minimize residuals over all the data.
- (v) Now vary only a to minimize residuals.
- (vi) Repeat iv and v until convergence.
- (vii) Repeat iii through v until convergence.
- In
step 109, the presence or absence of fetal DNA is determined using the models described above. The best overall fit for such models yields the values of β, α that can be called βmax, αmax. The likelihood of observing the data given βmax can be compared to the likelihood given β=0. The ratio is a measure of the amount of evidence for fetal DNA. A threshold for declaring fetal DNA is the likelihood ratio of approximately 1000 or more. The likelihood calculation can be approximated by a Chi-squared calculation involving the sum of squared residuals between the data and the model, where each residual is normalized by the expected rms error. - If it is determined that fetal DNA is not present in the mixed sample as calculated above, then the test is declared to be non-informative. On the other hand, if it is decided that fetal DNA is present in the mixed sample, then the likelihoods of the data given the different data model types can be compared to declare trisomy or another condition.
- In
step 110, the likelihood ratios of trisomy models (Equations 1 and 3) to the normal model (Equation 2) are calculated and these ratios are compared to a predefined threshold. This threshold can be set so that in controlled tests all the trisomic cases are declared aneuploid, and so that it is expected that the vast majority (>99.9%) of all truly trisomic cases are declared aneuploid by the test. In one embodiment, to accomplish a detection rate of >90% or 95% or approximately 99.9%, the likelihood ratio threshold is increased beyond what is necessary to declare all the known trisomic cases in the validation set by a factor of 1000/N, where N is the number of trisomy cases in the validation set. - In
step 111, errors that may arise from the experimental procedure used to obtain the data can be taken into account in the model calculation(s). For instance, in the example described above, CGE data contain small additive errors associated with CGE readout and larger multiplicative errors associated with PCR amplification efficiencies being different from locus to locus and from allele to allele within a locus. By using the maternal-only data to define m1 and m2 peak characteristics at each locus, the effects of PCR amplification biases associated with different primers and different amplicons from the same primers have been mostly controlled. Nevertheless, small variations in the process from day to day and the statistics of small numbers of starting genome copies will cause some random errors to remain. These tend to be multiplicative errors in the resulting CGE peak heights; e.g. two peaks may be 20% different in height although the starting concentrations of the alleles were identical. In one embodiment, it may be assumed that errors are random from peak to peak, and have relatively small additive errors, and larger Poisson and multiplicative error components. The magnitudes of these error components can be estimated from repeated PCR/CGE processing of identical samples. The Chi-square residuals calculation for any data-model fit then can be supported with these modeled squared errors for any peak height or data bin. - In another aspect of the present invention, the presence of fetal cells in a mixed sample and fetal abnormalities in said cells is determined without trying to integrate them in a data-model fitting procedure described above. For example, steps 100-107 can be performed as described above. Then,
analysis using Equations Equations - In another aspect of the invention, the methods herein only determine presence or absence of fetal DNA, and aneuploidy information is known from another sources (e.g. fluorescence in situ hybridization (FISH) assay). For example, it may be desirable only to verify the presence or absence of fetal cells to ensure that a diploid test result is truly due to a normal fetus and not to failure of an assay (e.g. FISH). In this case, the process may be simplified by focusing on detecting the presence of non-maternal alleles without regard to associating them with increases in the maternal allele strengths at the same locus. Thus a process similar to the one outlined above may be used but it is not as necessary to arrange the PCR product lengths so that the products from different loci have distinct length windows in the CGE readout. The alleles from the different loci can be allowed to fall essentially anywhere in the effective measurement length window of the CGE. It also is not necessary to ‘lineate’ the PCR result(s) via multiple CGE readouts at different stages in the PCR cycling as is suggested in
step 107. - Therefore, maternal-only and mixed samples are run and mapped to each other to align maternal allele peak locations, as described above. PCR is run to saturation, or nearly to saturation, to be sure to detect the low abundance fetal sequences. The evidence for fetal DNA then arises from extra peaks in the mixed-sample data with respect to the maternal-sample data. Based on typical heterozygosities of approximately 0.7 for highly polymorphic STRs, the chance of not seeing a distinct paternal allele (distinct from both maternal alleles) when fetal DNA is in fact present decreases approximately as (0.72)N, where N is the number of loci included. Thus approximately ten STR loci will provide ˜99.9% probability of detection. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample. In some embodiments, one or more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 DNA polymorphism loci (particularly STRs) per target chromosome are analyzed to verify presence of fetal cells.
- Any of the steps above can be performed by a computer program product that comprises a computer executable logic that is recorded on a computer readable medium. For example, the computer program can execute some or all of the following functions: (i) controlling enrichment of fetal cells or DNA from mixed sample and reference sample, (ii) pre-amplifying DNA from both samples, (iii) amplifying specific polymorphic DNA regions from both samples, (iv) identifying and quantifying maternal alleles in the reference sample, (v) identifying maternal and non-maternal alleles in the mixed sample, (vi) fitting data on alleles detected from mixed and/or reference samples into data models, (vii) determining the presence or absence of fetal cells in the mixed sample, (viii) declaring nodal or abnormal phenotype for a fetus based on data models or declaring non-informative results, and (ix) declaring a specific fetal abnormality based on the above results. In particular, the computer executable logic can fit data on the quantity of DNA polymorphism(s) (e.g. STR's) into one or more data models. One example of a data model provides a determination of a fetal abnormality from given data signals obtained by molecular analysis e.g. CGE. The computer executable logic provides for a determination of the presence or absence of a trisomy, and distinguish whether the trisomy is paternally derived or if it originates from a maternal non-disjunction event. For example, given the following data signals that can be obtained by molecular analysis (e.g. CGE)
- m1, which represents a signal obtained from one of the maternal alleles (m1) at a given locus,
- m2, which represents a signal obtained from the other maternal allele, which might be the same allele,
- p, which is a signal that is obtained from the paternal allele at a given locus, and
- p1 and p2, which are signals obtained from the paternal alleles at one given locus when a paternally derived trisomy occurs, and
- letting α and β, which denote the relative number of maternal and fetal cells, respectively,
- the following determinations can be made. In the case of a chromosome with maternal non-disjunction trisomy, the data will have the form
x=α(m1m2)+β(m1m2+p). (1)
A normal (diploid) chromosome will give - x=α(m1m2)+β([m1 or m2]+p), (2)
- and a paternally derived trisomy will give
x=α(m1+m2)+β([m1 or m2]p1+p2). (3) - The computer executable logic can work in any computer that may be any of a variety of types of general-purpose computers such as a personal computer, network server, workstation, or other computer platform now or later developed. In some embodiments, a computer program product is described comprising a computer usable medium having the computer executable logic (computer software program, including program code) stored therein. The computer executable logic can be executed by a processor, causing the processor to perform functions described herein. In other embodiments, some functions are implemented primarily in hardware using, for example, a hardware state machine. Implementation of the hardware state machine so as to perform the functions described herein will be apparent to those skilled in the relevant arts.
- The program can provide a method of evaluating the presence or absence of trisomy in a mixed cell sample by accessing data that reflects the level of polymorphism(s) at two alleles at two or more given loci in a mixed sample (maternal and fetal cells) and in a sample enriched in fetal cells, relating the levels of polymorphism(s) to the number of maternal and fetal cells (α and β in equations 1-3), and determining the presence or absence of trisomy in the samples.
- In one embodiment, the computer executing the computer logic of the invention may also include a digital input device such as a scanner. The digital input device can provide information on the polymorphism levels/quantity. For example, a scanner of this invention can provide an image of the DNA polymorphism (particularly STRs) according to method herein. For instance, a scanner can provide an image by detecting fluorescent, radioactive, or other emission; by detecting transmitted, reflected, or scattered radiation, by detecting electromagnetic properties or other characteristics; or by other techniques. The data detected is typically stored in a memory device in the form of a data file. In one embodiment, a scanner may identify one or more labeled targets. For instance, a first DNA polymorphism may be labeled with a first dye that fluoresces at a particular characteristic frequency, or narrow band of frequencies, in response to an excitation source of a particular frequency. A second DNA polymorphism may be labeled with a second dye that fluoresces at a different characteristic frequency. The excitation sources for the second dye may, but need not, have a different excitation frequency than the source that excites the first dye, e.g., the excitation sources could be the same, or different, lasers.
- Another aspect of the invention includes kits containing the devices and reagents for performing the enrichment and genetic analysis. Such kits may include the materials for any individual step disclosed, any combination of devices and reagents or the devices and reagents for performing all of the steps. For example, a kit may include the arrays for size-based enrichment, the device for magnetic separation of the cells and reagents for performing PCR or CGE. Also included may be the reagents for performing multiple displacement amplification. This is an exemplary kit and the kits can be constructed using any combination of disclosed materials and devices. The use of the size-based enrichment provides gentle handling that is particularly advantageous for permitting subsequent genetic analysis.
- While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
-
FIGS. 7A-7D illustrates a schematic of the device used to separate nucleated cells from fetal cord blood. - Dimensions: 100 mm×28 mm×1 mm
- Array design: 3 stages, gap size=18, 12 and 8 μm for the first, second and third stage, respectively.
- Device fabrication: The arrays and channels were fabricated in silicon using standard photolithography and deep silicon reactive etching techniques. The etch depth is 140 μm. Through holes for fluid access are made using KOH wet etching. The silicon substrate was sealed on the etched face to form enclosed fluidic channels using a blood compatible pressure sensitive adhesive (9795, 3M, St Paul, Minn.).
- Device packaging: The device was mechanically mated to a plastic manifold with external fluidic reservoirs to deliver blood and buffer to the device and extract the generated fractions.
- Device operation: An external pressure source was used to apply a pressure of 2.0 PSI to the buffer and blood reservoirs to modulate fluidic delivery and extraction from the packaged device.
- Experimental conditions: Human fetal cord blood was drawn into phosphate buffered saline containing Acid Citrate Dextrose anticoagulants. Ira of blood was processed at 3 mL/hr using the device described above at room temperature and within 48 hrs of draw. Nucleated cells from the blood were separated from enucleated cells (red blood cells and platelets), and plasma delivered into a buffer stream of calcium and magnesium-free Dulbecco's Phosphate Buffered Saline (14190-144, Invitrogen, Carlsbad, Calif.) containing 1% Bovine Serum Albumin (BSA) (A8412-100 ML, Sigma-Aldrich, St Louis, Mo.) and 2 mM EDTA (15575-020, Invitrogen, Carlsbad, Calif.).
- Measurement techniques: Cell smears of the product and waste fractions (
FIG. 8A-8B ) were prepared and stained with modified Wright-Giemsa (WG16, Sigma Aldrich, St. Louis, Mo.). - Performance: Fetal nucleated red blood cells were observed in the product fraction (
FIG. 8A ) and absent from the waste fraction (FIG. 8B ). - The device and process described in detail in Example 1 were used in combination with immunomagnetic affinity enrichment techniques to demonstrate the feasibility of isolating fetal cells from maternal blood.
- Experimental conditions: blood from consenting maternal donors carrying male fetuses was collected into K2EDTA vacutainers (366643, Becton Dickinson, Franklin Lakes, N.J.) immediately following elective termination of pregnancy. The undiluted blood was processed using the device described in Example 1 at room temperature and within 9 hrs of draw. Nucleated cells from the blood were separated from enucleated cells (red blood cells and platelets), and plasma delivered into a buffer stream of calcium and magnesium-free Dulbecco's Phosphate Buffered Saline (14190-144, Invitrogen, Carlsbad, Calif.) containing 1% Bovine Serum Albumin (BSA) (A8412-100 mL, Sigma-Aldrich, St Louis, Mo.). Subsequently, the nucleated cell fraction was labeled with anti-CD71 microbeads (130-046-201, Miltenyi Biotech Inc., Auburn, Calif.) and enriched using the MiniMACS™ MS column (130-042-201, Miltenyi Biotech Inc., Auburn, Calif.) according to the manufacturer's specifications. Finally, the CD71-positive fraction was spotted onto glass slides.
- Measurement techniques: Spotted slides were stained using fluorescence in situ hybridization (FISH) techniques according to the manufacturer's specifications using Vysis probes (Abbott Laboratories, Downer's Grove, Ill.). Samples were stained from the presence of X and Y chromosomes. In one case, a sample prepared from a known
Trisomy 21 pregnancy was also stained forchromosome 21. - Performance: Isolation of fetal cells was confirmed by the reliable presence of male cells in the CD71-positive population prepared from the nucleated cell fractions (
FIG. 9 ). In the single abnormal case tested, thetrisomy 21 pathology was also identified (FIG. 10 ). - Confirmation of the presence of a male fetal cell in an enriched sample is performed using qPCR with primers specific for DYZ, a marker repeated in high copy number on the Y chromosome. After enrichment of fnRBC by any of the methods described herein, the resulting enriched fnRBC are binned by dividing the sample into 100 PCR wells. Prior to binning, enriched samples may be screened by FISH to determine the presence of any fnRBC containing an aneuploidy of interest. Because of the low number of fnRBC in maternal blood, only a portion of the wells will contain a single fnRBC (the other wells are expected to be negative for fnRBC). The cells are fixed in 2% Paraformaldehyde and stored at 4° C. Cells in each bin are pelleted and resuspended in 5
μl PBS plus 1 μl 20 mg/ml Proteinase K (Sigma #P-2308). Cells are lysed by incubation at 65° C. for 60 minutes followed by inactivation of the Proteinase K by incubation for 15 minutes at 95° C. For each reaction, primer sets (DYZ forward primer TCGAGTGCAATTCCATTCCG; DYZ reverse primer ATGGAATGGCATCAAACGGAA; and DYZ Taqman Probe 6FAM-TGGCTGTCCATTCCA-MGBNFQ), TaqMan Universal PCR master mix, No AmpErase and water are added. The samples are run and analysis is performed on an ABI 7300: 2 minutes at 50° C., 10 minutes 95° C. followed by 40 cycles of 95° C. (15 seconds) and 60° C. (1 minute). Following confirmation of the presence of male fetal cells, further analysis of bins containing fnRBC is performed. Positive bins may be pooled prior to further analysis. -
FIG. 20 shows the results expected from such an experiment. The data inFIG. 20 was collected by the following protocol. Nucleated red blood cells were enriched from cord cell blood of a male fetus by sucrose gradient two Heme Extractions (HE). The cells were fixed in 2% paraformaldehyde and stored at 4° C. Approximately 10×1000 cells were pelleted and resuspended each in 5μl PBS plus 1 μl 20 mg/ml Proteinase K (Sigma #P-2308). Cells were lysed by incubation at 65° C. for 60 minutes followed by a inactivation of the Proteinase K by 15 minute at 95° C. Cells were combined and serially diluted 10-fold in PBS for 100, 10 and 1 cell per 6 μl final concentration were obtained. Six μl of each dilution was assayed in quadruplicate in 96 well format. For each reaction, primer sets (DYZ forward primer TCGAGTGCATTCCATCCCG; 0.9 uM DYX reverse primer ATGGAATGGCATCAAACGGAA; and 0.5 uM DYZ TaqMan Probe 6FAM-TGGCTGTCCATFTCCA-MGBNFQ), TaqMan Universal PCR master mix, No AmpErase and water were added to a final volume of 25 μl per reaction. Plates were run and analyzed on an ABI 7300: 2 minutes at 50° C., 10 minutes 95° C. followed by 40 cycles of 95° C. (15 seconds) and 60° C. (1 minute). These results show that detection of a single fnRBC in a bin is possible using this method. - Maternal blood is processed through a size-based separation module, with or without subsequent MHEM enhancement of fnRBCs. The enhanced sample is then subjected to FISH analysis using probes specific to the aneuploidy of interest (e.g.,
triploidy 13,triploidy 18, and XYY). Individual positive cells are isolated by “plucking” individual positive cells from the enhanced sample using standard micromanipulation techniques. Using a nested PCR protocol, STR marker sets are amplified and analyzed to confirm that the FISH-positive aneuploid cell(s) are of fetal origin. For this analysis, comparison to the maternal genotype is typical. An example of a potential resulting data set is shown in Table 2. Non-maternal alleles may be proven to be paternal alleles by paternal genotyping or genotyping of known fetal tissue samples. As can be seen, the presence of paternal alleles in the resulting cells, demonstrates that the cell is of fetal origin (cells # TABLE 2 STR locus alleles in maternal and fetal cells STR locus STR locus STR locus STR locus STR locus DNA Source D14S D16S D8S F13B vWA Maternal 14, 17 11, 12 12, 14 9, 9 16, 17 alleles Cell # 1 alleles 8 19 Cell # 2alleles 17 15 Cell # 3alleles 14 Cell # 4alleles Cell # 5 alleles 17 12 9 Cell # 6 allelesCell #7 alleles 19 Cell # 8alleles Cell # 9 alleles 17 14 7, 9 17, 19 Cell # 10alleles 15 - Maternal blood is processed through a size-based separation module, with or without subsequent MHEM enhancement of fnRBCs. The enhanced sample is then subjected to FISH analysis using probes specific to the aneuploidy of interest (e.g.,
triploidy 13,triploidy 18, and XYY). Samples testing positive with FISH analysis are then binned into 96 microtiter wells, each well containing 15 μl of the enhanced sample. Of the 96 wells, 5-10 are expected to contain a single fnRBC and each well should contain approximately 1000 nucleated maternal cells (both WBC and mnRBC). Cells are pelleted and resuspended in 5μl PBS plus 1 μl 20 mg/ml Proteinase K (Sigma #P-2308). Cells are lysed by incubation at 65° C. for 60 minutes followed by a inactivation of the Proteinase K by 15 minute at 95° C. - In this example, the maternal genotype (BB) and fetal genotype (AB) for a particular set of SNPs is known. The genotypes A and B encompass all three SNPs and differ from each other at all three SNPs. The following sequence from chromosome 7 contains these three SNPs (rs7795605, rs7795611 and rs7795233 indicated in brackets, respectively) (ATGCAGCAAGGCACAGACTAA[G/A]CAAGGAGA[G/C]GCAAAATTTTC[A/G]TAGGGGAGAGAAATGGGTCATT).
- In the first round of PCR, genomic DNA from binned enriched cells is amplified using primers specific to the outer portion of the fetal-specific allele A and which flank the interior SNP (forward primer ATGCAGCAAGGCACAGACTACG; reverse primer AGAGGCGACAGAAATGGGTCATT). In the second round of PCR, amplification using real time SYBR Green PCR is performed with primers specific to the inner portion of allele A and which encompass the interior SNP (forward primer CAAGGCACAGACTAAGCAAGGAGAG; reverse primer GGCAAAATTTTCATAGGGGAGAGAAATGGGTCATT).
- Expected results are shown in
FIG. 31 . Here, six of the 96 wells test positive for allele A, confirming the presence of cells of fetal origin, because the maternal genotype (BB) is known and cannot be positive for allele A. DNA from positive wells may be pooled for further analysis or analyzed individually. -
FIG. 11 illustrates a diagram of the planned protocol for clinical practice where a reference sample (maternal blood) and a fetal enriched sample will be processed in parallel. Twelve polymorphic STRs are chosen (SeeFIG. 12 ) and associated nested PCR primers were designed (FIG. 13-14 ). - Cell Lysis: Cells are lysed in a proteinase K solution by heating samples for 60 minutes at 65° C., followed by a heating step of 15 minutes at 95° C.
- 1st round of PCR; A polymerase mix that includes 12 specialized STR primer pairs is added to the crude lysate. A master PCR mix is generated according to the number of samples as per the recipe below. For the reference sample 44 μL of the master mix are added directly to the cell lysate. For the sample recovered from the slide the volume of the reaction is adjusted as necessary. (e.g. 32 μL crude lysate in a 100 μL total reaction volume). A no template or negative control is generated to test for contamination.
Master mix Multiplex PCR cylce outer 12- plex 1 rxn Step Temp (C.) Time (mins) 2X Qiagen Mix 25.0 1.0 95 0.5 titanium 1.0 2.0 94 0.5 Qiagen Q factor 5.0 3.0 68 1.5 water 10.0 4.0 72 1.5 4.2 uM 12 plex3.0 5.0 cycle to step 2, 44 times primers Cell lysate 6.0 6.0 72 10 50.0 - Nested PCR: After PCR, optionally, diluted products are added to a second nested primer PCR reaction. Two ul aliquot of each 12-plex PCR reaction is diluted 40 fold (to 80 ul total) with nuclease free water from the PCR kit. The diluted fetal enriched 12-plex reaction could be used as template for a master mix for 8 nested PCR reactions with HAM labeled primers. A second master mix can be generated using the dilution from the maternal reference for 8 nested PCR reactions with VIC labeled primers. The following primer pairs are suggested. A no template or negative control is generated to test for contamination.
Nested STR primer facts Reaction Fragment size rxn# temp STR primers ranges 1 68 CSF1P0 THO1 295-327, 171-215 2 68 TPOX CYARO4 220-256, 172-205 3 68 F13A 179-235 4 68 FIBRA 158-286 5 63 VWA D21S11 122-182 202-265 6 63 CD4 86-141 7 63 D14S1434 70-102 8 63 D22S1045 76-109 -
Master mix for nested primers 1 rxn 9 rxns 2X Q Mix 12.5 112.5 titanium 0.5 4.5 Q 2.5 22.5 water 3.3 29.3 5 uM primers 1.3 40X diluted template 5.0 45.0 25.0 213.8 -
Nested PCR cycle Step Temp (C.) Time (mins) 1.0 95 0.5 2.0 94 0.5 3.0 X 1.5 4.0 72 1.5 5.0 cycle to step 2, 44 times 6.0 72 10 - The amplification with the nested PCR primers is run with an annealing temperature of 63° C. or 68° C. depending on the primer pair being amplified as indicated in
FIG. 13 andFIG. 14 . - Detection on ABI 310 Instrument: PCR products are detected on an Agilent Bioanalyzer. The maternal reference VIC labeled PCR reaction products is diluted 10 fold in nano-pure water (17.8 uOhms). Another 10 fold dilution of the fetal enriched FAM-PCR products is generated. The ABI loading buffer is prepared by adding 0.5
μL LIZ 500 size standard to 12 μL Hi Di Formamide (scale as appropriate to the number of samples, include enough buffer for the negative control to test for contamination). 1 μL diluted PCR product is added to 12 ul loading buffer. The sample is heated to 95° C. for 2 minutes and then placed on ice. The samples are loaded onto the ABI 310 as per the manufacturer's instructions. - Analysis: For analysis the ABI fragments output are examined for the expected peak sizes as per the nested STR primer facts table (
FIG. 13 andFIG. 14 ). For each STR locus is determined whether there are 1 or 2 alleles (homozygous or heterozygous) for the fetal enriched (PAM labeled sample) or the maternal reference (VIC labeled sample). Alleles generated from the fetal enriched (FAM labeled sample) that are not present in the maternal reference (VIC labeled sample) are unique to the fetus and verify the presence of fetal cells in the sample. If the number of fetal cells is particularly low (<5 cells), not all loci or alleles will always amplify. Allele drop out can generate a false negative. A false positive is most likely generated from contamination and has not been observed in tests to date. If the purity of fetal cells is particularly low (<10% in tests executed on the bioanalyzer) signal intensity of paternal alleles can be very weak. This can also generate a false negative result. In clinical practice the amplicons will have different fluorescent labels incorporated into them marking them as the maternal reference or the fetal enriched samples. The labels allow the samples to be loaded simultaneously into an ABI 310 capillary and differentiated. Paternal alleles are identified as those unique to the fetal enriched sample in comparison to the maternal reference. The efficiency of the overall process is determined after sufficient samples have been analyzed on the ABI 310 to establish the input cell purity and minimum number of fetal cells necessary to achieve 99% detection at 0.1% false positive rate. - The protocol detection limit was determined using fixed cells from cord blood. Cord blood from clinical sample SVH0003C was subjected to erythrocyte lysis and the remaining leukocytes were fixed in a solution of PBS and 2% para-formaldehyde. Cell numbers were estimated from hemocytometer counts and dilutions made into a Tris protienase K (PK) solution. After cell lysis and PK inactivation a PCR cocktail including primers for STR loci TPOX and CSF1P0 was added directly to the crude lysate and amplified as described in Example 6. The products were analyzed on an Agilent bioanalyzer.
FIGS. 15A-15B shows representative results. TPOX and CSF1P0 amplification products are underline in boxes. Detection for the PCR protocol from fixed cord blood can occur with less than 10 cells as shown by the result inFIG. 16 . - An estimated 10 fetal cells were mixed with increasing amounts of material cells (approximately 0-4000 cells as measured by hemocytometer counts). After proteinase K lysis, only a 1st round of PCR with primers to STR loci D21S11 and VWA was executed as described in Example 6.
FIG. 17 shows representative results. The mother and fetus are identical at the D21S11 locus but the child has a unique (paternal) allele at the VWA locus.FIG. 17 shows that detection of the paternal VWA allele is lost when the fetal purity drops below 10%. - Approximately 100 cells were spotted onto a poly-L-lysine slide and heat dried. Cells were fixed in a MeOH acetic acid solution and rinsed in MeOH. After air drying the slide was treated with 2% para-formaldehyde for 10 minutes then washed in 1×PBS. The slide was dehydrated in passes of EtOH for 1 ruin each in 70%, 80%, 90%, and finally 100%. A dam was applied around the cells and 30 ul of proteinase K was added on top of the cells and a cover slip adhered over the dam. The slide was incubated on a heat block at 65° C. for 60 minutes and 95° C. for 15 minutes. The lysate solution was then transferred directly to a 100 ul PCR reaction with VWA and LIPOL primer. PCR protocol and analysis were performed as described in Example 6.
FIG. 18 shows representative results. VWA and LIPOL amplicons are underlined by boxes in the figure. These results show that STRs markers can be generated from fixed cells recovered from a slide. - Mutliplex PCR reactions from samples with 10 fetal cells in a background of maternal cells generating at 10%, 5% and 2% fetal cells purity concentration were performed as described in Example 6. A dilution of the three multiplex PCR reactions was used as template in nested PCR reactions for STRs TPOX/CYAR04, VWA/D21S11, and D14S1434 as described in Example 6.
FIG. 19 shows representative results. The underlined loci are known to have unique fetal alleles which are designated by arrows when visible in the gel. The three loci were visible when fetal cells constituted 10% of the sample. D14S1434 loci was visible when fetal cells constituted 5% and 2% of the sample. -
FIG. 15A shows that the Bioanalyzer can resolve a 16 base pair difference between the 99 base pair D14S1434 maternal allele and the 83 base pair paternal allele in a mixed fetal sample at 5% purity (also shown inFIG. 11 , lane 6).FIG. 15B shows that the output of fragments calibration standards. The output of an ABI310 fragment calibration standard is shown in blue or FAM label. Fragments of 232, 234, 236 and 238 are easily resolved from one another. For a resolution comparison note that the orange, VIC labeled, 246 size standard peak is 8 bases away from the FAM labeled 238 peak, half the distance as the maternal and paternal alleles in the Bioanalyzer trace. - Genomic DNA from enriched fetal cells and a maternal control sample will be genotyped for specific STR loci in order to assess the presence of chromosomal abnormalities, such as trisomy. Due to the small number of fetal cells typically isolated from maternal blood it is advantageous to perform a pre-amplification step prior to analysis, using a protocol such as improved primer extension pre-amplification (IPEP) PCR. Cell lysis is carried out in 10 ul High Fidelity buffer (50 mM Tris-HCL, 22 mM (NH.sub.4).sub.2 SO.sub.4 2.5 mM MgCl.sub.2, pH 8.9) which also contained 4 mg/ml proteinase K and 0.5 vol % Tween 20 (Merck) for 12 hours at 48° C. The enzyme is then inactivated for 15 minutes at 94° C. Lysis is performed in parallel batches in 5 ul, 200 mM KOH, 50 mM dithiothreitol for 10 minutes at 65.degree. The batches are then neutralized with 5 ul 900 mM Tris HCl pH 8.3, 300 mM KCl. Preamplication is then carried out for each sample using completely randomized 15-mer primers (16 uM) and dNTP (100 uM) with 5 units of a mixture of Taq polymerase (Boehringer Mannheim) and Pwo polymerase (Boehringer Mannheim) in a ratio of 10:1 under standard PCR buffer conditions (50 mM Tris-HCL, 22 mM (NH4)2 SO4, 2.5 mM Mg2, pH 8.9, also containing 5% by vol. of DMSO) in a total volume of 60 ul with the following 50 thermal cycles: Step Temperature Time (1) 92° C. 1
Min 30 Sec; (2) 92° C. 40 Min (3) 37° C. 2 Min; (4) ramp: 0.1° C./sec to 55° C. (5) 55° C. 4 Min (6) 68° C. 30 Sec (7) go to step 2, 49 times (8) 8° C. 15 Min. - Dye labeled primers will then be selected from Table 3 based on STR loci on a chromosomes of interest, such as 13, 18, 21 or X. The primers are designed so that one primer of each pair contains a fluorescent dye, such as ROX, HEX, JOE, NED, PAM, TAMARA or LIZ. The primers are placed into multiplex mixes based on expected product size, fluorescent tag compatibility and melting temperature. This allows multiple STR loci to be assayed at once and yet still conserves the amount of initial starting material required. All primers are initially diluted to a working dilution of 10 pM. The primers are then combined in a cocktail that has a final volume of 40 ul. Final primer concentration is determined by reaction optimization. Additional PCR grade water is added if the primer mix is below 40 ul. A reaction mix containing 6 ul of Sigma PCR grade water, 1.25 ul of Perkin Elmer Goldamp PCR buffer, 0.5 ul of dNTPs, 5 ul of the primer cocktail, 0.12 ul of Perkin Elmer Taq Gold Polymerase and 1.25 ul of Mg (25 mM) is mixed for each sample. To this a 1 ul sample containing preamplified DNA from enriched fetal cells or maternal control genomic DNA is added.
- The reaction mix is amplified in a DNA thermocyler, (PTC-200; MJ Research) using an amplification cycle optimized for the melting temperature of the primers and the amount of sample DNA.
- The amplification product will then analyzed using an automated DNA sequencer system, such as the ABI 310, 377, 3100, 3130, 3700 or 3730, or the Li-
Cor 4000, 4100, 4200 or 4300. For example when the amplification products are prepared for analysis on a ABI 377 sequencer, 6 ul of products will be removed and combined with 1.6 ul of loading buffer mix. The master loading buffer mix contains 90 ul deionized formamide combined with 25 ul Perkin Elmer loading dye and 10 ul of a size standard, such as the ROX 350 size standard. Various other standards can be used interchangeably depending on the sizes of the labeled PCR products. The loading buffer and sample are then heat denatured at 95° C. for 3 minutes followed by flash cooling on ice. 2 ul of the product/buffer mix is then electrophoresed on a 12inch 6% (19:1) polyacrylamide gel on an ARI 377 sequencer. - The results will then be analyzed using ABI Genotyper software. The incorporation of a fluorochrome during amplification allows product quantification for each chromosome specific STR, with 2 fluorescent peaks observed in a normal heterozygous individual with an approximate ratio of 1:1. By comparison in trisomic samples, either 3 fluorescent peaks with a ratio of 1:1:1 (trialleleic) or 2 peaks with a ratio of around 2:1 (diallelic) are observed. Using this method screening may be carried out for common trisomies and sex chromosome aneuploidy in a single reaction.
TABLE 3 Primer Sets for STRs on Chromsomes Ch. STR Marker Primer 1 Primer 2 13 D13S317 5ACAGAAGTCTGGGATGTGGA (SEQ ID NO 1) GCCCAAAAAGACAGACAGAA (SEQ ID NO 2) D13S1493 ACCTGTTGTATGGCAGCAGT (SEQ ID NO 3) AGTTGACTCTTTCCCCAACTA (SEQ ID NO 4) D1351807 TTTGGTAAGAAAAACATCTCCC (SEQ ID NO 5) GGCTGCAGTTAGCTGTCATT (SEQ ID NO 6) D13S256 CCTGGGCAACAAGAGCAAA (SEQ ID NO 7) AGCAGAGAGACATAATTGTG (SEQ ID NO 8) D13S258- ACCTGCCAAATTTTACCAGG (SEQ ID NO 9) GACAGAGAGAGGGAATAAACC (SEQ ID NO 10) D13S285 ATATATGCACATCCATCCATG (SEQ ID NO 11) GGCCAAAGATAGATAGCAAGGTA (SEQ ID NO 12) D13S303 ACATCGCTCCTTACCCCATC (SEQ ID NO 13) TGTACCCATTAACCATCCCCA (SEQ ID NO 14) D13S317 ACAGAAGTCTGGGATGTGGA (SEQ ID NO 15) GCCCAAAAAGACAGACAGAA (SEQ ID NO 16) D13S779 AGAGTGAGATTCTGTCTCAATTAA (SEQ ID NO 17) GGCCCTGTGTAGAAGCTGTA (SEQ ID NO 18) D13S787 ATCAGGATTCCAGGAGGAAA (SEQ ID NO 19) ACCTGGGAGGCGGAGCTC (SEQ ID NO 20) D13S793 GGCATAAAAATAGTACAGCAAGC (SEQ ID NO 21) ATTTGAACAGAGGCATGTAC (SEQ ID NO 22) D13S796 CATGGATGCAGAATTCACAG (SEQ ID NO 23) TCATCTCCCTGTTTGGTAGC (SEQ ID NO 24) D13S800 AGGGATCTTCAGAGAAACAGG (SEQ ID NO 25) TGACACTATCAGCTCTCTGGC (SEQ ID NO 26) D13S894 GGTGCTTGCTGTAAATATAATTG (SEQ ID NO 27) CACTACAGCAGATTGCACCA (SEQ ID NO 28) 18 D18S51 CAAACCCGACTACCAGCAAC (SEQ ID NO 29) GAGCCATGTTCATGCCACTG (SEQ ID NO 30) D18S1002 CAAAGAGTGAATGCTGTACAAACAGC (SEQ ID NO 31) CAAGATGTGAGTGTGCTTTTCAGGAG (SEQ ID NO 32) D18S1357 ATCCCACAGGATGCCTATTT (SEQ ID NO 33) ACGGGAGCTTTTGAGAAGTT (SEQ ID NO 34) D18S1364 TCAAATTTTTAAGTCTCACCAGG (SEQ ID NO 35) GCCTGTAGAAAGCAACAACC (SEQ ID NO 36) D18S1370 GGTGACAGAGCAAGACCTTG (SEQ ID NO 37) GCCTCTTGTCATCCCAAGTA (SEQ ID NO 38) D18S1371 CTCTCTTCATCCACCATTGG (SEQ ID NO 39) GCTGTAAGAGACCTGTGTTG (SEQ ID NO 40) D18S1376 TGGAACCACTTCATTCTTGG (SEQ ID NO 41) ATTTCAGACCAAGATAGGC (SEQ ID NO 42) D18S1390 CCTATTTAAGTTTCTGTAAGG (SEQ ID NO 43) ATGGTGTAGACCCTGTGGAA (SEQ ID NO 44) D18S499 CTGCACAACATAGTGAGACCTG (SEQ ID NO 45) AGATTACCCAGAAATGAGATCAGC (SEQ ID NO 46) D18S535 TCATGTGACAAAAGCCACAC (SEQ ID NO 47) AGACAGAAATATAGATGAGAATGCA (SEQ ID NO 48) D18S535 TCATGTGACAAAAGCCACAC (SEQ ID NO 49) AGACAGAAATATAGATGAGAATGCA (SEQ ID NO 50) D18S542 TTTCCAGTGGAAACCAAACT (SEQ ID NO 51) TCCAGCAACAACAAGAGACA (SEQ ID NO 52) D18S843 GTCCTCATCCTGTAAAACGGG (SEQ ID NO 53) CCACTAACTAGTTTGTGACTTTGG (SEQ ID NO 54) D18S851 CTGTCCTCTAGGCTCATTTAGC (SEQ ID NO 55) TTATGAAGCAGTGATGCCAA (SEQ ID NO 56) D18S858 AGCTGGAGAGGGATAGCATT (SEQ ID NO 57) TGCATTGCATGAAAGTAGGA (SEQ ID NO 58) D18S877 GATGATAGAGATGGCACATGA (SEQ ID NO 59) TCTTCATACATGCTTTATCATGC (SEQ ID NO 60) D21S11 GTGAGTCAATTCCCCAAG (SEQ ID NO 61) GTTGTATTAGTCAATGTTCTCC (SEQ ID NO 62) D21S1411 ATGATGAATGCATAGATGGATG (SEQ ID NO 63) AATGTGTGTCCTTCCAGGC (SEQ ID NO 64) D21S1413 TTGCAGGGAAACCACAGTT (SEQ ID NO 65) TCCTTGGAATAAATTCCCGG (SEQ ID NO 66) D21S1432 CTTAGAGGGACAGAACTAATAGGC (SEQ ID NO 67) AGCCTATTGTGGGTTTGTGA (SEQ ID NO 68) D21S1437 ATGTACATGTGTCTGGGAAGG (SEQ ID NO 69) TTCTCTACATATTTACTGCCAACA (SEQ ID NO 70) D21S1440 GAGTTTGAAAATAAAGTGTTCTGC (SEQ ID NO 71) CCCCACCCCTTTTAGTTTTA (SEQ ID NO 72) D21S1446 ATGTACGATACGTAATACTTGACAA (SEQ ID NO 73) GTCCCAAAGGACCTGCTC (SEQ ID NO 74) D21S2052 GCACCCCTTTATACTTGGGTG (SEQ ID NO 75) TAGTACTCTACCATCCATCTATCCC (SEQ ID NO 76) D21S2055 AACAGAACCAATAGGCTATCTATC (SEQ ID NO 77) TACAGTAAATCACTTGGTAGGAGA (SEQ ID NO 78) X SBMA TCCGCGAAGTGAAGAAC (SEQ ID NO 79) CTTGGGGAGAACCATCCTCA (SEQ ID NO 80) DXS1047 CCGGCTACAAGTGATGTCTA (SEQ ID NO 81) CCTAGGTAACATAGTGAGACCTTG (SEQ ID NO 82) DXS1068 CCTCTAAAGCATAGGGTCCA (SEQ ID NO 83) CCCATCTGAGAACACGCTG (SEQ ID NO 84) DXS1283E AGTTTAGGAGATTATCAAGCTGG (SEQ ID NO 85) GTTCCCATAATAGATGTATCCAG (SEQ ID NO 86) DXS6789 TTGGTACTTAATAAACCCTCTTTT (SEQ ID NO 87) CTAGAGGGACAGAACCAATAGG (SEQ ID NO 88) DXS6795 TGTCTGCTAATGAATGATTTGG (SEQ ID NO 89) CCATCCCCTAAACCTCTCAT (SEQ ID NO 90) DXS6800 GTGGGACCTTGTGATTGTGT (SEQ ID NO 91) CTGGCTGACACTTAGGGAAA (SEQ ID NO 92) DXS6810 ACAGAAAACCTTTTGGGACC (SEQ ID NO 93) CCCAGCCCTGAATATTATCA (SEQ ID NO 94) DXS7127 TGCACTTAATATCTGGTGATGG (SEQ ID NO 95) ATTTCTTTCCCTCTGCAACC (SEQ ID NO 96) DXS7132 AGCCCATTTTCATAATAAATCC (SEQ ID NO 97) AATCAGTGCTTTCTGTACTATTGG (SEQ ID NO 98) DXS8377 CACTTCATGGCTTACCACAG (SEQ ID NO 99) GACCTTTGGAAAGCTAGTGT (SEQ ID NO 100) DXS9893 TGTCACGTTTACCCTGGAAC (SEQ ID NO 101) TATTCTTCTATCCAACCAACAGC (SEQ ID NO 102) DXS9895 TTGGGTGGGGACACAGAG (SEQ ID NO 103) CCTGGCTCAAGGAATTACAA (SEQ ID NO 104) DXS9896 CCAGCCTGGCTGTTAGAGTA (SEQ ID NO 105) ATATTCTTATATTCCATATGGCACA (SEQ ID NO 106) DXS9902 TGGAGTCTCTGGGTGAAGAG (SEQ ID NO 107) CAGGAGTATGGGATCACCAG (SEQ ID NO 108) DXS998 CAGCAATTTTTCAAAGGC (SEQ ID NO 109) AGATCATTCATATAACCTCAAAAGA (SEQ ID NO 110) -
Claims (33)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/763,426 US20080050739A1 (en) | 2006-06-14 | 2007-06-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/413,485 US20090280492A1 (en) | 2006-06-14 | 2009-03-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/725,240 US20110171638A1 (en) | 2006-06-14 | 2010-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/751,908 US20100291571A1 (en) | 2006-06-14 | 2010-03-31 | Diagnosis of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/433,232 US20120183963A1 (en) | 2006-06-14 | 2012-03-28 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/738,268 US20130288242A1 (en) | 2006-06-14 | 2013-01-10 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/830,871 US10591391B2 (en) | 2006-06-14 | 2013-03-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US16/819,992 US11378498B2 (en) | 2006-06-14 | 2020-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US17/850,599 US20230168160A1 (en) | 2006-06-14 | 2022-06-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80481506P | 2006-06-14 | 2006-06-14 | |
US82077806P | 2006-07-28 | 2006-07-28 | |
US11/763,426 US20080050739A1 (en) | 2006-06-14 | 2007-06-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/413,485 Continuation US20090280492A1 (en) | 2006-06-14 | 2009-03-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/725,240 Continuation US20110171638A1 (en) | 2006-06-14 | 2010-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/751,908 Continuation US20100291571A1 (en) | 2006-06-14 | 2010-03-31 | Diagnosis of fetal aneuploidy by quantification of genomic dna from mixed samples |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080050739A1 true US20080050739A1 (en) | 2008-02-28 |
Family
ID=39113892
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/763,426 Abandoned US20080050739A1 (en) | 2006-06-14 | 2007-06-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/413,485 Abandoned US20090280492A1 (en) | 2006-06-14 | 2009-03-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/725,240 Abandoned US20110171638A1 (en) | 2006-06-14 | 2010-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/751,908 Abandoned US20100291571A1 (en) | 2006-06-14 | 2010-03-31 | Diagnosis of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/433,232 Abandoned US20120183963A1 (en) | 2006-06-14 | 2012-03-28 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/738,268 Abandoned US20130288242A1 (en) | 2006-06-14 | 2013-01-10 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/830,871 Active 2027-06-27 US10591391B2 (en) | 2006-06-14 | 2013-03-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US16/819,992 Active US11378498B2 (en) | 2006-06-14 | 2020-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US17/850,599 Pending US20230168160A1 (en) | 2006-06-14 | 2022-06-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/413,485 Abandoned US20090280492A1 (en) | 2006-06-14 | 2009-03-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/725,240 Abandoned US20110171638A1 (en) | 2006-06-14 | 2010-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US12/751,908 Abandoned US20100291571A1 (en) | 2006-06-14 | 2010-03-31 | Diagnosis of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/433,232 Abandoned US20120183963A1 (en) | 2006-06-14 | 2012-03-28 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/738,268 Abandoned US20130288242A1 (en) | 2006-06-14 | 2013-01-10 | Determination of fetal aneuploidy by quantification of genomic dna from mixed samples |
US13/830,871 Active 2027-06-27 US10591391B2 (en) | 2006-06-14 | 2013-03-14 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US16/819,992 Active US11378498B2 (en) | 2006-06-14 | 2020-03-16 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US17/850,599 Pending US20230168160A1 (en) | 2006-06-14 | 2022-06-27 | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
Country Status (1)
Country | Link |
---|---|
US (9) | US20080050739A1 (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026418A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070202525A1 (en) * | 2006-02-02 | 2007-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US20080070792A1 (en) * | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US20080138809A1 (en) * | 2006-06-14 | 2008-06-12 | Ravi Kapur | Methods for the Diagnosis of Fetal Abnormalities |
US20080220422A1 (en) * | 2006-06-14 | 2008-09-11 | Daniel Shoemaker | Rare cell analysis using sample splitting and dna tags |
US20090029377A1 (en) * | 2007-07-23 | 2009-01-29 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
US20090280492A1 (en) * | 2006-06-14 | 2009-11-12 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US20100112575A1 (en) * | 2008-09-20 | 2010-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing |
US20100112590A1 (en) * | 2007-07-23 | 2010-05-06 | The Chinese University Of Hong Kong | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment |
US20100304978A1 (en) * | 2009-01-26 | 2010-12-02 | David Xingfei Deng | Methods and compositions for identifying a fetal cell |
US20110129841A1 (en) * | 2005-06-02 | 2011-06-02 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
US20110201507A1 (en) * | 2010-01-19 | 2011-08-18 | Rava Richard P | Sequencing methods and compositions for prenatal diagnoses |
US20110230358A1 (en) * | 2010-01-19 | 2011-09-22 | Artemis Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
WO2013015793A1 (en) * | 2011-07-26 | 2013-01-31 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
US8532936B2 (en) | 2011-04-14 | 2013-09-10 | Verinata Health, Inc. | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US9115401B2 (en) | 2010-01-19 | 2015-08-25 | Verinata Health, Inc. | Partition defined detection methods |
US9217131B2 (en) | 2010-01-21 | 2015-12-22 | Biocep Ltd. | Magnetic separation of rare cells |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9447453B2 (en) | 2011-04-12 | 2016-09-20 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
WO2016161081A1 (en) * | 2015-04-03 | 2016-10-06 | Fluxion Biosciences, Inc. | Molecular characterization of single cells and cell populations for non-invasive diagnostics |
US9547748B2 (en) | 2011-06-29 | 2017-01-17 | Bgi Health Service Co., Ltd. | Method for determining fetal chromosomal abnormality |
US9840732B2 (en) | 2012-05-21 | 2017-12-12 | Fluidigm Corporation | Single-particle analysis of particle populations |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11111545B2 (en) | 2010-05-18 | 2021-09-07 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US11186863B2 (en) | 2019-04-02 | 2021-11-30 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
CN113736876A (en) * | 2021-10-14 | 2021-12-03 | 胜亚生物科技(厦门)有限公司 | Kit for rapidly detecting chromosome number abnormality and application thereof |
US11230731B2 (en) | 2018-04-02 | 2022-01-25 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
US11286530B2 (en) | 2010-05-18 | 2022-03-29 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11306357B2 (en) | 2010-05-18 | 2022-04-19 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11306359B2 (en) | 2005-11-26 | 2022-04-19 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US11319595B2 (en) | 2014-04-21 | 2022-05-03 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US11332774B2 (en) | 2010-10-26 | 2022-05-17 | Verinata Health, Inc. | Method for determining copy number variations |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11390916B2 (en) | 2014-04-21 | 2022-07-19 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US11519028B2 (en) | 2016-12-07 | 2022-12-06 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010242073C1 (en) | 2009-04-30 | 2015-12-24 | Good Start Genetics, Inc. | Methods and compositions for evaluating genetic markers |
US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
US20130040375A1 (en) | 2011-08-08 | 2013-02-14 | Tandem Diagnotics, Inc. | Assay systems for genetic analysis |
US11203786B2 (en) | 2010-08-06 | 2021-12-21 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US10533223B2 (en) | 2010-08-06 | 2020-01-14 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
US20130261003A1 (en) | 2010-08-06 | 2013-10-03 | Ariosa Diagnostics, In. | Ligation-based detection of genetic variants |
US10167508B2 (en) | 2010-08-06 | 2019-01-01 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
US8700338B2 (en) | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
US20140342940A1 (en) | 2011-01-25 | 2014-11-20 | Ariosa Diagnostics, Inc. | Detection of Target Nucleic Acids using Hybridization |
US9163281B2 (en) | 2010-12-23 | 2015-10-20 | Good Start Genetics, Inc. | Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction |
US9994897B2 (en) | 2013-03-08 | 2018-06-12 | Ariosa Diagnostics, Inc. | Non-invasive fetal sex determination |
US10131947B2 (en) | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
US11270781B2 (en) | 2011-01-25 | 2022-03-08 | Ariosa Diagnostics, Inc. | Statistical analysis for non-invasive sex chromosome aneuploidy determination |
US8756020B2 (en) | 2011-01-25 | 2014-06-17 | Ariosa Diagnostics, Inc. | Enhanced risk probabilities using biomolecule estimations |
US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
CA2852665A1 (en) | 2011-10-17 | 2013-04-25 | Good Start Genetics, Inc. | Analysis methods |
US8209130B1 (en) | 2012-04-04 | 2012-06-26 | Good Start Genetics, Inc. | Sequence assembly |
US10227635B2 (en) | 2012-04-16 | 2019-03-12 | Molecular Loop Biosolutions, Llc | Capture reactions |
US10289800B2 (en) | 2012-05-21 | 2019-05-14 | Ariosa Diagnostics, Inc. | Processes for calculating phased fetal genomic sequences |
EP2875156A4 (en) | 2012-07-19 | 2016-02-24 | Ariosa Diagnostics Inc | Multiplexed sequential ligation-based detection of genetic variants |
US8778609B1 (en) | 2013-03-14 | 2014-07-15 | Good Start Genetics, Inc. | Methods for analyzing nucleic acids |
US10851414B2 (en) | 2013-10-18 | 2020-12-01 | Good Start Genetics, Inc. | Methods for determining carrier status |
WO2015175530A1 (en) | 2014-05-12 | 2015-11-19 | Gore Athurva | Methods for detecting aneuploidy |
US11408024B2 (en) | 2014-09-10 | 2022-08-09 | Molecular Loop Biosciences, Inc. | Methods for selectively suppressing non-target sequences |
WO2016048829A1 (en) | 2014-09-24 | 2016-03-31 | Good Start Genetics, Inc. | Process control for increased robustness of genetic assays |
CA3002133A1 (en) * | 2014-10-17 | 2016-04-21 | Good Start Genetics, Inc. | Pre-implantation genetic screening and aneuploidy detection |
EP3271480B8 (en) | 2015-01-06 | 2022-09-28 | Molecular Loop Biosciences, Inc. | Screening for structural variants |
CN104818323B (en) * | 2015-04-10 | 2017-08-29 | 上海五色石医学研究有限公司 | The mankind 13, the gene parting detecting reagent of 18 and No. 21 chromosome, 20 str locus seats |
KR101848438B1 (en) | 2015-10-29 | 2018-04-13 | 바이오코아 주식회사 | A method for prenatal diagnosis using digital PCR |
EP3518974A4 (en) | 2016-09-29 | 2020-05-27 | Myriad Women's Health, Inc. | Noninvasive prenatal screening using dynamic iterative depth optimization |
KR102036609B1 (en) * | 2018-02-12 | 2019-10-28 | 바이오코아 주식회사 | A method for prenatal diagnosis using digital PCR |
Citations (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5296375A (en) * | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5707799A (en) * | 1994-09-30 | 1998-01-13 | Abbott Laboratories | Devices and methods utilizing arrays of structures for analyte capture |
US5709943A (en) * | 1995-05-04 | 1998-01-20 | Minnesota Mining And Manufacturing Company | Biological adsorption supports |
US5715946A (en) * | 1995-06-07 | 1998-02-10 | Reichenbach; Steven H. | Method and apparatus for sorting particles suspended in a fluid |
US5726026A (en) * | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5858649A (en) * | 1992-07-17 | 1999-01-12 | Aprogenex, Inc. | Amplification of mRNA for distinguishing fetal cells in maternal blood |
US5866345A (en) * | 1992-05-01 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5879883A (en) * | 1991-10-03 | 1999-03-09 | Indiana University Foundation | Method for screening for alzheimer's disease |
US6013188A (en) * | 1996-06-07 | 2000-01-11 | Immunivest Corporation | Methods for biological substance analysis employing internal magnetic gradients separation and an externally-applied transport force |
US6176962B1 (en) * | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
US6184043B1 (en) * | 1992-09-14 | 2001-02-06 | FODSTAD øYSTEIN | Method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
US6186660B1 (en) * | 1997-10-09 | 2001-02-13 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
US6197523B1 (en) * | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
US20020006621A1 (en) * | 1989-11-13 | 2002-01-17 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
US20020009738A1 (en) * | 2000-04-03 | 2002-01-24 | Houghton Raymond L. | Methods, compositions and kits for the detection and monitoring of breast cancer |
US20020012931A1 (en) * | 2000-03-27 | 2002-01-31 | Waldman Scott A. | High specificity marker detection |
US20020012930A1 (en) * | 1999-09-16 | 2002-01-31 | Rothberg Jonathan M. | Method of sequencing a nucleic acid |
US6344326B1 (en) * | 1996-07-30 | 2002-02-05 | Aclara Bio Sciences, Inc. | Microfluidic method for nucleic acid purification and processing |
US20020016450A1 (en) * | 1997-10-31 | 2002-02-07 | Bbi Bioseq, Inc., A Masachusetts Corporation | Pressure-enhanced extraction and purification |
US20020019001A1 (en) * | 1999-10-15 | 2002-02-14 | Ventana Medical Systems, Inc. | Method of detecting single gene copies in-situ |
US20020028431A1 (en) * | 1998-08-25 | 2002-03-07 | Julien Jean-Claude Bisconte De Saint | Process, device and reagent for cell separation |
US6361958B1 (en) * | 1999-11-12 | 2002-03-26 | Motorola, Inc. | Biochannel assay for hybridization with biomaterial |
US20030004402A1 (en) * | 2000-07-18 | 2003-01-02 | Hitt Ben A. | Process for discriminating between biological states based on hidden patterns from biological data |
US20030013101A1 (en) * | 1999-09-29 | 2003-01-16 | Shankar Balasubramanian | Polynucleotide sequencing |
US20030017514A1 (en) * | 2001-06-02 | 2003-01-23 | Katharina Pachmann | Method for quantitative detection of vital epithelial tumor cells in a body fluid |
US6511967B1 (en) * | 1999-04-23 | 2003-01-28 | The General Hospital Corporation | Use of an internalizing transferrin receptor to image transgene expression |
US20030022207A1 (en) * | 1998-10-16 | 2003-01-30 | Solexa, Ltd. | Arrayed polynucleotides and their use in genome analysis |
US20030033091A1 (en) * | 2001-04-20 | 2003-02-13 | Sequenom, Inc. | Systems and methods for testing a biological sample |
US20030044388A1 (en) * | 2001-08-31 | 2003-03-06 | The Chinese University Of Hong Kong | Methods for detecting DNA originating from different individuals |
US20030044781A1 (en) * | 1999-05-19 | 2003-03-06 | Jonas Korlach | Method for sequencing nucleic acid molecules |
US6673541B1 (en) * | 1998-09-18 | 2004-01-06 | Micromet Ag | DNA amplification of a single cell |
US6674525B2 (en) * | 2001-04-03 | 2004-01-06 | Micronics, Inc. | Split focusing cytometer |
US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
US20040009471A1 (en) * | 2002-04-25 | 2004-01-15 | Bo Cao | Methods and kits for detecting a target cell |
US20040018116A1 (en) * | 2002-07-26 | 2004-01-29 | Desmond Sean M. | Microfluidic size-exclusion devices, systems, and methods |
US6685841B2 (en) * | 2001-02-14 | 2004-02-03 | Gabriel P. Lopez | Nanostructured devices for separation and analysis |
US6689615B1 (en) * | 2000-10-04 | 2004-02-10 | James Murto | Methods and devices for processing blood samples |
US20040037470A1 (en) * | 2002-08-23 | 2004-02-26 | Simske Steven J. | Systems and methods for processing text-based electronic documents |
US20040043506A1 (en) * | 2002-08-30 | 2004-03-04 | Horst Haussecker | Cascaded hydrodynamic focusing in microfluidic channels |
US20040048360A1 (en) * | 1999-08-26 | 2004-03-11 | Caliper Technologies Corp. | Microfluidic analytic detection assays, devices, and integrated systems |
US20040053352A1 (en) * | 1998-09-28 | 2004-03-18 | Tianmei Ouyang | Diagnostics based on tetrazolium compounds |
US20050014208A1 (en) * | 2001-09-06 | 2005-01-20 | Alf-Andreas Krehan | Method and kit for diagnosing or controlling the treatment of breast cancer |
US20050019792A1 (en) * | 2001-11-30 | 2005-01-27 | Fluidigm Corporation | Microfluidic device and methods of using same |
US20050037388A1 (en) * | 2001-06-22 | 2005-02-17 | University Of Geneva | Method for detecting diseases caused by chromosomal imbalances |
US6858439B1 (en) * | 1999-03-15 | 2005-02-22 | Aviva Biosciences | Compositions and methods for separation of moieties on chips |
US20050042623A1 (en) * | 2002-10-30 | 2005-02-24 | Dana Ault-Riche | Systems for capture and analysis of biological particles and methods using the systems |
US20050042685A1 (en) * | 2001-09-06 | 2005-02-24 | Winfried Albert | Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells |
US20050049793A1 (en) * | 2001-04-30 | 2005-03-03 | Patrizia Paterlini-Brechot | Prenatal diagnosis method on isolated foetal cell of maternal blood |
US20050052773A1 (en) * | 2003-09-05 | 2005-03-10 | Hitachi Global Storage Technologies | Increasing head-disk interface reliability using controlled heating |
US20050064476A1 (en) * | 2002-11-11 | 2005-03-24 | Affymetrix, Inc. | Methods for identifying DNA copy number changes |
US20050061962A1 (en) * | 2003-07-31 | 2005-03-24 | Arryx, Inc. | Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components |
US20060000772A1 (en) * | 2002-11-29 | 2006-01-05 | Toru Sano | Separation apparatus and separation method |
US20060008807A1 (en) * | 2002-08-23 | 2006-01-12 | O'hara Shawn M | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
US20060008824A1 (en) * | 2004-05-20 | 2006-01-12 | Leland Stanford Junior University | Methods and compositions for clonal amplification of nucleic acid |
US20060024711A1 (en) * | 2004-07-02 | 2006-02-02 | Helicos Biosciences Corporation | Methods for nucleic acid amplification and sequence determination |
US20060024756A1 (en) * | 2002-02-14 | 2006-02-02 | Arjan Tibbe | Methods and algorithms for cell enumeration in low-cost cytometer |
US20060024678A1 (en) * | 2004-07-28 | 2006-02-02 | Helicos Biosciences Corporation | Use of single-stranded nucleic acid binding proteins in sequencing |
US20060046258A1 (en) * | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
US20060051265A1 (en) * | 2004-09-08 | 2006-03-09 | Health Research, Inc. | Apparatus and method for sorting microstructures in a fluid medium |
US20060060767A1 (en) * | 2001-04-27 | 2006-03-23 | Wang Mark M | Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles |
US20070017633A1 (en) * | 2005-03-23 | 2007-01-25 | Tonkovich Anna L | Surface features in microprocess technology |
US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026469A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026419A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026418A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026381A1 (en) * | 2005-04-05 | 2007-02-01 | Huang Lotien R | Devices and methods for enrichment and alteration of cells and other particles |
US7171975B2 (en) * | 2002-02-12 | 2007-02-06 | Kionix, Inc. | Fabrication of ultra-shallow channels for microfluidic devices and systems |
US20070037275A1 (en) * | 2001-04-25 | 2007-02-15 | Michael Shuler | Devices and methods for pharmacokinetic-based cell culture system |
US20070037173A1 (en) * | 2005-08-12 | 2007-02-15 | Allard Jeffrey W | Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients |
US20070037172A1 (en) * | 2005-08-11 | 2007-02-15 | Chiu Daniel T | Separation and concentration of biological cells and biological particles using a one-dimensional channel |
US20070042339A1 (en) * | 2003-08-08 | 2007-02-22 | Massachusetts General Hospital | Preservation of biomaterials with transported preservation agents |
US20070042360A1 (en) * | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20070042238A1 (en) * | 2005-08-22 | 2007-02-22 | Lg Electronics Inc. | Fuel cell having water type radiating device |
US20070042368A1 (en) * | 2003-03-24 | 2007-02-22 | Corixa Corporation | Detection and monitoring of lung cancer |
US20070048750A1 (en) * | 2005-09-01 | 2007-03-01 | National Health Research Institute | Rapid efficacy assessment method for lung cancer therapy |
US20070054287A1 (en) * | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
US20070054268A1 (en) * | 2002-09-05 | 2007-03-08 | Robert Sutherland | Methods of diagnosis and prognosis of ovarian cancer |
US20080020390A1 (en) * | 2006-02-28 | 2008-01-24 | Mitchell Aoy T | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
US20080026390A1 (en) * | 2006-06-14 | 2008-01-31 | Roland Stoughton | Diagnosis of Fetal Abnormalities by Comparative Genomic Hybridization Analysis |
US20080023399A1 (en) * | 2006-06-01 | 2008-01-31 | Inglis David W | Apparatus and method for continuous particle separation |
US20080038733A1 (en) * | 2006-03-28 | 2008-02-14 | Baylor College Of Medicine | Screening for down syndrome |
US7332277B2 (en) * | 2002-03-01 | 2008-02-19 | Ravgen, Inc. | Methods for detection of genetic disorders |
US7476363B2 (en) * | 2003-04-03 | 2009-01-13 | Fluidigm Corporation | Microfluidic devices and methods of using same |
US20090029377A1 (en) * | 2007-07-23 | 2009-01-29 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US7645576B2 (en) * | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
US7655399B2 (en) * | 2003-10-08 | 2010-02-02 | Trustees Of Boston University | Methods for prenatal diagnosis of chromosomal abnormalities |
Family Cites Families (466)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3560754A (en) | 1965-11-17 | 1971-02-02 | Ibm | Photoelectric particle separator using time delay |
DE3274800D1 (en) | 1981-02-05 | 1987-02-05 | Asahi Chemical Ind | Apparatus for separating blood components |
US5310674A (en) | 1982-05-10 | 1994-05-10 | Bar-Ilan University | Apertured cell carrier |
US4508625A (en) | 1982-10-18 | 1985-04-02 | Graham Marshall D | Magnetic separation using chelated magnetic ions |
US4675286A (en) | 1985-01-28 | 1987-06-23 | Aspen Diagnostics, Inc. | Fetal cell separation and testing |
US5164598A (en) | 1985-08-05 | 1992-11-17 | Biotrack | Capillary flow device |
US7115709B1 (en) | 1986-01-16 | 2006-10-03 | The Regents Of The University Of California | Methods of staining target chromosomal DNA employing high complexity nucleic acid probes |
US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
US4789628A (en) | 1986-06-16 | 1988-12-06 | Vxr, Inc. | Devices for carrying out ligand/anti-ligand assays, methods of using such devices and diagnostic reagents and kits incorporating such devices |
US4886761A (en) | 1987-03-26 | 1989-12-12 | Yellowstone Diagnostics Corporation | Polysilicon binding assay support and methods |
US4971904A (en) | 1987-06-26 | 1990-11-20 | E. I. Du Pont De Nemours And Company | Heterogeneous immunoassay |
US4936465A (en) | 1987-12-07 | 1990-06-26 | Zoeld Tibor | Method and apparatus for fast, reliable, and environmentally safe dispensing of fluids, gases and individual particles of a suspension through pressure control at well defined parts of a closed flow-through system |
US4977078A (en) | 1987-12-22 | 1990-12-11 | Olympus Optical Co., Ltd. | Plate substrate immunoassay device and method for performing a multi-test immunoassay on a specimen |
CA1339210C (en) | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5215926A (en) | 1988-06-03 | 1993-06-01 | Cellpro, Inc. | Procedure for designing efficient affinity cell separation processes |
ES2112833T3 (en) | 1988-12-06 | 1998-04-16 | Flinders Technologies Pty Ltd | ISOLATION OF FETAL CELLS FROM MATERNAL BLOOD TO ALLOW PRENATAL DIAGNOSIS. |
CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
ATE162631T1 (en) | 1989-11-13 | 1998-02-15 | Childrens Medical Center | A NON-INVASIVE METHOD FOR SEPARATION AND DETECTION OF FETAL DNA |
US5770029A (en) | 1996-07-30 | 1998-06-23 | Soane Biosciences | Integrated electrophoretic microdevices |
US5153117A (en) | 1990-03-27 | 1992-10-06 | Genetype A.G. | Fetal cell recovery method |
CA2036946C (en) | 1990-04-06 | 2001-10-16 | Kenneth V. Deugau | Indexing linkers |
CA2081203A1 (en) | 1990-04-23 | 1991-10-24 | Ronald J. Berenson | Method for enriching fetal cells from maternal blood |
US5622831A (en) | 1990-09-26 | 1997-04-22 | Immunivest Corporation | Methods and devices for manipulation of magnetically collected material |
US5541072A (en) | 1994-04-18 | 1996-07-30 | Immunivest Corporation | Method for magnetic separation featuring magnetic particles in a multi-phase system |
US5217627A (en) | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
US5646001A (en) | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5846708A (en) | 1991-11-19 | 1998-12-08 | Massachusetts Institiute Of Technology | Optical and electrical methods and apparatus for molecule detection |
WO1993022058A1 (en) | 1992-05-01 | 1993-11-11 | Trustees Of The University Of Pennsylvania | Polynucleotide amplification analysis using a microfabricated device |
US5304487A (en) | 1992-05-01 | 1994-04-19 | Trustees Of The University Of Pennsylvania | Fluid handling in mesoscale analytical devices |
US6156270A (en) | 1992-05-21 | 2000-12-05 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
WO1994003638A1 (en) | 1992-07-30 | 1994-02-17 | Applied Biosystems, Inc. | Method of detecting aneuploidy by amplified short tandem repeats |
DE4244715C2 (en) | 1992-08-26 | 1995-06-14 | Kuebler Gmbh Dr | Process for the preparation of individual-specific anti-tumor antigen monoclonal antibodies |
US5489506A (en) | 1992-10-26 | 1996-02-06 | Biolife Systems, Inc. | Dielectrophoretic cell stream sorter |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
CA2147499C (en) | 1992-11-05 | 2010-10-19 | Ron S. Israeli | Prostate-specific membrane antigen |
US5427663A (en) | 1993-06-08 | 1995-06-27 | British Technology Group Usa Inc. | Microlithographic array for macromolecule and cell fractionation |
US6027923A (en) | 1993-07-23 | 2000-02-22 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
US5556773A (en) | 1993-08-06 | 1996-09-17 | Yourno; Joseph | Method and apparatus for nested polymerase chain reaction (PCR) with single closed reaction tubes |
WO1995009245A1 (en) | 1993-09-27 | 1995-04-06 | Oncor, Inc. | Methods for detecting and analyzing individual rare cells in a population |
DK0725682T3 (en) | 1993-10-28 | 2002-07-15 | Houston Advanced Res Ct | Micro-made, porous pass-through apparatus for discrete detection of bonding reactions |
US5432054A (en) | 1994-01-31 | 1995-07-11 | Applied Imaging | Method for separating rare cells from a population of cells |
US5798042A (en) | 1994-03-07 | 1998-08-25 | Regents Of The University Of California | Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters |
NO180658C (en) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Method and Device for Detecting Specific Target Cells in Specialized or Mixed Cell Populations and Solutions Containing Mixed Cell Populations |
US5962332A (en) | 1994-03-17 | 1999-10-05 | University Of Massachusetts | Detection of trinucleotide repeats by in situ hybridization |
US6071394A (en) | 1996-09-06 | 2000-06-06 | Nanogen, Inc. | Channel-less separation of bioparticles on a bioelectronic chip by dielectrophoresis |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US5695934A (en) | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
US5662813A (en) | 1994-10-21 | 1997-09-02 | Bioseparations, Inc. | Method for separation of nucleated fetal erythrocytes from maternal blood samples |
CA2181190C (en) | 1994-11-14 | 2001-02-06 | Peter Wilding | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5750339A (en) | 1994-11-30 | 1998-05-12 | Thomas Jefferson University | Methods for identifying fetal cells |
US7037647B1 (en) | 1995-02-24 | 2006-05-02 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US5639669A (en) | 1995-06-07 | 1997-06-17 | Ledley; Robert | Separation of fetal cells from maternal blood |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US6190870B1 (en) | 1995-08-28 | 2001-02-20 | Amcell Corporation | Efficient enrichment and detection of disseminated tumor cells |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
WO1997018322A2 (en) | 1995-11-16 | 1997-05-22 | Dahm Michael W | Method of quantifying tumour cells in a body fluid and a suitable test kit |
US5780231A (en) | 1995-11-17 | 1998-07-14 | Lynx Therapeutics, Inc. | DNA extension and analysis with rolling primers |
ATE199572T1 (en) | 1995-11-21 | 2001-03-15 | Univ Yale | UNIMOLECULAR SEGMENT AMPLIFICATION AND DETERMINATION |
US20030119724A1 (en) | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
US5994517A (en) | 1995-11-22 | 1999-11-30 | Paul O. P. Ts'o | Ligands to enhance cellular uptake of biomolecules |
AU724393B2 (en) | 1995-11-30 | 2000-09-21 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
US6718053B1 (en) | 1996-11-27 | 2004-04-06 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
US5670325A (en) | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US5863502A (en) | 1996-01-24 | 1999-01-26 | Sarnoff Corporation | Parallel reaction cassette and associated devices |
NO961031D0 (en) | 1996-03-13 | 1996-03-13 | Det Norske Radiumshospital Tum | Procedure for killing unwanted target cells |
US5972721A (en) | 1996-03-14 | 1999-10-26 | The United States Of America As Represented By The Secretary Of The Air Force | Immunomagnetic assay system for clinical diagnosis and other purposes |
EP0929694A4 (en) | 1996-03-15 | 2002-05-02 | Penn State Res Found | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
US5891651A (en) | 1996-03-29 | 1999-04-06 | Mayo Foundation For Medical Education And Research | Methods of recovering colorectal epithelial cells or fragments thereof from stool |
US7297331B2 (en) | 1996-04-03 | 2007-11-20 | The Rogosin Institute | Beads containing restricted cancer cells producing material suppressing cancer cell proliferation |
EP0891550A1 (en) | 1996-04-05 | 1999-01-20 | The Johns Hopkins University School Of Medicine | A method of enriching rare cells |
US6387707B1 (en) | 1996-04-25 | 2002-05-14 | Bioarray Solutions | Array Cytometry |
US6958245B2 (en) | 1996-04-25 | 2005-10-25 | Bioarray Solutions Ltd. | Array cytometry |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US6890426B2 (en) | 1996-06-07 | 2005-05-10 | Immunivest Corporation | Magnetic separation apparatus and methods |
WO1998000231A1 (en) | 1996-06-28 | 1998-01-08 | Caliper Technologies Corporation | High-throughput screening assay systems in microscale fluidic devices |
IT1294964B1 (en) | 1996-07-12 | 1999-04-23 | Domenico Valerio | INSULATION AND CULTURE OF FETAL CELLS FROM THE MATERNAL PERIPHERAL BLOOD |
US6280967B1 (en) | 1996-08-02 | 2001-08-28 | Axiom Biotechnologies, Inc. | Cell flow apparatus and method for real-time of cellular responses |
US6300077B1 (en) | 1996-08-14 | 2001-10-09 | Exact Sciences Corporation | Methods for the detection of nucleic acids |
US6100029A (en) | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
WO1998008931A1 (en) | 1996-08-26 | 1998-03-05 | Princeton University | Reversibly sealable microstructure sorting devices |
DK0925494T3 (en) | 1996-09-04 | 2002-07-01 | Scandinavian Micro Biodevices | Microfluidic system for particle separation and analysis |
GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
AU6909098A (en) | 1996-10-31 | 1998-05-22 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
US6008010A (en) | 1996-11-01 | 1999-12-28 | University Of Pittsburgh | Method and apparatus for holding cells |
NO308755B1 (en) | 1996-12-20 | 2000-10-23 | Iystein Fodstad | Method for characterizing abnormal cells, use and kits for carrying out the method |
US6235474B1 (en) | 1996-12-30 | 2001-05-22 | The Johns Hopkins University | Methods and kits for diagnosing and determination of the predisposition for diseases |
US5879624A (en) | 1997-01-15 | 1999-03-09 | Boehringer Laboratories, Inc. | Method and apparatus for collecting and processing blood |
US6306584B1 (en) | 1997-01-21 | 2001-10-23 | President And Fellows Of Harvard College | Electronic-property probing of biological molecules at surfaces |
US6008007A (en) | 1997-01-31 | 1999-12-28 | Oncotech, Inc. | Radiation resistance assay for predicting treatment response and clinical outcome |
GB2337113B (en) | 1997-02-28 | 2001-03-21 | Burstein Lab Inc | Laboratory in a disk |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
US20010051341A1 (en) | 1997-03-04 | 2001-12-13 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
US6623983B1 (en) | 1997-03-25 | 2003-09-23 | Immunivest Corporation | Apparatus and methods for capture and analysis of particulate entities |
US6391622B1 (en) | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US6066449A (en) | 1997-04-15 | 2000-05-23 | The Trustees Of Columbia University In The City Of New York | Method of detecting metastatic thyroid cancer |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
WO1998049344A1 (en) | 1997-04-28 | 1998-11-05 | Lockheed Martin Energy Research Corporation | Method and apparatus for analyzing nucleic acids |
US6632619B1 (en) | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
US6156273A (en) | 1997-05-27 | 2000-12-05 | Purdue Research Corporation | Separation columns and methods for manufacturing the improved separation columns |
ATE498838T1 (en) | 1997-06-12 | 2011-03-15 | Clinical Micro Sensors Inc | ELECTRONIC METHOD AND DEVICE FOR DETECTING ANALYTES |
US6566101B1 (en) | 1997-06-16 | 2003-05-20 | Anthony P. Shuber | Primer extension methods for detecting nucleic acids |
US6294331B1 (en) | 1997-08-08 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for assessing genetic and phenotypic markers by simultaneous multicolor visualization of chromogenic dyes using brightfield microscopy and spectral imaging |
US6368871B1 (en) | 1997-08-13 | 2002-04-09 | Cepheid | Non-planar microstructures for manipulation of fluid samples |
US7214298B2 (en) | 1997-09-23 | 2007-05-08 | California Institute Of Technology | Microfabricated cell sorter |
US6540895B1 (en) | 1997-09-23 | 2003-04-01 | California Institute Of Technology | Microfabricated cell sorter for chemical and biological materials |
US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
US5962234A (en) | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
US6120985A (en) | 1997-10-31 | 2000-09-19 | Bbi Bioseq, Inc. | Pressure-enhanced extraction and purification |
CA2253965C (en) | 1997-11-22 | 2003-01-21 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood |
JP4388694B2 (en) | 1998-02-04 | 2009-12-24 | アプライド バイオシステムズ, エルエルシー | Genotyping of amplification products at multiple allele sites |
EP1062515B1 (en) | 1998-02-12 | 2009-11-25 | Immunivest Corporation | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
US20020172987A1 (en) | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
US6036857A (en) | 1998-02-20 | 2000-03-14 | Florida State University Research Foundation, Inc. | Apparatus for continuous magnetic separation of components from a mixture |
CA2322282A1 (en) | 1998-02-27 | 1999-09-02 | Cli Oncology, Inc. | Method and compositions for differential detection of primary tumor cells and metastatic cells |
US6210910B1 (en) | 1998-03-02 | 2001-04-03 | Trustees Of Tufts College | Optical fiber biosensor array comprising cell populations confined to microcavities |
GB9805918D0 (en) | 1998-03-19 | 1998-05-13 | Nycomed Amersham Plc | Sequencing by hybridisation |
WO1999047923A2 (en) | 1998-03-20 | 1999-09-23 | The Rockefeller University | Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof |
US20070092917A1 (en) | 1998-05-01 | 2007-04-26 | Isabelle Guyon | Biomarkers for screening, predicting, and monitoring prostate disease |
WO1999058972A1 (en) | 1998-05-09 | 1999-11-18 | Ikonisys Inc. | Method and apparatus for computer controlled rare cell, including fetal cell, based diagnosis |
ATE530891T1 (en) | 1998-05-22 | 2011-11-15 | California Inst Of Techn | MINIATURIZED CELL SORTER |
US6606413B1 (en) | 1998-06-01 | 2003-08-12 | Trestle Acquisition Corp. | Compression packaged image transmission for telemicroscopy |
US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6576478B1 (en) | 1998-07-14 | 2003-06-10 | Zyomyx, Inc. | Microdevices for high-throughput screening of biomolecules |
EP1097378A2 (en) | 1998-07-21 | 2001-05-09 | Burstein Laboratories Inc. | Optical disc-based assay devices and methods |
CA2339121A1 (en) | 1998-07-30 | 2000-02-10 | Shankar Balasubramanian | Arrayed biomolecules and their use in sequencing |
US6245227B1 (en) | 1998-09-17 | 2001-06-12 | Kionix, Inc. | Integrated monolithic microfabricated electrospray and liquid chromatography system and method |
US6637463B1 (en) | 1998-10-13 | 2003-10-28 | Biomicro Systems, Inc. | Multi-channel microfluidic system design with balanced fluid flow distribution |
CA2350692A1 (en) | 1998-10-29 | 2000-05-11 | Cell Works Inc. | Multiple marker characterization of single cells |
US6086740A (en) | 1998-10-29 | 2000-07-11 | Caliper Technologies Corp. | Multiplexed microfluidic devices and systems |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
ATE408695T1 (en) | 1998-12-16 | 2008-10-15 | Novartis Vaccines & Diagnostic | HUMAN CYCLIN DEPENDENT KINASE (HPNQALRE) |
BR9916840A (en) | 1998-12-23 | 2001-10-09 | Nanogen Inc | Integrated portable biological detection system |
GB9828785D0 (en) | 1998-12-30 | 1999-02-17 | Amersham Pharm Biotech Ab | Sequencing systems |
US6150119A (en) | 1999-01-19 | 2000-11-21 | Caliper Technologies Corp. | Optimized high-throughput analytical system |
US6960449B2 (en) | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
AU3372800A (en) | 1999-02-23 | 2000-09-14 | Caliper Technologies Corporation | Manipulation of microparticles in microfluidic systems |
TW496775B (en) | 1999-03-15 | 2002-08-01 | Aviva Bioscience Corp | Individually addressable micro-electromagnetic unit array chips |
CA2366524A1 (en) | 1999-04-13 | 2000-10-19 | Chromavision Medical Systems, Inc. | Histological reconstruction and automated image analysis |
US6942771B1 (en) | 1999-04-21 | 2005-09-13 | Clinical Micro Sensors, Inc. | Microfluidic systems in the electrochemical detection of target analytes |
US6994969B1 (en) | 1999-04-30 | 2006-02-07 | Methexis Genomics, N.V. | Diagnostic sequencing by a combination of specific cleavage and mass spectrometry |
US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
US6878540B2 (en) | 1999-06-25 | 2005-04-12 | Cepheid | Device for lysing cells, spores, or microorganisms |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
FR2798673B1 (en) | 1999-09-16 | 2004-05-28 | Exonhit Therapeutics Sa | METHODS AND COMPOSITIONS FOR DETECTION OF PATHOLOGICAL EVENTS |
US6623945B1 (en) | 1999-09-16 | 2003-09-23 | Motorola, Inc. | System and method for microwave cell lysing of small samples |
AU4504001A (en) | 1999-11-04 | 2001-06-04 | Princeton University | Electrodeless dielectrophoresis for polarizable particles |
US20060128006A1 (en) | 1999-11-10 | 2006-06-15 | Gerhardt Antimony L | Hydrodynamic capture and release mechanisms for particle manipulation |
US6692952B1 (en) | 1999-11-10 | 2004-02-17 | Massachusetts Institute Of Technology | Cell analysis and sorting apparatus for manipulation of cells |
JP2003514236A (en) | 1999-11-10 | 2003-04-15 | マサチューセッツ・インスティテュート・オブ・テクノロジー | Cell analysis and sorting equipment for manipulating cells |
US6875619B2 (en) | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
US7346200B1 (en) | 1999-11-18 | 2008-03-18 | Ikonisys, Inc. | Method and apparatus for computer controlled cell based diagnosis |
AU2001227913A1 (en) | 2000-01-13 | 2001-07-24 | Immunivest Corporation | Ferrofluid based arrays |
CA2398107C (en) | 2000-01-28 | 2013-11-19 | Althea Technologies, Inc. | Methods for analysis of gene expression |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
US20030219765A1 (en) | 2000-03-23 | 2003-11-27 | Jose Costa | Methods for evaluating cancer risk |
US20030170631A1 (en) | 2000-04-03 | 2003-09-11 | Corixa Corporation | Methods, compositions and kits for the detection and monitoring of breast cancer |
US7641856B2 (en) | 2004-05-14 | 2010-01-05 | Honeywell International Inc. | Portable sample analyzer with removable cartridge |
US6790330B2 (en) | 2000-06-14 | 2004-09-14 | Board Of Regents, The University Of Texas System | Systems and methods for cell subpopulation analysis |
US7083924B2 (en) | 2000-07-10 | 2006-08-01 | Btg International Limited | Diagnostic method for the identification of foetal DNA in a material sample |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
CA2417341A1 (en) | 2000-08-08 | 2002-02-14 | Jing Cheng | Methods for manipulating moieties in microfluidic systems |
US6610499B1 (en) | 2000-08-31 | 2003-08-26 | The Regents Of The University Of California | Capillary array and related methods |
GB0021617D0 (en) | 2000-09-02 | 2000-10-18 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
WO2002020825A1 (en) | 2000-09-09 | 2002-03-14 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
US20020164825A1 (en) | 2000-09-09 | 2002-11-07 | Wen-Tien Chen | Cell separation matrix |
WO2002023163A1 (en) | 2000-09-15 | 2002-03-21 | California Institute Of Technology | Microfabricated crossflow devices and methods |
CA2421828A1 (en) | 2000-09-30 | 2002-04-11 | Xiao-Bo Wang | Apparatuses containing multiple force generating elements and uses thereof |
CA2424996A1 (en) | 2000-10-09 | 2002-04-18 | Aviva Biosciences Corporation | Compositions and methods for separation of moieties on chips |
WO2002030562A1 (en) | 2000-10-10 | 2002-04-18 | Aviva Biosciences Corporation | An integrated biochip system for sample preparation and analysis |
US6664056B2 (en) | 2000-10-17 | 2003-12-16 | The Chinese University Of Hong Kong | Non-invasive prenatal monitoring |
US20020127575A1 (en) | 2000-10-30 | 2002-09-12 | Glenn Hoke | Partially double-stranded nucleic acids, methods of making, and use thereof |
US6744038B2 (en) | 2000-11-13 | 2004-06-01 | Genoptix, Inc. | Methods of separating particles using an optical gradient |
US6784420B2 (en) | 2000-11-13 | 2004-08-31 | Genoptix, Inc. | Method of separating particles using an optical gradient |
US6833542B2 (en) | 2000-11-13 | 2004-12-21 | Genoptix, Inc. | Method for sorting particles |
US20020108859A1 (en) | 2000-11-13 | 2002-08-15 | Genoptix | Methods for modifying interaction between dielectric particles and surfaces |
US20020123112A1 (en) | 2000-11-13 | 2002-09-05 | Genoptix | Methods for increasing detection sensitivity in optical dielectric sorting systems |
US20020115163A1 (en) | 2000-11-13 | 2002-08-22 | Genoptix | Methods for sorting particles by size and elasticity |
AU2002243263A1 (en) | 2000-11-15 | 2002-07-24 | Roche Diagnostics Corporation | Methods and reagents for identifying rare fetal cells in the material circulation |
US6495340B2 (en) | 2000-11-28 | 2002-12-17 | Medis El Ltd. | Cell carrier grids |
CN100406065C (en) | 2000-12-01 | 2008-07-30 | 细胞工厂治疗公司 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker and nucleotidic monomers/polymers, and related compositions and method of use |
US6770434B2 (en) | 2000-12-29 | 2004-08-03 | The Provost, Fellows And Scholars Of The College Of The Holy & Undivided Trinity Of Queen Elizabeth Near Dublin | Biological assay method |
US7205157B2 (en) | 2001-01-08 | 2007-04-17 | Becton, Dickinson And Company | Method of separating cells from a sample |
US6993169B2 (en) | 2001-01-11 | 2006-01-31 | Trestle Corporation | System and method for finding regions of interest for microscopic digital montage imaging |
DE60221115T2 (en) | 2001-01-18 | 2008-03-13 | The Regents Of The University Of Michigan, Ann Arbor | COMPOSITIONS AND METHODS FOR USE OF FIBRONECTIN FRAGMENTS IN CANCER DIAGNOSIS |
WO2002061143A2 (en) | 2001-01-31 | 2002-08-08 | Ambion, Inc. | Comparative analysis of nucleic acids using population tagging |
US20020160363A1 (en) | 2001-01-31 | 2002-10-31 | Mcdevitt John T. | Magnetic-based placement and retention of sensor elements in a sensor array |
US20020110835A1 (en) | 2001-02-13 | 2002-08-15 | Rajan Kumar | Microfluidic devices and methods |
US6913697B2 (en) | 2001-02-14 | 2005-07-05 | Science & Technology Corporation @ Unm | Nanostructured separation and analysis devices for biological membranes |
GB0104690D0 (en) | 2001-02-26 | 2001-04-11 | Cytogenetic Dna Services Ltd | Diagnostic test |
US7078168B2 (en) | 2001-02-27 | 2006-07-18 | Biotage Ab | Method for determining allele frequencies |
US20050196785A1 (en) | 2001-03-05 | 2005-09-08 | California Institute Of Technology | Combinational array for nucleic acid analysis |
EP1373896A2 (en) | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
US20030190602A1 (en) | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
WO2002081710A1 (en) | 2001-04-06 | 2002-10-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells |
EP1384022A4 (en) | 2001-04-06 | 2004-08-04 | California Inst Of Techn | Nucleic acid amplification utilizing microfluidic devices |
US20020164816A1 (en) | 2001-04-06 | 2002-11-07 | California Institute Of Technology | Microfluidic sample separation device |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US7262030B2 (en) | 2001-05-09 | 2007-08-28 | Virginia Commonwealth University | Multiple sequencible and ligatible structures for genomic analysis |
US20020166760A1 (en) | 2001-05-11 | 2002-11-14 | Prentiss Mara G. | Micromagentic systems and methods for microfluidics |
US7118907B2 (en) | 2001-06-06 | 2006-10-10 | Li-Cor, Inc. | Single molecule detection systems and methods |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
WO2003003057A2 (en) | 2001-06-27 | 2003-01-09 | Bioview Ltd. | System and method for capturing multi-color fish images |
US20060019235A1 (en) | 2001-07-02 | 2006-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular and functional profiling using a cellular microarray |
US20050009022A1 (en) | 2001-07-06 | 2005-01-13 | Weiner Michael P. | Method for isolation of independent, parallel chemical micro-reactions using a porous filter |
US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
US6783928B2 (en) | 2001-07-17 | 2004-08-31 | Georgi Hvichia | Microstructures for cell proliferation assays and semen analysis |
US7993908B2 (en) | 2001-07-17 | 2011-08-09 | Parsortix, Inc. | Microstructure for particle and cell separation, identification, sorting, and manipulation |
JP2005502863A (en) | 2001-08-23 | 2005-01-27 | イムニベスト・コーポレイション | Analysis of circulating tumor cells, fragments and debris |
US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
DE50209932D1 (en) | 2001-09-06 | 2007-05-24 | Adnagen Gmbh | METHOD AND KIT FOR THE DIAGNOSTIC OR TREATMENT CONTROL OF DARM CANCER |
AUPR749901A0 (en) | 2001-09-06 | 2001-09-27 | Monash University | Method of identifying chromosomal abnormalities and prenatal diagnosis |
US7202045B2 (en) | 2001-09-19 | 2007-04-10 | Regents Of The University Of Michigan | Detection and treatment of cancers of the lung |
US7258987B2 (en) | 2001-09-21 | 2007-08-21 | The Regents Of The University Of California | Methods of cytodiagnostic staging of neoplasia and squamous cell carcinoma |
US7166443B2 (en) | 2001-10-11 | 2007-01-23 | Aviva Biosciences Corporation | Methods, compositions, and automated systems for separating rare cells from fluid samples |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
DE60237531D1 (en) | 2001-10-11 | 2010-10-14 | Aviva Biosciences Corp | METHOD FOR DISCONNECTING RARE CELLS FROM FLUID SAMPLES |
US20030072682A1 (en) | 2001-10-11 | 2003-04-17 | Dan Kikinis | Method and apparatus for performing biochemical testing in a microenvironment |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
US6783647B2 (en) | 2001-10-19 | 2004-08-31 | Ut-Battelle, Llc | Microfluidic systems and methods of transport and lysis of cells and analysis of cell lysate |
BR0213520A (en) | 2001-10-26 | 2006-05-23 | Immunivest Corp | method for diagnosing the severity of a disease in a test subject; and, testing kit for screening a patient sample for the presence of circulating cancer cells. |
US7262269B2 (en) | 2001-10-26 | 2007-08-28 | The Regents Of University Of California | Method for screening combinational bead library; ligands for cancer cells |
US20050095606A1 (en) | 2001-10-30 | 2005-05-05 | Glenn Hoke | Partially double-stranded nucleic acids, methods of making, and use thereof |
WO2003040064A2 (en) | 2001-11-07 | 2003-05-15 | Bioview Ltd. | Kits and methods for preparing cell samples optimized for dual staining |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20050244843A1 (en) | 2001-11-16 | 2005-11-03 | Wen-Tien Chen | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
US7510829B2 (en) | 2001-11-19 | 2009-03-31 | Affymetrix, Inc. | Multiplex PCR |
JP2005509871A (en) | 2001-11-20 | 2005-04-14 | エグザクト サイエンシーズ コーポレイション | Automated sample preparation method and apparatus |
EP1448792A1 (en) | 2001-11-22 | 2004-08-25 | Adnagen AG | Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer |
AU2002351187A1 (en) | 2001-11-30 | 2003-06-17 | Fluidigm Corporation | Microfluidic device and methods of using same |
AU2002357588B2 (en) | 2001-12-11 | 2008-11-20 | Netech Inc. | Blood cell separation system |
US7452725B2 (en) | 2002-01-10 | 2008-11-18 | Board Of Regents, The University Of Texas System | Flow sorting system and methods regarding same |
US7383134B2 (en) | 2002-01-15 | 2008-06-03 | Piper James R | Method and/or system for analyzing biological samples using a computer system |
US20030178641A1 (en) | 2002-01-23 | 2003-09-25 | Blair Steven M. | Microfluidic platforms for use with specific binding assays, specific binding assays that employ microfluidics, and methods |
AU2003216175A1 (en) | 2002-02-04 | 2003-09-02 | Colorado School Of Mines | Laminar flow-based separations of colloidal and cellular particles |
US6826666B2 (en) * | 2002-02-07 | 2004-11-30 | Microsoft Corporation | Method and system for transporting data content on a storage area network |
US7764821B2 (en) | 2002-02-14 | 2010-07-27 | Veridex, Llc | Methods and algorithms for cell enumeration in a low-cost cytometer |
JP2006508632A (en) | 2002-03-01 | 2006-03-16 | ラブジェン, インコーポレイテッド | Methods for detecting genetic diseases |
EP2241636A1 (en) * | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US7223371B2 (en) | 2002-03-14 | 2007-05-29 | Micronics, Inc. | Microfluidic channel network device |
WO2004023105A2 (en) | 2002-03-20 | 2004-03-18 | Advanced Sensor Technologies, Inc. | Personal monitor to detect exposure to toxic agents |
US7214427B2 (en) | 2002-03-21 | 2007-05-08 | Aviva Biosciences Corporation | Composite beads comprising magnetizable substance and electro-conductive substance |
WO2003085379A2 (en) | 2002-04-01 | 2003-10-16 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US20040241707A1 (en) | 2002-04-01 | 2004-12-02 | Gao Chun L. | Enhanced diagnostic potential of prostate-specific antigen expressing cells |
US7312085B2 (en) | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
JP2005524833A (en) | 2002-05-03 | 2005-08-18 | イムニベスト・コーポレイション | Devices and methods for analytical cell imaging |
US7727720B2 (en) | 2002-05-08 | 2010-06-01 | Ravgen, Inc. | Methods for detection of genetic disorders |
US7442506B2 (en) | 2002-05-08 | 2008-10-28 | Ravgen, Inc. | Methods for detection of genetic disorders |
US20070178478A1 (en) | 2002-05-08 | 2007-08-02 | Dhallan Ravinder S | Methods for detection of genetic disorders |
AU2003232872A1 (en) | 2002-05-27 | 2003-12-12 | Ostergotlands Lans Landsting | Method for determining immune system affecting compounds |
US7272252B2 (en) | 2002-06-12 | 2007-09-18 | Clarient, Inc. | Automated system for combining bright field and fluorescent microscopy |
US6838056B2 (en) | 2002-07-08 | 2005-01-04 | Innovative Micro Technology | Method and apparatus for sorting biological cells with a MEMS device |
US7229838B2 (en) | 2002-07-08 | 2007-06-12 | Innovative Micro Technology | MEMS actuator and method of manufacture for MEMS particle sorting device |
US7220594B2 (en) | 2002-07-08 | 2007-05-22 | Innovative Micro Technology | Method and apparatus for sorting particles with a MEMS device |
US20040018611A1 (en) | 2002-07-23 | 2004-01-29 | Ward Michael Dennis | Microfluidic devices for high gradient magnetic separation |
US9435799B2 (en) | 2002-07-31 | 2016-09-06 | Janssen Diagnostics, Inc. | Methods and reagents for improved selection of biological materials |
US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
EP2359689B1 (en) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Microfluidic device for cell separation and use thereof |
JP2006500074A (en) | 2002-09-27 | 2006-01-05 | オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー | Polypeptides and nucleic acids encoding them and their use for prevention, diagnosis or treatment of liver damage and epithelial cancer |
ATE463292T1 (en) | 2002-10-23 | 2010-04-15 | Univ Princeton | METHOD FOR CONTINUOUS PARTICLE SEPARATION USING OBSTACLE ARRAYS ASYMMETRICALLY ALIGNED IN FIELDS |
US6811385B2 (en) | 2002-10-31 | 2004-11-02 | Hewlett-Packard Development Company, L.P. | Acoustic micro-pump |
AU2003294246A1 (en) | 2002-11-01 | 2004-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Circulating stem cells and uses related thereto |
US7122384B2 (en) | 2002-11-06 | 2006-10-17 | E. I. Du Pont De Nemours And Company | Resonant light scattering microparticle methods |
AU2002952696A0 (en) | 2002-11-14 | 2002-11-28 | Genomics Research Partners Pty Ltd | Status determination |
US7704687B2 (en) | 2002-11-15 | 2010-04-27 | The Johns Hopkins University | Digital karyotyping |
JP4078398B2 (en) * | 2002-12-11 | 2008-04-23 | ソニー・エリクソン・モバイルコミュニケーションズ株式会社 | Information processing device |
DE10259703A1 (en) | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | separation process |
ATE533857T1 (en) | 2003-01-17 | 2011-12-15 | Univ Hong Kong Chinese | CIRCULATIVE MRNA AS A DIAGNOSTIC MARKER FOR DISEASES RELATED TO PREGNANCY |
US20040146883A1 (en) | 2003-01-28 | 2004-07-29 | Affymetrix, Inc. | Methods for prenatal diagnosis |
US6746503B1 (en) | 2003-01-30 | 2004-06-08 | The Regents Of The University Of California | Precision gap particle separator |
DE602004030220D1 (en) | 2003-02-27 | 2011-01-05 | Veridex Llc | CIRCULATING TUMOR CELLS (CTCs): EARLY ASSESSMENT OF TIME-TO-PROGRESSION, SURVIVAL AND RESPONSE TO THERAPY IN PATIENTS WITH METASTASED CANCER |
EP1604184A4 (en) | 2003-02-27 | 2010-10-27 | Stephen A Lesko | Standardized evaluation of therapeutic efficacy based on cellular biomarkers |
EP1599608A4 (en) | 2003-03-05 | 2007-07-18 | Genetic Technologies Ltd | Identification of fetal dna and fetal cell markers in maternal plasma or serum |
EP1606417A2 (en) | 2003-03-07 | 2005-12-21 | Rubicon Genomics Inc. | In vitro dna immortalization and whole genome amplification using libraries generated from randomly fragmented dna |
DE10313201A1 (en) | 2003-03-21 | 2004-10-07 | Steag Microparts Gmbh | Microstructured separator and microfluidic process for separating liquid components from a liquid containing particles |
AU2003901671A0 (en) | 2003-04-02 | 2003-05-01 | The University Of Adelaide | Comparative genomic hybridization |
EP1613654A2 (en) | 2003-04-03 | 2006-01-11 | Laboratoire Français du Fractionnement et des Biotechnologies | Antibodies with enhanced ability to immunomodulate cell functions |
US7604965B2 (en) | 2003-04-03 | 2009-10-20 | Fluidigm Corporation | Thermal reaction device and method for using the same |
US20040197832A1 (en) | 2003-04-03 | 2004-10-07 | Mor Research Applications Ltd. | Non-invasive prenatal genetic diagnosis using transcervical cells |
US20050145496A1 (en) | 2003-04-03 | 2005-07-07 | Federico Goodsaid | Thermal reaction device and method for using the same |
US7666361B2 (en) | 2003-04-03 | 2010-02-23 | Fluidigm Corporation | Microfluidic devices and methods of using same |
US20040197839A1 (en) | 2003-04-04 | 2004-10-07 | Bioview Ltd. | Methods of detecting cancer cells in biological samples |
JP2004351309A (en) | 2003-05-28 | 2004-12-16 | Kyocera Corp | Microchemical chip and its production method |
CN1539992A (en) | 2003-04-23 | 2004-10-27 | 林大钦 | Method in use for testing gene of fetus in antepartum |
WO2004101762A2 (en) | 2003-05-12 | 2004-11-25 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the colon |
WO2005020784A2 (en) | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
US8043846B2 (en) | 2003-06-13 | 2011-10-25 | The General Hospital Corporation | Device and method for contacting picoliter volumes of fluid |
CA2529285A1 (en) | 2003-06-13 | 2004-12-29 | The General Hospital Corporation | Microfluidic systems for size based removal of red blood cells and platelets from blood |
US20070092881A1 (en) | 2003-07-10 | 2007-04-26 | Central Institute For Experimental Animals | Gene markers of tumor metastasis |
US7461048B2 (en) | 2003-07-21 | 2008-12-02 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
WO2005017493A2 (en) | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
CN1860363B (en) | 2003-08-28 | 2011-12-28 | 赛路拉公司 | Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network |
WO2005023091A2 (en) | 2003-09-05 | 2005-03-17 | The Trustees Of Boston University | Method for non-invasive prenatal diagnosis |
US20070178458A1 (en) | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
US7824856B2 (en) | 2003-09-10 | 2010-11-02 | Althea Technologies, Inc. | Expression profiling using microarrays |
WO2005025518A2 (en) | 2003-09-11 | 2005-03-24 | The Uab Research Foundation | Inhibition of inward sodium currents in cancer |
JP4629675B2 (en) | 2003-09-18 | 2011-02-09 | ベリデックス・リミテッド・ライアビリティ・カンパニー | Programmable sample preparation and analysis system without operator |
US20070202109A1 (en) | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
ATE435301T1 (en) | 2003-10-16 | 2009-07-15 | Sequenom Inc | NON-INVASIVE DETECTION OF FETAL GENETIC CHARACTERISTICS |
US20050221341A1 (en) | 2003-10-22 | 2005-10-06 | Shimkets Richard A | Sequence-based karyotyping |
EP1692264A2 (en) | 2003-10-28 | 2006-08-23 | The Johns Hopkins University | Quantitative multiplex methylation-specific pcr |
CA2544178A1 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal dna in amniotic fluid |
CN1922304A (en) | 2003-10-31 | 2007-02-28 | 维特克公司 | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
WO2005049168A2 (en) | 2003-11-17 | 2005-06-02 | Immunivest Corporation | Method and apparatus for pre-enrichment and recovery of cells from densified whole blood |
WO2005047532A1 (en) | 2003-11-17 | 2005-05-26 | Gribbles Molecular Science Pty Ltd | Improved method of performing genetic analyses on reproductive tract cell samples |
WO2005056838A1 (en) | 2003-12-08 | 2005-06-23 | The Clinic For Special Children | Association of tspyl polymorphisms with siddt syndrome |
EP1697399B1 (en) | 2003-12-12 | 2016-11-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
US7939249B2 (en) | 2003-12-24 | 2011-05-10 | 3M Innovative Properties Company | Methods for nucleic acid isolation and kits using a microfluidic device and concentration step |
US20050147977A1 (en) | 2003-12-29 | 2005-07-07 | Tae-Woong Koo | Methods and compositions for nucleic acid detection and sequence analysis |
PT2311873T (en) | 2004-01-07 | 2018-11-20 | Novartis Vaccines & Diagnostics Inc | M-csf-specific monoclonal antibody and uses thereof |
CN1590563A (en) | 2004-01-07 | 2005-03-09 | 四川大学 | Detecting method of biological noneuploid |
EP1561507A1 (en) | 2004-01-27 | 2005-08-10 | Future Diagnostics B.V. | System for characterising a fluid, microfluidic device for characterising or analysing concentration components, a method of characterising or analysing such concentrations and a measurement device |
WO2005072399A2 (en) | 2004-01-29 | 2005-08-11 | Massachusetts Institute Of Technology | Microscale sorting cytometer |
US20050181353A1 (en) | 2004-02-17 | 2005-08-18 | Rao Galla C. | Stabilization of cells and biological specimens for analysis |
CA2555259A1 (en) | 2004-02-27 | 2005-09-09 | Applera Corporation | Genetic polymorphisms associated with stroke, methods of detection and uses thereof |
US20100216153A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
US20100216151A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
US20050191636A1 (en) | 2004-03-01 | 2005-09-01 | Biocept, Inc. | Detection of STRP, such as fragile X syndrome |
US20070077578A1 (en) | 2004-03-02 | 2007-04-05 | Primagen Holding B.V. | Diagnosis of (a risk of ) disease and monitoring of therapy |
AU2005218622A1 (en) | 2004-03-03 | 2005-09-15 | Living Microsystems | Magnetic device for isolation of cells and biomolecules in a microfluidic environment |
US20060121624A1 (en) | 2004-03-03 | 2006-06-08 | Huang Lotien R | Methods and systems for fluid delivery |
EP1765503A2 (en) | 2004-03-03 | 2007-03-28 | The General Hospital Corporation | System for delivering a diluted solution |
WO2005085861A2 (en) | 2004-03-03 | 2005-09-15 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer |
US20070207351A1 (en) | 2004-03-23 | 2007-09-06 | Amminex A/S | Use Of An Ammonia Storage Device In Production Of Energy |
US7390388B2 (en) | 2004-03-25 | 2008-06-24 | Hewlett-Packard Development Company, L.P. | Method of sorting cells on a biodevice |
WO2005098046A2 (en) | 2004-04-01 | 2005-10-20 | Immunivest Corporation | Methods for the determination of cell specific biomarkers |
EP1781809A1 (en) | 2004-04-08 | 2007-05-09 | BRAUCH, Hiltrud | Ercc2 polymorphisms |
WO2005108621A1 (en) | 2004-04-30 | 2005-11-17 | Yale University | Methods and compositions for cancer diagnosis |
US20080195326A1 (en) | 2004-05-03 | 2008-08-14 | Martin Munzer | Method And System For Comprehensive Knowledge-Based Anonymous Testing And Reporting, And Providing Selective Access To Test Results And Report |
US7468249B2 (en) | 2004-05-05 | 2008-12-23 | Biocept, Inc. | Detection of chromosomal disorders |
US20080213821A1 (en) | 2004-05-06 | 2008-09-04 | Nanyang Technological University | Microfluidic Cell Sorter System |
US20050287611A1 (en) | 2004-05-07 | 2005-12-29 | Nugent C T Iv | MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells |
WO2005111242A2 (en) | 2004-05-10 | 2005-11-24 | Parallele Bioscience, Inc. | Digital profiling of polynucleotide populations |
WO2005116264A2 (en) | 2004-05-24 | 2005-12-08 | Immunivest Corporation | A blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (fish) |
US7709194B2 (en) | 2004-06-04 | 2010-05-04 | The Chinese University Of Hong Kong | Marker for prenatal diagnosis and monitoring |
EP1607485A1 (en) | 2004-06-14 | 2005-12-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for quantifying VEGF121 isoform in a biological sample |
DE102004036285A1 (en) | 2004-07-27 | 2006-02-16 | Advalytix Ag | Method for determining the frequency of sequences of a sample |
US7820382B2 (en) | 2004-08-03 | 2010-10-26 | Bauer A Robert | Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation |
EP1799348A2 (en) | 2004-08-04 | 2007-06-27 | Spinx, Inc. | Devices and methods for interfacing microfluidic devices with fluid handling devices |
WO2006020936A2 (en) | 2004-08-12 | 2006-02-23 | Immunivest Corporation | A method for assessing disease states by profile analysis of isolated circulating endothelial cells |
ES2457755T3 (en) | 2004-08-17 | 2014-04-29 | Veridex, Llc | A diagnostic imaging device for analysis of circulating rare cells |
US8024128B2 (en) | 2004-09-07 | 2011-09-20 | Gene Security Network, Inc. | System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data |
WO2006041453A1 (en) | 2004-09-30 | 2006-04-20 | Immunivest Corporation | Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients |
ES2301268B1 (en) | 2004-10-25 | 2009-05-01 | Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. | USE OF GEN SLUG, OR ITS REPLICATION, TRANSCRIPTION OR EXPRESSION PRODUCTS, IN THE IDENTIFICATION, DIAGNOSIS, PREVENTION OR TREATMENT OF CANCER DISSEMINATION AND / OR METASTASIS DEVELOPMENT. |
US20060094109A1 (en) | 2004-11-02 | 2006-05-04 | Immunivest Corporation | Device and method for analytical cell imaging |
JP2008526255A (en) | 2005-01-13 | 2008-07-24 | マイクロニクス, インコーポレイテッド | Microfluidic diluted cell detection device |
WO2006078470A2 (en) | 2005-01-18 | 2006-07-27 | Biocept, Inc. | Cell separation using microchannel having patterned posts |
US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US8158410B2 (en) | 2005-01-18 | 2012-04-17 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US7407757B2 (en) | 2005-02-10 | 2008-08-05 | Population Genetics Technologies | Genetic analysis by sequence-specific sorting |
US20060205057A1 (en) | 2005-02-18 | 2006-09-14 | Wayner Danial D M | Microfluidic microarray with high surface area active regions |
WO2007024264A2 (en) | 2005-02-23 | 2007-03-01 | Bioimagene, Inc. | Method and system for digital image based tissue independent simultaneous nucleus, cytoplasm and membrane quantitation |
EP1861509B1 (en) | 2005-03-14 | 2015-09-09 | Janssen Diagnostics, LLC | A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells |
US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
CN102010902B (en) | 2005-03-18 | 2012-05-23 | 香港中文大学 | Markers for prenatal diagnosis and monitoring |
FR2883488B1 (en) | 2005-03-24 | 2010-12-10 | Inst Nat Sante Rech Med | METHOD AND DEVICE FOR SEPARATING BY VERTICAL FILTRATION BIOLOGICAL PARTICLES CONTAINED IN A LIQUID |
WO2006104530A1 (en) | 2005-03-28 | 2006-10-05 | Cell Works Therapeutics, Inc. | Therapeutics targeted to renal cells |
US20060223178A1 (en) | 2005-04-05 | 2006-10-05 | Tom Barber | Devices and methods for magnetic enrichment of cells and other particles |
GB2427468B (en) | 2005-04-05 | 2011-03-02 | Cellpoint Diagnostics | Cell separation device and method for the detection of EpCAM positive cells |
US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
GB0509500D0 (en) | 2005-05-10 | 2005-06-15 | Revealcyte | Method of fetal cell enrichment |
WO2007044091A2 (en) | 2005-06-02 | 2007-04-19 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
CA2612021A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2007001259A1 (en) | 2005-06-16 | 2007-01-04 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods and materials for identifying polymorphic variants, diagnosing susceptibilities, and treating disease |
US8532930B2 (en) | 2005-11-26 | 2013-09-10 | Natera, Inc. | Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals |
US20070178501A1 (en) | 2005-12-06 | 2007-08-02 | Matthew Rabinowitz | System and method for integrating and validating genotypic, phenotypic and medical information into a database according to a standardized ontology |
US20070027636A1 (en) | 2005-07-29 | 2007-02-01 | Matthew Rabinowitz | System and method for using genetic, phentoypic and clinical data to make predictions for clinical or lifestyle decisions |
US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
US8515679B2 (en) | 2005-12-06 | 2013-08-20 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US7901950B2 (en) | 2005-08-12 | 2011-03-08 | Veridex, Llc | Method for assessing disease states by profile analysis of isolated circulating endothelial cells |
EP1915461B1 (en) | 2005-08-17 | 2018-08-01 | Dx4U GmbH | Composition and method for determination of ck19 expression |
WO2007028146A2 (en) | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
US20070104717A1 (en) | 2005-09-12 | 2007-05-10 | Regents Of The University Of Michigan | Compositions and methods for detecting and treating cancer |
US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
US20070059718A1 (en) * | 2005-09-15 | 2007-03-15 | Mehmet Toner | Systems and methods for enrichment of analytes |
US20070059781A1 (en) | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
CA2622332A1 (en) | 2005-09-15 | 2007-03-22 | Val-Chum, S.E.C. | Methods of diagnosing ovarian cancer and kits therefor |
CA2622745A1 (en) | 2005-09-15 | 2007-03-29 | Artemis Health, Inc. | Systems and methods for enrichment of analytes |
US20070059774A1 (en) | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2007053245A2 (en) | 2005-09-20 | 2007-05-10 | Immunivest Corporation | Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes |
EP1946114A4 (en) | 2005-09-21 | 2010-05-26 | Ccc Diagnostics Llc | Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac) |
US20110059069A1 (en) | 2005-09-22 | 2011-03-10 | Biogen Idec Ma Inc | Gapr-1 Methods |
GB0519405D0 (en) | 2005-09-23 | 2005-11-02 | Univ Aberdeen | Cancer therapy prognosis and target |
EP1937831B1 (en) | 2005-09-27 | 2012-08-01 | University of Saskatchewan | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis |
EP1770171A1 (en) | 2005-09-29 | 2007-04-04 | Universität Zu Köln | DNA microarray for rapid identification of Candida albicans in blood cultures. |
WO2007041610A2 (en) | 2005-09-30 | 2007-04-12 | National Jewish Medical And Research Center | Genes and proteins associated with angiogenesis and uses thereof |
US20070202106A1 (en) | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
WO2007044690A2 (en) | 2005-10-07 | 2007-04-19 | The General Hospital Corporation | Devices and methods for cell manipulation |
US20090176218A1 (en) | 2005-10-21 | 2009-07-09 | The General Hospital Corporation | Method for the Diagnosis and Prognosis of Cancer |
US20110052570A1 (en) | 2005-10-26 | 2011-03-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20100062426A1 (en) | 2005-11-03 | 2010-03-11 | O'hara Shawn Mark | AGR2 and TFF3 Regulation in the Diagnosis and Treatment of Cancer |
EP1945794A2 (en) | 2005-11-09 | 2008-07-23 | Chemimage Corporation | System and method for cytological analysis by raman spectroscopic imaging |
US20070122856A1 (en) | 2005-11-10 | 2007-05-31 | Aurelium Biopharma Inc. | Tissue diagnostics for ovarian cancer |
DE602006019128D1 (en) | 2005-11-10 | 2011-02-03 | Bristol Myers Squibb Pharma Co | MOESIN, CAVEOLIN 1 AND YES-ASSOCIATED PROTEIN 1 AS PREDICTIVE MARKERS OF THE RESPONSE TO DASATINIB IN BREAST CANCER |
GB0523276D0 (en) | 2005-11-15 | 2005-12-21 | London Bridge Fertility | Chromosomal analysis by molecular karyotyping |
EP1962892A4 (en) | 2005-11-22 | 2011-10-12 | Univ South Florida | Inhibition of cell proliferation |
US20070238094A1 (en) | 2005-12-09 | 2007-10-11 | Baylor Research Institute | Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis |
US7566573B2 (en) | 2005-12-19 | 2009-07-28 | Idexx Laboratories, Inc. | Dual standard curve immunoassay |
EP1979000B1 (en) | 2005-12-22 | 2011-07-13 | Memorial Sloan-Kettering Cancer Center | Method for detection of cancer cells using virus |
WO2007079250A2 (en) | 2005-12-29 | 2007-07-12 | Cellpoint Diagnostics, Inc. | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
EP1803822A1 (en) | 2005-12-30 | 2007-07-04 | Adnagen AG | Method for the individual characterization of therapeutic target molecules and use thereof |
WO2007082154A2 (en) | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
WO2007080583A2 (en) | 2006-01-10 | 2007-07-19 | Applied Spectral Imaging Ltd. | Methods and systems for analyzing biological samples |
US20070160974A1 (en) | 2006-01-10 | 2007-07-12 | South Eastern Sydney And Illawarra Area Health Service | Human embryonic stem cell clones |
US7842465B2 (en) | 2006-01-17 | 2010-11-30 | Palo Alto Research Center Incorporated | Immunocytostaining methods for enhanced dye ratio discrimination in rare event detection |
US7548145B2 (en) | 2006-01-19 | 2009-06-16 | Innovative Micro Technology | Hysteretic MEMS thermal device and method of manufacture |
EP1987161A4 (en) | 2006-01-20 | 2009-06-24 | Univ Mcgill | Method to identify cd40-sensitive cells |
WO2007087612A2 (en) | 2006-01-25 | 2007-08-02 | Board Of Regents, The University Of Texas System | Detection and diagnosis of smoking related cancers |
JP2009525468A (en) | 2006-01-30 | 2009-07-09 | ザ・スクリプス・リサーチ・インステイチユート | Method for detecting circulating tumor cells and method for diagnosing cancer in a mammalian subject |
WO2007089880A2 (en) | 2006-01-31 | 2007-08-09 | Georgetown University | Method to detect breast cancer cells |
EP3002338B1 (en) | 2006-02-02 | 2019-05-08 | The Board of Trustees of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
WO2007092713A2 (en) | 2006-02-02 | 2007-08-16 | Trustees Of The University Of Pennsylvania | Microfluidic system and method for analysis of gene expression in cell-containing samples and detection of disease |
JP2009526770A (en) | 2006-02-09 | 2009-07-23 | マイクロメット アクツィエン ゲゼルシャフト | Treatment of metastatic breast cancer |
EP1818413A1 (en) | 2006-02-10 | 2007-08-15 | Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon | Method of determining outcome of non small-cell lung cancer according to XRCC3 polymorphism |
KR20090020544A (en) | 2006-02-21 | 2009-02-26 | 더 트러스티즈 오브 프린스턴 유니버시티 | High-yield activation of polymer surfaces for covalent attachment of molecules |
EP1986675A2 (en) | 2006-02-24 | 2008-11-05 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor |
US8609338B2 (en) | 2006-02-28 | 2013-12-17 | University Of Louisville Research Foundation, Inc. | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
CN101395280A (en) | 2006-03-01 | 2009-03-25 | 凯津公司 | High throughput sequence-based detection of snps using ligation assays |
AU2007223102A1 (en) | 2006-03-06 | 2007-09-13 | The Trustees Of Columbia University In The City Of New York | Specific amplification of fetal DNA sequences from a mixed, fetal-maternal source |
EP1832661A1 (en) | 2006-03-09 | 2007-09-12 | Adnagen AG | Method for the individual staging of tumor diseases |
US8337755B2 (en) | 2006-03-13 | 2012-12-25 | Veridex, Llc | Operator independent programmable sample preparation and analysis system |
US20090181358A1 (en) | 2006-03-30 | 2009-07-16 | Gross Susan J | Marker for Chromosomal Abnormalities |
US8058055B2 (en) | 2006-04-07 | 2011-11-15 | Agilent Technologies, Inc. | High resolution chromosomal mapping |
US7901884B2 (en) | 2006-05-03 | 2011-03-08 | The Chinese University Of Hong Kong | Markers for prenatal diagnosis and monitoring |
US7754428B2 (en) | 2006-05-03 | 2010-07-13 | The Chinese University Of Hong Kong | Fetal methylation markers |
AU2007260676A1 (en) | 2006-06-14 | 2007-12-21 | Artemis Health, Inc. | Rare cell analysis using sample splitting and DNA tags |
WO2007147073A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
EP2366801B1 (en) | 2006-06-14 | 2016-10-19 | Verinata Health, Inc | Methods for the diagnosis of fetal abnormalities |
US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
WO2007147018A1 (en) | 2006-06-14 | 2007-12-21 | Cellpoint Diagnostics, Inc. | Analysis of rare cell-enriched samples |
WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
AU2007260750A1 (en) | 2006-06-16 | 2007-12-21 | Sequenom, Inc. | Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample |
WO2008014516A2 (en) | 2006-07-28 | 2008-01-31 | Living Microsystems, Inc. | Selection of cells using biomarkers |
GB0616045D0 (en) | 2006-08-11 | 2006-09-20 | Univ Bristol | Blood cell separation |
EP2076609A1 (en) | 2006-10-10 | 2009-07-08 | Illumina Inc. | Compositions and methods for representational selection of nucleic acids fro complex mixtures using hybridization |
US20080113350A1 (en) | 2006-11-09 | 2008-05-15 | Terstappen Leon W M M | Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH) |
WO2008098142A2 (en) | 2007-02-08 | 2008-08-14 | Sequenom, Inc. | Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification |
WO2008135986A2 (en) | 2007-05-04 | 2008-11-13 | Mor Research Applications Ltd | System, method and device for comprehensive individualized genetic information or genetic counseling |
WO2009009769A2 (en) | 2007-07-11 | 2009-01-15 | Artemis Health, Inc. | Diagnosis of fetal abnormalities using nucleated red blood cells |
US20100112590A1 (en) | 2007-07-23 | 2010-05-06 | The Chinese University Of Hong Kong | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment |
US20090053719A1 (en) | 2007-08-03 | 2009-02-26 | The Chinese University Of Hong Kong | Analysis of nucleic acids by digital pcr |
US7882722B2 (en) * | 2007-08-03 | 2011-02-08 | Hubbell Incorporated | Jaw assembly |
CA2737643C (en) | 2008-09-20 | 2020-10-06 | Hei-Mun Fan | Noninvasive diagnosis of fetal aneuploidy by sequencing |
WO2010045617A2 (en) | 2008-10-17 | 2010-04-22 | University Of Louisville Research Foundation | Detecting genetic abnormalities |
US8343440B2 (en) | 2009-03-27 | 2013-01-01 | Seiko Epson Corporation | Cell separating apparatus and cell separating method |
US8481699B2 (en) | 2009-07-14 | 2013-07-09 | Academia Sinica | Multiplex barcoded Paired-End ditag (mbPED) library construction for ultra high throughput sequencing |
RS58879B1 (en) | 2009-11-05 | 2019-08-30 | Univ Hong Kong Chinese | Fetal genomic analysis from a maternal biological sample |
US20120010085A1 (en) | 2010-01-19 | 2012-01-12 | Rava Richard P | Methods for determining fraction of fetal nucleic acids in maternal samples |
US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
WO2011094646A1 (en) | 2010-01-28 | 2011-08-04 | Medical College Of Wisconsin, Inc. | Methods and compositions for high yield, specific amplification |
-
2007
- 2007-06-14 US US11/763,426 patent/US20080050739A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/413,485 patent/US20090280492A1/en not_active Abandoned
-
2010
- 2010-03-16 US US12/725,240 patent/US20110171638A1/en not_active Abandoned
- 2010-03-31 US US12/751,908 patent/US20100291571A1/en not_active Abandoned
-
2012
- 2012-03-28 US US13/433,232 patent/US20120183963A1/en not_active Abandoned
-
2013
- 2013-01-10 US US13/738,268 patent/US20130288242A1/en not_active Abandoned
- 2013-03-14 US US13/830,871 patent/US10591391B2/en active Active
-
2020
- 2020-03-16 US US16/819,992 patent/US11378498B2/en active Active
-
2022
- 2022-06-27 US US17/850,599 patent/US20230168160A1/en active Pending
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US20020006621A1 (en) * | 1989-11-13 | 2002-01-17 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
US20040018509A1 (en) * | 1989-11-13 | 2004-01-29 | Bianchi Diana W. | Non-invasive method for isolation and detection of fetal DNA |
US20060051775A1 (en) * | 1989-11-13 | 2006-03-09 | The Children's Hospital | Non-invasive method for isolation and detection of fetal DNA |
US20070015171A1 (en) * | 1989-11-13 | 2007-01-18 | The Children's Hospital | Non-invasive method for isolation and detection of fetal DNA |
US6176962B1 (en) * | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
US5879883A (en) * | 1991-10-03 | 1999-03-09 | Indiana University Foundation | Method for screening for alzheimer's disease |
US5498392A (en) * | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5866345A (en) * | 1992-05-01 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5726026A (en) * | 1992-05-01 | 1998-03-10 | Trustees Of The University Of Pennsylvania | Mesoscale sample preparation device and systems for determination and processing of analytes |
US5486335A (en) * | 1992-05-01 | 1996-01-23 | Trustees Of The University Of Pennsylvania | Analysis based on flow restriction |
US5296375A (en) * | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5858649A (en) * | 1992-07-17 | 1999-01-12 | Aprogenex, Inc. | Amplification of mRNA for distinguishing fetal cells in maternal blood |
US6184043B1 (en) * | 1992-09-14 | 2001-02-06 | FODSTAD øYSTEIN | Method for detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
US5707799A (en) * | 1994-09-30 | 1998-01-13 | Abbott Laboratories | Devices and methods utilizing arrays of structures for analyte capture |
US5709943A (en) * | 1995-05-04 | 1998-01-20 | Minnesota Mining And Manufacturing Company | Biological adsorption supports |
US5715946A (en) * | 1995-06-07 | 1998-02-10 | Reichenbach; Steven H. | Method and apparatus for sorting particles suspended in a fluid |
US6013188A (en) * | 1996-06-07 | 2000-01-11 | Immunivest Corporation | Methods for biological substance analysis employing internal magnetic gradients separation and an externally-applied transport force |
US6344326B1 (en) * | 1996-07-30 | 2002-02-05 | Aclara Bio Sciences, Inc. | Microfluidic method for nucleic acid purification and processing |
US6186660B1 (en) * | 1997-10-09 | 2001-02-13 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
US6517234B1 (en) * | 1997-10-09 | 2003-02-11 | Caliper Technologies Corp. | Microfluidic systems incorporating varied channel dimensions |
US20020016450A1 (en) * | 1997-10-31 | 2002-02-07 | Bbi Bioseq, Inc., A Masachusetts Corporation | Pressure-enhanced extraction and purification |
US6197523B1 (en) * | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
US20020028431A1 (en) * | 1998-08-25 | 2002-03-07 | Julien Jean-Claude Bisconte De Saint | Process, device and reagent for cell separation |
US6673541B1 (en) * | 1998-09-18 | 2004-01-06 | Micromet Ag | DNA amplification of a single cell |
US20040053352A1 (en) * | 1998-09-28 | 2004-03-18 | Tianmei Ouyang | Diagnostics based on tetrazolium compounds |
US20030022207A1 (en) * | 1998-10-16 | 2003-01-30 | Solexa, Ltd. | Arrayed polynucleotides and their use in genome analysis |
US6858439B1 (en) * | 1999-03-15 | 2005-02-22 | Aviva Biosciences | Compositions and methods for separation of moieties on chips |
US6511967B1 (en) * | 1999-04-23 | 2003-01-28 | The General Hospital Corporation | Use of an internalizing transferrin receptor to image transgene expression |
US20030044781A1 (en) * | 1999-05-19 | 2003-03-06 | Jonas Korlach | Method for sequencing nucleic acid molecules |
US20040048360A1 (en) * | 1999-08-26 | 2004-03-11 | Caliper Technologies Corp. | Microfluidic analytic detection assays, devices, and integrated systems |
US20020012930A1 (en) * | 1999-09-16 | 2002-01-31 | Rothberg Jonathan M. | Method of sequencing a nucleic acid |
US20030013101A1 (en) * | 1999-09-29 | 2003-01-16 | Shankar Balasubramanian | Polynucleotide sequencing |
US20020019001A1 (en) * | 1999-10-15 | 2002-02-14 | Ventana Medical Systems, Inc. | Method of detecting single gene copies in-situ |
US6361958B1 (en) * | 1999-11-12 | 2002-03-26 | Motorola, Inc. | Biochannel assay for hybridization with biomaterial |
US20020012931A1 (en) * | 2000-03-27 | 2002-01-31 | Waldman Scott A. | High specificity marker detection |
US20020009738A1 (en) * | 2000-04-03 | 2002-01-24 | Houghton Raymond L. | Methods, compositions and kits for the detection and monitoring of breast cancer |
US20030004402A1 (en) * | 2000-07-18 | 2003-01-02 | Hitt Ben A. | Process for discriminating between biological states based on hidden patterns from biological data |
US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
US6689615B1 (en) * | 2000-10-04 | 2004-02-10 | James Murto | Methods and devices for processing blood samples |
US6685841B2 (en) * | 2001-02-14 | 2004-02-03 | Gabriel P. Lopez | Nanostructured devices for separation and analysis |
US6674525B2 (en) * | 2001-04-03 | 2004-01-06 | Micronics, Inc. | Split focusing cytometer |
US20030033091A1 (en) * | 2001-04-20 | 2003-02-13 | Sequenom, Inc. | Systems and methods for testing a biological sample |
US20070037273A1 (en) * | 2001-04-25 | 2007-02-15 | Michael Shuler | Devices and methods for pharmacokinetic-based cell culture system |
US20070037275A1 (en) * | 2001-04-25 | 2007-02-15 | Michael Shuler | Devices and methods for pharmacokinetic-based cell culture system |
US20060060767A1 (en) * | 2001-04-27 | 2006-03-23 | Wang Mark M | Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles |
US20050049793A1 (en) * | 2001-04-30 | 2005-03-03 | Patrizia Paterlini-Brechot | Prenatal diagnosis method on isolated foetal cell of maternal blood |
US20030017514A1 (en) * | 2001-06-02 | 2003-01-23 | Katharina Pachmann | Method for quantitative detection of vital epithelial tumor cells in a body fluid |
US20050037388A1 (en) * | 2001-06-22 | 2005-02-17 | University Of Geneva | Method for detecting diseases caused by chromosomal imbalances |
US20030044388A1 (en) * | 2001-08-31 | 2003-03-06 | The Chinese University Of Hong Kong | Methods for detecting DNA originating from different individuals |
US20050014208A1 (en) * | 2001-09-06 | 2005-01-20 | Alf-Andreas Krehan | Method and kit for diagnosing or controlling the treatment of breast cancer |
US20050042685A1 (en) * | 2001-09-06 | 2005-02-24 | Winfried Albert | Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells |
US20070042360A1 (en) * | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US20050019792A1 (en) * | 2001-11-30 | 2005-01-27 | Fluidigm Corporation | Microfluidic device and methods of using same |
US7171975B2 (en) * | 2002-02-12 | 2007-02-06 | Kionix, Inc. | Fabrication of ultra-shallow channels for microfluidic devices and systems |
US20060024756A1 (en) * | 2002-02-14 | 2006-02-02 | Arjan Tibbe | Methods and algorithms for cell enumeration in low-cost cytometer |
US7332277B2 (en) * | 2002-03-01 | 2008-02-19 | Ravgen, Inc. | Methods for detection of genetic disorders |
US20040009471A1 (en) * | 2002-04-25 | 2004-01-15 | Bo Cao | Methods and kits for detecting a target cell |
US20040018116A1 (en) * | 2002-07-26 | 2004-01-29 | Desmond Sean M. | Microfluidic size-exclusion devices, systems, and methods |
US20060008807A1 (en) * | 2002-08-23 | 2006-01-12 | O'hara Shawn M | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
US20040037470A1 (en) * | 2002-08-23 | 2004-02-26 | Simske Steven J. | Systems and methods for processing text-based electronic documents |
US20040043506A1 (en) * | 2002-08-30 | 2004-03-04 | Horst Haussecker | Cascaded hydrodynamic focusing in microfluidic channels |
US20070054268A1 (en) * | 2002-09-05 | 2007-03-08 | Robert Sutherland | Methods of diagnosis and prognosis of ovarian cancer |
US20050042623A1 (en) * | 2002-10-30 | 2005-02-24 | Dana Ault-Riche | Systems for capture and analysis of biological particles and methods using the systems |
US20050064476A1 (en) * | 2002-11-11 | 2005-03-24 | Affymetrix, Inc. | Methods for identifying DNA copy number changes |
US20060000772A1 (en) * | 2002-11-29 | 2006-01-05 | Toru Sano | Separation apparatus and separation method |
US20070042368A1 (en) * | 2003-03-24 | 2007-02-22 | Corixa Corporation | Detection and monitoring of lung cancer |
US7476363B2 (en) * | 2003-04-03 | 2009-01-13 | Fluidigm Corporation | Microfluidic devices and methods of using same |
US20050061962A1 (en) * | 2003-07-31 | 2005-03-24 | Arryx, Inc. | Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components |
US20070042339A1 (en) * | 2003-08-08 | 2007-02-22 | Massachusetts General Hospital | Preservation of biomaterials with transported preservation agents |
US20050052773A1 (en) * | 2003-09-05 | 2005-03-10 | Hitachi Global Storage Technologies | Increasing head-disk interface reliability using controlled heating |
US7655399B2 (en) * | 2003-10-08 | 2010-02-02 | Trustees Of Boston University | Methods for prenatal diagnosis of chromosomal abnormalities |
US20060046258A1 (en) * | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
US20060008824A1 (en) * | 2004-05-20 | 2006-01-12 | Leland Stanford Junior University | Methods and compositions for clonal amplification of nucleic acid |
US20060024711A1 (en) * | 2004-07-02 | 2006-02-02 | Helicos Biosciences Corporation | Methods for nucleic acid amplification and sequence determination |
US20060024678A1 (en) * | 2004-07-28 | 2006-02-02 | Helicos Biosciences Corporation | Use of single-stranded nucleic acid binding proteins in sequencing |
US20060051265A1 (en) * | 2004-09-08 | 2006-03-09 | Health Research, Inc. | Apparatus and method for sorting microstructures in a fluid medium |
US7645576B2 (en) * | 2005-03-18 | 2010-01-12 | The Chinese University Of Hong Kong | Method for the detection of chromosomal aneuploidies |
US20070017633A1 (en) * | 2005-03-23 | 2007-01-25 | Tonkovich Anna L | Surface features in microprocess technology |
US20070026381A1 (en) * | 2005-04-05 | 2007-02-01 | Huang Lotien R | Devices and methods for enrichment and alteration of cells and other particles |
US20070054287A1 (en) * | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026419A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026418A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070026469A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070037172A1 (en) * | 2005-08-11 | 2007-02-15 | Chiu Daniel T | Separation and concentration of biological cells and biological particles using a one-dimensional channel |
US20070037173A1 (en) * | 2005-08-12 | 2007-02-15 | Allard Jeffrey W | Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients |
US20070042238A1 (en) * | 2005-08-22 | 2007-02-22 | Lg Electronics Inc. | Fuel cell having water type radiating device |
US20070048750A1 (en) * | 2005-09-01 | 2007-03-01 | National Health Research Institute | Rapid efficacy assessment method for lung cancer therapy |
US20080020390A1 (en) * | 2006-02-28 | 2008-01-24 | Mitchell Aoy T | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
US20080038733A1 (en) * | 2006-03-28 | 2008-02-14 | Baylor College Of Medicine | Screening for down syndrome |
US20080023399A1 (en) * | 2006-06-01 | 2008-01-31 | Inglis David W | Apparatus and method for continuous particle separation |
US20080026390A1 (en) * | 2006-06-14 | 2008-01-31 | Roland Stoughton | Diagnosis of Fetal Abnormalities by Comparative Genomic Hybridization Analysis |
US20090029377A1 (en) * | 2007-07-23 | 2009-01-29 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
Cited By (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364829B2 (en) | 2005-06-02 | 2016-06-14 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20110143949A1 (en) * | 2005-06-02 | 2011-06-16 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20110129841A1 (en) * | 2005-06-02 | 2011-06-02 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
US20070026418A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
US11306359B2 (en) | 2005-11-26 | 2022-04-19 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US20100124751A1 (en) * | 2006-02-02 | 2010-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US20100255493A1 (en) * | 2006-02-02 | 2010-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US9777329B2 (en) | 2006-02-02 | 2017-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US8008018B2 (en) | 2006-02-02 | 2011-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Determination of fetal aneuploidies by massively parallel DNA sequencing |
US20100124752A1 (en) * | 2006-02-02 | 2010-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US20090170113A1 (en) * | 2006-02-02 | 2009-07-02 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US20100255492A1 (en) * | 2006-02-02 | 2010-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US9777328B2 (en) | 2006-02-02 | 2017-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US20100256013A1 (en) * | 2006-02-02 | 2010-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US8293470B2 (en) | 2006-02-02 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US10072295B2 (en) | 2006-02-02 | 2018-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digtal analysis |
US7888017B2 (en) | 2006-02-02 | 2011-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US20090170114A1 (en) * | 2006-02-02 | 2009-07-02 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Invasive Fetal Genetic Screening by Digital Analysis |
US11692225B2 (en) | 2006-02-02 | 2023-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US9441273B2 (en) | 2006-02-02 | 2016-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US20070202525A1 (en) * | 2006-02-02 | 2007-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
US11781187B2 (en) | 2006-06-14 | 2023-10-10 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US10704090B2 (en) | 2006-06-14 | 2020-07-07 | Verinata Health, Inc. | Fetal aneuploidy detection by sequencing |
US9273355B2 (en) | 2006-06-14 | 2016-03-01 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US9347100B2 (en) | 2006-06-14 | 2016-05-24 | Gpb Scientific, Llc | Rare cell analysis using sample splitting and DNA tags |
US10591391B2 (en) | 2006-06-14 | 2020-03-17 | Verinata Health, Inc. | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US9017942B2 (en) | 2006-06-14 | 2015-04-28 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20080070792A1 (en) * | 2006-06-14 | 2008-03-20 | Roland Stoughton | Use of highly parallel snp genotyping for fetal diagnosis |
US10155984B2 (en) | 2006-06-14 | 2018-12-18 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20080138809A1 (en) * | 2006-06-14 | 2008-06-12 | Ravi Kapur | Methods for the Diagnosis of Fetal Abnormalities |
US8168389B2 (en) | 2006-06-14 | 2012-05-01 | The General Hospital Corporation | Fetal cell analysis using sample splitting |
US20080220422A1 (en) * | 2006-06-14 | 2008-09-11 | Daniel Shoemaker | Rare cell analysis using sample splitting and dna tags |
US20100291572A1 (en) * | 2006-06-14 | 2010-11-18 | Artemis Health, Inc. | Fetal aneuploidy detection by sequencing |
US11674176B2 (en) | 2006-06-14 | 2023-06-13 | Verinata Health, Inc | Fetal aneuploidy detection by sequencing |
US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
US20090280492A1 (en) * | 2006-06-14 | 2009-11-12 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
US8972202B2 (en) | 2007-07-23 | 2015-03-03 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US11142799B2 (en) | 2007-07-23 | 2021-10-12 | The Chinese University Of Hong Kong | Detecting chromosomal aberrations associated with cancer using genomic sequencing |
US10619214B2 (en) | 2007-07-23 | 2020-04-14 | The Chinese University Of Hong Kong | Detecting genetic aberrations associated with cancer using genomic sequencing |
US9051616B2 (en) | 2007-07-23 | 2015-06-09 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US8442774B2 (en) | 2007-07-23 | 2013-05-14 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using paired end |
US20100112590A1 (en) * | 2007-07-23 | 2010-05-06 | The Chinese University Of Hong Kong | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment |
US20090029377A1 (en) * | 2007-07-23 | 2009-01-29 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing |
US9121069B2 (en) | 2007-07-23 | 2015-09-01 | The Chinese University Of Hong Kong | Diagnosing cancer using genomic sequencing |
US8296076B2 (en) | 2008-09-20 | 2012-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuoploidy by sequencing |
US10669585B2 (en) | 2008-09-20 | 2020-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US9404157B2 (en) | 2008-09-20 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US20100112575A1 (en) * | 2008-09-20 | 2010-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing |
US20100138165A1 (en) * | 2008-09-20 | 2010-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing |
US9353414B2 (en) | 2008-09-20 | 2016-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8195415B2 (en) | 2008-09-20 | 2012-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
EP2334812A4 (en) * | 2008-09-20 | 2013-02-27 | Univ Leland Stanford Junior | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US8682594B2 (en) | 2008-09-20 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
EP3751005A3 (en) * | 2008-09-20 | 2021-02-24 | The Board of Trustees of the Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
US20100304978A1 (en) * | 2009-01-26 | 2010-12-02 | David Xingfei Deng | Methods and compositions for identifying a fetal cell |
US20110224087A1 (en) * | 2010-01-19 | 2011-09-15 | Stephen Quake | Simultaneous determination of aneuploidy and fetal fraction |
EP2513339A1 (en) * | 2010-01-19 | 2012-10-24 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acid in maternal samples |
US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9115401B2 (en) | 2010-01-19 | 2015-08-25 | Verinata Health, Inc. | Partition defined detection methods |
EP3006573A1 (en) | 2010-01-19 | 2016-04-13 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acids in maternal samples |
US9323888B2 (en) | 2010-01-19 | 2016-04-26 | Verinata Health, Inc. | Detecting and classifying copy number variation |
EP2883965A1 (en) * | 2010-01-19 | 2015-06-17 | Verinata Health, Inc | Method for determining copy number variations |
EP2848704A1 (en) * | 2010-01-19 | 2015-03-18 | Verinata Health, Inc | Sequencing methods and compositions for prenatal diagnoses |
EP2848703A1 (en) * | 2010-01-19 | 2015-03-18 | Verinata Health, Inc | Simultaneous determination of aneuploidy and fetal fraction |
EP2376661B1 (en) * | 2010-01-19 | 2015-01-21 | Verinata Health, Inc | Simultaneous determination of aneuploidy and fetal fraction |
US11697846B2 (en) | 2010-01-19 | 2023-07-11 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US11875899B2 (en) | 2010-01-19 | 2024-01-16 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
EP2513341A4 (en) * | 2010-01-19 | 2013-08-14 | Verinata Health Inc | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
EP2513339A4 (en) * | 2010-01-19 | 2013-05-29 | Verinata Health Inc | Methods for determining fraction of fetal nucleic acid in maternal samples |
US9493828B2 (en) | 2010-01-19 | 2016-11-15 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acids in maternal samples |
US11884975B2 (en) | 2010-01-19 | 2024-01-30 | Verinata Health, Inc. | Sequencing methods and compositions for prenatal diagnoses |
WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
EP4074838A1 (en) * | 2010-01-19 | 2022-10-19 | Verinata Health, Inc. | Novel protocol for preparing sequencing libraries |
US9657342B2 (en) | 2010-01-19 | 2017-05-23 | Verinata Health, Inc. | Sequencing methods for prenatal diagnoses |
US11952623B2 (en) | 2010-01-19 | 2024-04-09 | Verinata Health, Inc. | Simultaneous determination of aneuploidy and fetal fraction |
EP2513341A1 (en) * | 2010-01-19 | 2012-10-24 | Verinata Health, Inc | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
US10941442B2 (en) | 2010-01-19 | 2021-03-09 | Verinata Health, Inc. | Sequencing methods and compositions for prenatal diagnoses |
EP3260555A1 (en) * | 2010-01-19 | 2017-12-27 | Verinata Health, Inc | Novel protocol for preparing sequencing libraries |
EP2366031A4 (en) * | 2010-01-19 | 2012-03-21 | Verinata Health Inc | Sequencing methods and compositions for prenatal diagnoses |
EP3382037A1 (en) | 2010-01-19 | 2018-10-03 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acids in maternal samples |
EP2376661A4 (en) * | 2010-01-19 | 2012-03-21 | Verinata Health Inc | Simultaneous determination of aneuploidy and fetal fraction |
US11286520B2 (en) | 2010-01-19 | 2022-03-29 | Verinata Health, Inc. | Method for determining copy number variations |
EP3492601A1 (en) * | 2010-01-19 | 2019-06-05 | Verinata Health, Inc | Novel protocol for preparing sequencing libraries |
EP2370599A4 (en) * | 2010-01-19 | 2012-03-21 | Verinata Health Inc | Method for determining copy number variations |
US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US10415089B2 (en) | 2010-01-19 | 2019-09-17 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US10482993B2 (en) | 2010-01-19 | 2019-11-19 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
US10586610B2 (en) | 2010-01-19 | 2020-03-10 | Verinata Health, Inc. | Detecting and classifying copy number variation |
EP2376661A1 (en) * | 2010-01-19 | 2011-10-19 | Verinata Health, Inc | Simultaneous determination of aneuploidy and fetal fraction |
US10612096B2 (en) | 2010-01-19 | 2020-04-07 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acids in maternal samples |
EP2370599A1 (en) * | 2010-01-19 | 2011-10-05 | Verinata Health, Inc | Method for determining copy number variations |
US11130995B2 (en) | 2010-01-19 | 2021-09-28 | Verinata Health, Inc. | Simultaneous determination of aneuploidy and fetal fraction |
US10662474B2 (en) | 2010-01-19 | 2020-05-26 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing |
US20110230358A1 (en) * | 2010-01-19 | 2011-09-22 | Artemis Health, Inc. | Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing |
EP2366031A1 (en) * | 2010-01-19 | 2011-09-21 | Verinata Health, Inc | Sequencing methods and compositions for prenatal diagnoses |
EP3878973A1 (en) | 2010-01-19 | 2021-09-15 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic in maternal samples |
US20110201507A1 (en) * | 2010-01-19 | 2011-08-18 | Rava Richard P | Sequencing methods and compositions for prenatal diagnoses |
US9217131B2 (en) | 2010-01-21 | 2015-12-22 | Biocep Ltd. | Magnetic separation of rare cells |
US9546392B2 (en) | 2010-01-21 | 2017-01-17 | Biocep Ltd. | Magnetic separation of rare cells |
US9493831B2 (en) | 2010-01-23 | 2016-11-15 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US8318430B2 (en) | 2010-01-23 | 2012-11-27 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US10718020B2 (en) | 2010-01-23 | 2020-07-21 | Verinata Health, Inc. | Methods of fetal abnormality detection |
US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11482300B2 (en) * | 2010-05-18 | 2022-10-25 | Natera, Inc. | Methods for preparing a DNA fraction from a biological sample for analyzing genotypes of cell-free DNA |
US11111545B2 (en) | 2010-05-18 | 2021-09-07 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11746376B2 (en) | 2010-05-18 | 2023-09-05 | Natera, Inc. | Methods for amplification of cell-free DNA using ligated adaptors and universal and inner target-specific primers for multiplexed nested PCR |
US11286530B2 (en) | 2010-05-18 | 2022-03-29 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11306357B2 (en) | 2010-05-18 | 2022-04-19 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11519035B2 (en) | 2010-05-18 | 2022-12-06 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11312996B2 (en) | 2010-05-18 | 2022-04-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11525162B2 (en) | 2010-05-18 | 2022-12-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11332774B2 (en) | 2010-10-26 | 2022-05-17 | Verinata Health, Inc. | Method for determining copy number variations |
US9447453B2 (en) | 2011-04-12 | 2016-09-20 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
US10658070B2 (en) | 2011-04-12 | 2020-05-19 | Verinata Health, Inc. | Resolving genome fractions using polymorphism counts |
US8532936B2 (en) | 2011-04-14 | 2013-09-10 | Verinata Health, Inc. | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
US9411937B2 (en) | 2011-04-15 | 2016-08-09 | Verinata Health, Inc. | Detecting and classifying copy number variation |
US9547748B2 (en) | 2011-06-29 | 2017-01-17 | Bgi Health Service Co., Ltd. | Method for determining fetal chromosomal abnormality |
WO2013015793A1 (en) * | 2011-07-26 | 2013-01-31 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
US9840732B2 (en) | 2012-05-21 | 2017-12-12 | Fluidigm Corporation | Single-particle analysis of particle populations |
US11408037B2 (en) | 2014-04-21 | 2022-08-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11319596B2 (en) | 2014-04-21 | 2022-05-03 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11486008B2 (en) | 2014-04-21 | 2022-11-01 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11319595B2 (en) | 2014-04-21 | 2022-05-03 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11390916B2 (en) | 2014-04-21 | 2022-07-19 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11414709B2 (en) | 2014-04-21 | 2022-08-16 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11371100B2 (en) | 2014-04-21 | 2022-06-28 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US11530454B2 (en) | 2014-04-21 | 2022-12-20 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
US10167502B2 (en) | 2015-04-03 | 2019-01-01 | Fluxion Biosciences, Inc. | Molecular characterization of single cells and cell populations for non-invasive diagnostics |
US11098352B2 (en) | 2015-04-03 | 2021-08-24 | Fluxion Biosciences, Inc. | Molecular characterization of single cells and cell populations for non-invasive diagnostics |
WO2016161081A1 (en) * | 2015-04-03 | 2016-10-06 | Fluxion Biosciences, Inc. | Molecular characterization of single cells and cell populations for non-invasive diagnostics |
US11946101B2 (en) | 2015-05-11 | 2024-04-02 | Natera, Inc. | Methods and compositions for determining ploidy |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
US11519028B2 (en) | 2016-12-07 | 2022-12-06 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11530442B2 (en) | 2016-12-07 | 2022-12-20 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
US11788121B2 (en) | 2018-04-02 | 2023-10-17 | Enumera Molecular, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
US11230731B2 (en) | 2018-04-02 | 2022-01-25 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
US11186863B2 (en) | 2019-04-02 | 2021-11-30 | Progenity, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
US11959129B2 (en) | 2019-04-02 | 2024-04-16 | Enumera Molecular, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
CN113736876A (en) * | 2021-10-14 | 2021-12-03 | 胜亚生物科技(厦门)有限公司 | Kit for rapidly detecting chromosome number abnormality and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20130280709A1 (en) | 2013-10-24 |
US11378498B2 (en) | 2022-07-05 |
US20110171638A1 (en) | 2011-07-14 |
US20210010913A1 (en) | 2021-01-14 |
US20090280492A1 (en) | 2009-11-12 |
US20130288242A1 (en) | 2013-10-31 |
US20100291571A1 (en) | 2010-11-18 |
US20230168160A1 (en) | 2023-06-01 |
US10591391B2 (en) | 2020-03-17 |
US20120183963A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11378498B2 (en) | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats | |
EP2029778B1 (en) | Diagnosis of fetal abnormalities | |
US11674176B2 (en) | Fetal aneuploidy detection by sequencing | |
US20230021752A1 (en) | Methods For The Diagnosis Of Fetal Abnormalities | |
US20080026390A1 (en) | Diagnosis of Fetal Abnormalities by Comparative Genomic Hybridization Analysis | |
EP3406736B1 (en) | Methods for the diagnosis of fetal abnormalities | |
US20080113358A1 (en) | Selection of cells using biomarkers | |
US20100304978A1 (en) | Methods and compositions for identifying a fetal cell | |
EP4108780A1 (en) | Rare cell analysis using sample splitting and dna tags |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIVING MICROSYSTEMS INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STOUGHTON, ROLAND;KAPUR, RAVI;COHEN, BARB ARIEL;REEL/FRAME:019908/0877;SIGNING DATES FROM 20070813 TO 20070816 |
|
AS | Assignment |
Owner name: ARTEMIS HEALTH, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:LIVING MICROSYSTEMS, INC.;REEL/FRAME:019931/0171 Effective date: 20070815 |
|
AS | Assignment |
Owner name: VERINATA HEALTH, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:ARTEMIS HEALTH, INC.;REEL/FRAME:026711/0626 Effective date: 20110413 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |